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AďstƌaĐt      
 
Hoǁ to esĐape fƌoŵ jail:  
EŶgiŶeeƌed ĐǇtoĐhƌoŵe PϰϱϬ ŵoŶooǆǇgeŶases aƌe used foƌ the depƌoteĐioŶ of difeƌeŶt etheƌs, 
theƌeďǇ ƌeleasiŶg uŶĐaged alĐohols, ǁhiĐh iŶ this Đase displaǇ luoƌesĐeŶĐe pƌopeƌies. BiooƌthogoŶal 
eŶzǇŵe / pƌoteĐioŶ gƌoup paiƌs pƌoǀide possiďle soluioŶs foƌ the seleĐiǀe ƌelease of iŵagiŶg ageŶts as 
ǁell as the ĐatalǇiĐ aĐiǀaioŶ of pƌodƌugs at theiƌ site of aĐioŶ. Figuƌe ƌepƌoduĐed ǁith peƌŵissioŶ 
fƌoŵ JOHN WILEY & SONS LTD.[ϭ] 
In this thesis, engineered cytochrome PŚśŖ monooxygenase mutants are reported as highly 
active and selective catalysts for the bioorthogonal uncaging of diferent ether protected 
substrates, including the successful transfer of the uncaging reaction into living bacteria. This 
proof-of-principle study points towards the utility of bioorthogonal enzyme/protecting 
group pairs for applications in the life sciences. 
In the irst part of this thesis, enzyme-substrate pairs were identiied and characterizedǱ First, 
various ether-protected luorescein derivatives were synthesized via WILLI“MSON ether 
synthesis. Existing protocols for the evaluation of PŚśŖ”Mř variants were then modiied for 
their applicability towards these luorescent substrates, and enzyme libraries available from 
the REETZ group with a total of over ŗŖŖŖ mutants were screened for their activity. Motivated 
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by promising initial results, two diferent coumarin scafolds were modiied with the same 
ether protection groups and the libraries screened again for their activity towards these new 
substrates. “ctive ǻȃhitȄǼ mutants were isolated, sequenced, and expressed at larger scales 
for puriication. Puriied mutants were then characterized with regard to their kinetic 
performance, while theoretical investigations using induced-it docking and molecular 
dynamics simulations supported the rationalization of site inluences.   
The second part of the study concentrates on the transfer of the uncaging system into a 
biological environment. Experiments using mammalian cells were conducted in 
collaboration with the P“R“K lab. Either the puriied protein or the corresponding mRN“ 
was transfected using commercially available delivery agents, with only modest success. “t 
the same time, microcapsules were investigated for suitability towards this system, and 
extensive enzyme stability tests were performed in the process. Ultimately, a successful 
transfer of the system to living E. coli is reported, proving the general feasibility of the 
deprotection system for in vivo applications. 
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AďstƌaĐt ;DeutsĐhͿ    
 
Wie ŵaŶ eŶtkoŵŵt:  
 Eǀolǀieƌte CǇtoĐhƌoŵ-PϰϱϬ-MoŶooǆǇgeŶaseŶ ǁeƌdeŶ geŶutzt, uŵ ǀeƌsĐhiedeŶe etheƌ-ŵaskieƌte 
VeƌďiŶduŶgeŶ iŶ vitƌo uŶd iŶ leďeŶdeŶ E. Đoli zu eŶtsĐhützeŶ, uŶd daďei Alkohole fƌeizusetzeŶ, die iŶ 
dieseŵ Fall luoƌeszeŶzakiǀ siŶd. SolĐhe ďiooƌthogoŶaleŶ Paaƌe aus EŶzǇŵ uŶd SĐhutzgƌuppe 
eƌŵögliĐheŶ die selekiǀe FƌeisetzuŶg ďildgeďeŶdeƌ VeƌďiŶduŶgeŶ odeƌ die katalǇisĐhe AkiǀieƌuŶg ǀoŶ 
WiƌkstofǀoƌläufeƌŶ aŶ deƌeŶ )ieloƌt. Gƌaik ƌepƌoduzieƌt ŵit EƌlauďŶis ǀoŶ JOHN WILEY & SONS LTD.[Ϯ] 
In der vorliegenden “rbeit wird die Verwendung evolvierter Mutanten von Cytochrom-
PŚśŖ-Monooxygenasen als hochaktive und hochselektive Katalysatoren f(r die 
bioorthogonale “ktivierung ethermaskierter Substrate berichtet, einschließlich der 
erfolgreichen Entsch(zung in lebenden ”akterien. Der mögliche Nuzen von 
bioorthogonalen Paaren aus Enzym und Schuzgruppe f(r “nwendungen in den 
Lebenswissenschaften wird veranschaulicht. 
Der Fokus des ersten Teils der “rbeit liegt auf der Identiikation und Charakterisierung von 
Paaren aus Schuzgruppe und EnzymǱ zunächst wurden verschiedene ethermaskierte 
Fluoreszein-Derivate nach einer WILLI“MSON-Ethersynthese dargestellt. Literaturbekannte 
Protokolle zur Untersuchung von PŚśŖ”Mř-Mutanten wurden modiiziert, um sie an die 
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Verwendung mit luoreszenzaktiven Substraten anzupassen. Darauhin wurden 
Enzymbibliotheken aus der REETZ-Gruppe mit insgesamt (ber ŗŖŖŖ Varianten auf ihre 
“ktivität hin untersucht. “ubauend auf den ersten positiven Ergebnissen, wurden zwei 
verschiedene Cumaringer(ste mit analogen Ether-Schuzgruppen versehen, und die 
”ibliotheken wiederum auf aktive Mutanten ǻ„HitsȃǼ durchsucht. Gefundene Hit-Mutanten 
wurden sequenziert und zur “ufreinigung im größeren Maßstab exprimiert. “ufgereinigte 
Enzyme wurden in Hinsicht auf ihre kinetischen Parameter untersucht, wobei theoretische 
”etrachtungen mitels induced it docking und molekulardynamischen Simulationen genuzt 
wurden, um die Einl(sse einzelner veränderter Positionen abzuschäzen.  
Der zweite Teil der Studie beschäftigt sich mit dem Transfer des Demaskierungs-Systems in 
ein biologisches Umfeld. Experimente mit Säugerzellen wurden in Kollaboration mit der 
P“R“K-Gruppe durchgef(hrt. Entweder das aufgereinigte Protein oder die korrespondieren-
de mRN“ wurde mitels kommerziell erhältlicher “genzien transiziert, allerdings mit 
mäßigem Erfolg. Gleichzeitig wurden Micro-Kapseln auf ihre Eignung f(r das vorliegende 
PŚśŖ”Mř-System hin untersucht, und das Enzym wurde daf(r ausgiebigen Stabilitätstests 
unterzogen. Schlussendlich gelang der Transfer des Demaskierungs-Systems in lebende 
E. coli, und damit der ”eweis f(r die generelle Eignung des Systems f(r in vivo 
“nwendungen. 
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ϭ IŶtƌoduĐioŶ     
ϭ.ϭ CheŵiĐal BiologǇ 
The curiosity about our surroundings is the driving force behind all science. People have 
always tried to understand and manipulate their environment for their own advantage, 
creating the technologically advanced society we now live in. With our growing knowledge 
about the intricate interplay of diferent aspects, our tools have to become ever more 
sophisticated to match our increasingly complex questions. This is especially true on the 
frontier of life, where inanimate mater comes together in an elaborate symphony to create 
natureȂs diversity.  
Studies in biochemistry have made great leaps in understanding the involved processes, 
showing us just how complex life is. Countless scientists are working in this ield, and the 
fact that multiple Nobel prizes have been awarded emphasizes their importanceǱ It was 
”ÜCHNER who, in the early ŘŖth century, achieved a breakthrough in this area, when he 
performed cell-free fermentation experiments. Thereafter, studies covered pigments, 
cofactors, vitamins, nucleobases, and their derivatives, before they continued to the isolation, 
crystallization, sequencing, and structural investigation of proteins. Later, manipulation 
techniques like PCR and mutagenesis were devised, allowing researchers to investigate 
entire pathways, involving for example the molecular backgrounds of transcription, protein 
degradation, or the immune system.[ř,Ś]  
Nowadays, the comparably new ield of chemical biology takes up the challenge of creating 
chemical tools and probes for the investigation of biological systems. It connects various 
diferent ields and draws from their expertise, including, but not limited to, chemistry, 
synthetic biology, genetics, structural biology, and the range of newer –omics studies ǻcf. 
Figure ŗ-ŗǼ. This interdisciplinary approach with its combined methods not only allows 
 ϭ    IŶtƌoduĐioŶ  
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sampling vast amounts of data, but also making sense of them and puting them in a larger 
context of interactions between various classes of ǻbioǼmolecules.  
 
Figure ϭ-ϭ.  CheŵiĐal ďiologǇ pƌoǀides the tools Ŷeeded to iŶlueŶĐe aŶd studǇ Đellulaƌ pƌoĐesses, 
ĐoŶŶeĐiŶg ďioĐheŵistƌǇ ǁith ŵaŶǇ otheƌ ďƌaŶĐhes of the life sĐieŶĐes. 
 
ϭ.ϭ.ϭ BiooƌthogoŶalitǇ 
It is advantageous to study and control chemical reactions inside living cells without 
interfering with their native biochemistry, i.e. using bioorthogonal approaches. The term 
ȃbioorthogonalityȄ was coined around the turn of the century in ”ERTOZZIȂS lab, and was 
irst mentioned in literature in ŘŖŖř, kickstarting a new ield of research.[ś] The development 
of autonomous, reliable reactions that can take place inside living cells soon led to a 
multitude of options allowing the temporally or spatially controlled activation, modiication, 
or tracking of molecules.[Ŝ,ŝ] “pplications can be found not only in biochemistry and chemical 
biology, but also in cellular biology ǻe.g. labelling of proteins,[Ş] lipids,[ş] sugars,[ŗŖ] and nucleic 
acids[ŗŗ]Ǽ and medicinal chemistry ǻe.g. activation of inactivated compoundsǼ.[ŗŘ,ŗř] “ versatile 
and probably the most widely used approach for detection, quantiication, and imaging of 
the targeted compounds or structures is the chemical reporter strategy, which relies on a 
two-step mechanism ǻcf. Figure ŗ-ŘǼ. “ cellular target ǻdark green rectangleǼ can be tagged 
using a modiied substrate derivative ǻlight green rectangleǼ, that carries a chemical reporter 
moiety ǻblue circleǼ. In the second step, the reporter is selectively connected to a probe ǻblue 
arcǼ carrying a marker ǻorange starǼ that can be detected, for example using luorescence. 
”oth steps have to selectively react with the intended partners and avoid side reactions with 
ϭ    IŶtƌoduĐioŶ  
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the plethora of biomolecules ǻgray shapesǼ. The range of feasible targets is constantly being 
extended, and methods are continually reined and specialized, optimizing selectivity and 
reliability. The ongoing relevance of the concept is expressed in the recent endeavor initiated 
by a large group of researchers from academia and industry around EDW“RD to create the 
Chemical Probes Portal, an open database listing and annotating chemical probes and their 
respective targets.[ŗŚ,ŗś] 
 
Figure ϭ-Ϯ.  SĐheŵaiĐ ƌepƌeseŶtaioŶ of a ĐheŵiĐal ƌepoƌteƌ stƌategǇ used iŶ ĐheŵiĐal ďiologǇ: ateƌ 
the taƌget ;daƌk gƌeeŶͿ is tagged usiŶg a ƌepoƌteƌ ;ďlueͿ, deteĐioŶ oĐĐuƌs ďǇ fusiŶg the 
ƌepoƌteƌ to a sigŶaliŶg pƌoďe ;oƌaŶgeͿ. Adapted fƌoŵ PRESCHER et al. ǁith peƌŵissioŶ fƌoŵ 
MACMILLAN PUBLISHERS LTD.[ϲ] 
Recent research in the area of bioorthogonal reactions generally has mostly concentrated on 
bond formation rather than cleavage,[ŗŜ] often utilizing metal-induced or metal-catalyzed 
transformations,[ŗŝ,ŗŞ] or click chemistry. The later term has come to describe a family of 
reactions with very speciic properties, mostly resulting in the formation of carbon-
heteroatom bonds. These reactions have to be reliable, versatile, eicient and create no or 
only inconspicuous byproducts.[ŗş] Due to these favorable features, some of them have been 
adapted for applications in biological surroundings.[ŘŖ–Řř] The irst approaches used azide 
groups as biostable handles to introduce functionality, either by ST“UDINGER ligation[ŘŚ] or 
via a modiied version of classical copperǻIǼ-catalyzed HUISGEN cycloadditions.[Řś,ŘŜ] “ 
copper-free version utilizing ring-strain in cyclic alkynes to drive the reaction was developed 
later on.[Řŝ] Great progress has been made since, mastering the art of selectively and rapidly 
coupling compounds with various functionalities, for example allowing the covalent tagging 
of biomolecules in vivo.[ŘŞ,Řş] These strategies peak in the development of mutually 
orthogonal, bioorthogonal reactions allowing the use of multiple tags, probes, or sensors in 
the same system.[řŖ]  
 
ϭ.ϭ.Ϯ CagiŶg 
However, not every problem in chemical biology can be solved by tagging and bond 
formation reactions, so that in some cases bond cleavage can be a beter option - for example 
for compound activation. Caging is one of the most versatile routes for the controlled release 
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of active species, with methods available for various classes of compounds ǻe.g. peptides,[řŗ] 
nucleic acids,[řŘ] or small molecules like drugs or dyes[řř]Ǽ. The term describes the 
modiication of a bioactive or luorogenic compound with a protection group, resulting in a 
temporary loss of function. This allows the caged, i.e. inactivated, compound to reach its 
intended site of action, minimizing unintended interference on the way. Upon arrival at the 
target site, some form of controlled activation mechanism is then required. Classical 
protection groups used in synthetic chemistry often rely on ester or amide bonds, which are 
easily cleaved in biological systems[řŚ] and therefore have limited feasibility for this type of 
biological applications. Consequently it is a more promising approach for the caging of 
desired molecules for in vivo applications to use more inert connection motifs, such as aza or 
ether groups. The caged compound can subsequently be released, with multiple options 
available as a trigger ǻcf. Figure ŗ-řǼ.  
The most widely used approach works by applying light ǻphoto-uncaging, path “Ǽ.[ŗŘ,řś] 
Examples and details of commonly used photocages and their respective advantages have 
been reviewed repeatedly.[řŜ,řŝ] The combination of this method with a luorescent signal 
allows the application for example as probes in chemical biology[řŞ] or as a diagnostic cancer 
marker,[řş] and is extensively used for bioimaging on a par with reversible photoswitches. [ŚŖ] 
However, photo-cleavage often relies on tissue-damaging UV-light and requires the 
operation of a light source, necessarily conining the method to tissue close to the irradiation 
source.[řŝ]  
Chemically induced cleaving reactions ǻpath ”Ǽ on the other hand rely on stoichiometric 
amounts of additional reagents to release the caged group. Unfortunately, they are often not 
reactive or speciic enough and can be toxic. Some major improvements in this regard are the 
recently popular approaches to modify established bioorthogonal reversed DIELS-“LDER 
reactions to trigger the release of a leaving group.[ŗř,Śŗ] Probably the smallest caging group 
described in the literature is an azide moiety, which in a case presented by P“WL“K et al. is 
repurposed from the common click reactions and instead introduced as a cage on cell surface 
proteins to modulate an immune response, activatable by biocompatible reduction.[ŚŘ] “ new 
technique for intracellular deprotection presented by KIM and ”ERTOZZI utilizes small 
molecule boron reagents, which undergo a speciic reaction with N-oxides.[Śř] Derivatives of 
the later do occur naturally in some microbial species, but are absent in most higher 
organisms, rendering them inherently bioorthogonal. 
The third option is shown in path C, activation via catalysis, which relies on the turnover of 
multiple molecules and thus basically constitutes a signal ampliication mechanism. “ 
challenge, especially for conventional metal catalysts, is their often limited eiciency due to 
deactivation of catalysts in physiological environments, although some progress has been 
made in this area.[ŚŚ,Śś] “ more detailed discussion of the general concept of catalysis in vivo is 
given in the next chapter. 
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Figure ϭ-ϯ.  TǇpiĐal uŶĐagiŶg appƌoaĐhes. Cleaǀage of the pƌoteĐioŶ gƌoup ĐaŶ eitheƌ ďe light-
tƌiggeƌed ;AͿ, ĐheŵiĐallǇ iŶduĐed ;BͿ, oƌ faĐilitated ďǇ a ĐatalǇst ;CͿ. The gƌaǇ spheƌes 
ƌepƌeseŶt the site of ataĐhŵeŶt foƌ the Đaged ŵoleĐule, ǁhile R ƌesidues shoǁ ǀaƌiaďle 
posiioŶs foƌ deƌiǀaizaioŶ. Eǆaŵples foƌ eaĐh appƌoaĐh aƌe shoǁŶ ďeloǁ: AͿ CoŵŵoŶlǇ 
used sĐafolds foƌ photo-uŶĐagiŶg ƌeaĐioŶs, as ƌeǀieǁed ďǇ CASEY et al.[ϯϲ] BͿ CheŵiĐallǇ 
iŶduĐed aĐiǀaioŶ ďǇ a ĐliĐk-to-ƌelease appƌoaĐh[ϭϯ,ϰϭ] ;topͿ aŶd N-oǆide/ďoƌoŶ ƌelease 
sǇsteŵ ;ďotoŵͿ.[ϰϯ] CͿ Metal-ŵediated uŶĐagiŶg ƌeaĐioŶs ƌepoƌted iŶ ďiologiĐal 
eŶǀiƌoŶŵeŶts.[ϰϱ] 
The ultimate showcase application of caged compounds is again the successful 
implementation of not only one, but multiple independently controlled release systems in 
the same environment. Reports about this type of orthogonal reactions have been published, 
utilizing photo-uncaging with diferent wavelengths for the selective activation of two 
antibiotics or luorophores.[řř,ŚŜ]  
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ϭ.ϭ.ϯ CatalǇsis iŶ LiǀiŶg SǇsteŵs 
The use of catalyzed reactions has undebatable advantages over their slower counterpart in 
terms of reaction rate. “pplied as a drug, dosages could be cut drastically, thus helping to 
eliminate side efects or toxicity.[Śŝ,ŚŞ] “dditionally, catalysts can increase the selectivity of a 
transformation to convey stereo-information and reduce undesired side products. However, 
the application of metal-based catalysts most often used in conventional organic synthesis is 
impeded in biological systems by the plethora of biomolecules that can interfere with the 
reaction, either by atacking the reactants or by poisoning the catalyst itself.[Śş] Nevertheless, 
this formidable challenge has been addressed in a variety of studies over the last ŗś years, 
achieving some progress in the area, and diferent methods are illustrated in Figure ŗ-ŚǱ One 
approach omits metal-catalysts, and instead relies on cellular DN“ or RN“ oligonucleotides 
to act as a template and thus facilitate the reaction by placing the reactants in close proximity 
ǻpanel “Ǽ.[śŖ] The template can undergo multiple turnovers, thus acting as a signal 
ampliier.[śŗ] Reported reactions cover a wide range, from organocatalytic transformations[śŘ]  
to coupling-driven uncaging reactions, similar to panel ” in Figure ŗ-ř.[śř] Especially redox 
reactions are being investigated for their anti-tumor activity, since cancerous cells show an 
inherently diferent reaction to oxidative and reductive stress and are less able to counteract 
these interferences.[śŚ,śś] “lthough some cases of reductive strategies are reported,[śŜ,śŝ] the 
main approach is to increase levels of reactive oxygen species ǻROSǼ, inducing cell death 
ǻpanel EǼ. In combination with photo-activation, this method has long been used in medicine 
for the treatment of accessible tumors, with the roots dating back to the early ŘŖth century,[śŞ] 
and is now termed photo-dynamic therapy ǻPDTǼ.[śş] The catalyst, in this special case serving 
as a photo-sensitizer, can be based on purely organic scafolds like porphyrins, or transition 
metal complexes.[ŜŖ] 
In fact, due to the familiarity with their design and their broad applicability, most eforts for 
the use of catalyzed reactions in physiological environments are based on metal-derived 
compounds, despite their downsides. Some of them have already been mentioned above, 
with the most common being the bioorthogonal copperǻIǼ-catalyzed HUISGEN cycloaddi- 
tion, [Řś,ŘŜ] but other bond forming reactions as well, which are especially useful for tagging 
biomolecules ǻpanel CǼ.[ŗŞ] The large majority of metal-based catalytic transformations in cells 
is not developed for bioorthogonality, but for the use as catalytic metallodrugs.[Śŝ,Ŝŗ] Their 
profound ability for the catalysis of hydrolysis reactions can be harnessed by ataching 
selective probes for proteins or RN“ sequences, allowing the targeted lysis of intracellular 
compounds ǻpanel ”Ǽ.[ŜŘ,Ŝř] This technique is being investigated to be used against amyloid 
diseases,[ŜŚ] as well as for its antimicrobial activity, opening a gate to the solution of the rising 
bacterial resistance problem.[Ŝś] However, not only deactivation can be achieved by 
hydrolysis, but it is equally feasible to restore functionality upon the removal of a caging 
group ǻpanel DǼǱ proteins[ŜŜ] or small molecules, used for example for DN“ binding[Ŝŝ] or as 
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drugs,[ŗŝ,ŜŞ] can be activated in this manner, and the activity can even be controlled with 
light.[Ŝş] Multiple general or metal speciic reviews on the topic are available,[ŗŞ,Śś,ŝŖ] and 
recently a general method for the evaluation of metal catalysis in living systems was 
reported.[ŝŗ] 
 
Figure ϭ-ϰ.  CatalǇsis iŶ vivo – eǆaŵples foƌ difeƌeŶt appƌoaĐhes. AͿ NuĐleiĐ aĐid teŵplated ƌeaĐioŶs 
use ŶatuƌallǇ oĐĐuƌƌiŶg oligoŵeƌs to faĐilitate ƌeaĐioŶs, eitheƌ foƌ deteĐioŶ oƌ pƌodƌug 
ƌelease; BͿ aƌiiĐial pƌoteases aŶd ŶuĐleases aƌe eƋuipped ǁith a speĐiiĐ ligaŶd, diƌeĐiŶg 
theŵ to theiƌ taƌget, ǁhiĐh ĐaŶ theŶ ďe deaĐiǀated ďǇ hǇdƌolǇsis; CͿ taggiŶg of 
ďioŵoleĐules foƌ theiƌ deteĐioŶ ĐaŶ ďe aĐhieǀed eitheƌ ďǇ usiŶg a speĐiiĐ ligaŶd ǁith a 
ĐliĐk-haŶdle ;letͿ oƌ ďǇ diƌeĐtlǇ iŶtƌoduĐiŶg the haŶdle ǀia ŶoŶ-Ŷatuƌal aŵiŶo aĐids ;ƌightͿ; 
DͿ a ǀaƌietǇ of ŵethods aƌe used foƌ the aĐiǀaioŶ of difeƌeŶt ĐoŵpouŶds, aŶd 
appliĐaioŶs ƌaŶge fƌoŵ seŶsiŶg to pƌodƌug aĐiǀaioŶ; EͿ iŶteƌfeƌiŶg ǁith the ƌedoǆ state 
of Đells ĐaŶ ďe ďeŶeiĐial iŶ aŶi-ĐaŶĐeƌ tƌeatŵeŶts, ǁith the geŶeƌaioŶ of ƌeaĐiǀe oǆǇgeŶ 
speĐies ;ROSͿ as ŵaiŶ appƌoaĐh.  
“n alternative strategy to metal-based catalysts would be the use of a biomolecule, which 
has multiple advantages, especially when working in aqueous media or biosystems. NatureȂs 
biocatalysts – enzymes in most cases, but also catalytically active oligonucleotides – are 
speeding up and controlling almost every reaction in living organisms. Without them, life as 
we know it would not be possible. They are highly selective towards substrates and reaction 
types, and have evolved to be extremely eicient in physiological environments [ŝŘ] that often 
prove detrimental to conventional metal-based catalysts, which are particularly vulnerable 
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towards the thiols ubiquitously present inside cells. Moreover, the use of biopolymers 
consisting of natural building blocks could reduce the risk of the formation of toxic 
degradation products, while addressing performance issues present in metal-dependent 
bioorthogonal uncaging reactions. “t the same time, they can avoid the detrimental 
mutagenic efects in cells and tissues when employing classical deprotection methods based 
on irradiation using UV-light. “nd in fact, oligonucleotides with catalytic activity 
ǻRN“/DN“zymesǼ are easily adjusted for their speciic properties, and already widely 
investigated as selective metal ion sensors or for the recognition of other cofactors.[ŝř] “n 
even wider scope is ofered by enzymes, natureȂs all-purpose workhorses, either in their 
natural form or adapted for speciic applications. “part from our own work,[Ř,ŗ] only one 
bioorthogonal approach has been published so far where an engineered enzyme was used 
for mRN“ modiication, priming them for a subsequent click reaction.[ŝŚ] 
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ϭ.Ϯ EŶzǇŵes iŶ MediĐiŶe aŶd IŶdustƌǇ  
Due to the advantages described above, the use of enzymes in biocatalysis,[ŝś–ŝŝ] and for 
medical applications is rapidly increasing.[ŝŞ] However, it is by no means a new concept to 
use enzymes for our needsǱ Historically probably best known, and still appreciated by many 
today, is rennet, an enzymatic extract from the stomach of ruminants used to make cheese. 
The nature of these powerful tools was not understood for a long time, until P“YEN and 
PERSOZ successfully isolated diastase from malt solution in ŗŞřř, which is able to break down 
starch during the brewing process.[ŝş] It took almost another century until SUMNER was able 
to prove in ŗşŘş on the case of urease that enzymes are ǻusuallyǼ proteins.[ŞŖ,Şŗ] Since then, 
scientists have been tirelessly working on improving the available methods for isolation, 
puriication, and characterization. Structure determination, both by sequencing and 
crystallography, is well established today, so that thousands of enzymes are known. 
Often without us knowing, they are part of our daily lifeǱ breaking down stains as part of 
laundry detergents,[ŞŘ] softening our bread,[Şř] protecting our skin in cosmetics,[ŞŚ] whitening 
our paper,[Şś] or cleaning our waste water.[ŞŜ] Chemical and pharmaceutical industry have 
accepted their superior selectivity over conventional catalysts and use them for particularly 
challenging synthesis steps or sequences in the production of ine chemicals. [ŝś,ŝŜ,Şŝ] “n 
overview of uses in industry is given by “EHLE.[ŞŞ]  
In medicine, freshly prepared ointments from plant and animal mater were used in early 
civilizations, some of which undoubtedly had enzymatic activity. ”ut probably the earliest 
intentional example of an enzyme as a drug is the protecting activity of a parenterally 
administered enzyme against Pneumococcus infections by breaking down their protective 
polysaccharide capsules.[Şş] Following achievements include the treatment of ibrin clots by 
proteolysis with plasmin,[şŖ] the anti-tumor activity of L-asparaginase,[şŗ] and of course 
various replacement therapies for patients with enzyme deiciency conditions,[şŘ] the later of 
which are now so widely applied that most reviews can only cover speciic diseases. [şř–şś] “ 
general overview over the role of enzymes in medical therapy is covered in multiple review 
articles.[ŝŞ,şŜ–şŞ] Examples include the topical application of proteolytic enzymes to burned 
skin, which can be used to facilitate the breakdown of denatured enzymes and thus replace 
traditional mechanical debridement methods.[şş,ŗŖŖ] “nti-cancer eforts focus either on 
depleting the blood stream of nutrients essential for cancer cells,[ŗŖŗ,ŗŖŘ] or removing metabolic 
products of chemotherapy to alleviate side efects.[ŗŖř] Generally, treatment with 
polyethylene-glycol ǻPEGylationǼ has proven beneicial to the pharmacological properties of 
enzymes, prolonging their plasma lifetime and preventing premature lysis by proteases and 
kidney iltration.[ŗŖŚ,ŗŖś]  
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ϭ.Ϯ.ϭ PƌoteiŶ EŶgiŶeeƌiŶg 
Unfortunately, natural enzymes do not always display the necessary traits required for 
selectively catalyzing reactions of non-native substrates, such as enhanced activity, stereo- 
and regioselectivity, and/or thermal or chemical stability, which are desirable for speciic 
applications. ”ut proteins are known to be highly evolvable,[ŗŖŜ] a trait that is harnessed by 
protein engineers to enhance stability towards temperature[ŗŖŝ] or organic solvents,[ŗŖŞ] or to 
control enantio-, stereo- and regioselectivity, as has been shown in lipases, esterases, epoxide 
hydrolases, aldolases, nitrilases, aminotransferases, and oxidases including ”“YER-VILLIGER 
and cytochrome PŚśŖ monooxygenases ǻCYPsǼ.[ŗŖş,ŗŗŖ] 
“s a tool to address these shortcomings, directed evolution ǻcf. Figure ŗ-śǼ has emerged as 
one of the most promising methods in protein engineering.[ŗŖş,ŗŗŗ,ŗŗŘ] It consists of repeated 
cycles of diversity generation by random or focused mutagenesis, which is always followed 
either by screening or selection of the properties to be improved. “fter the screening, 
ǻusuallyǼ the best mutant is isolated, and can be used as a starting point for the next iterative 
round.  
 
Figure ϭ-ϱ.  Iteƌaiǀe ĐǇĐle of diƌeĐted eǀoluioŶ. StaƌiŶg fƌoŵ a paƌeŶt geŶe usuallǇ fouŶd iŶ Ŷatuƌe, 
diǀeƌsitǇ is geŶeƌated ďǇ ŵutageŶesis. The ƌesuliŶg geŶe liďƌaƌǇ is theŶ tƌaŶsfeĐted iŶto a 
host speĐies foƌ eǆpƌessioŶ, iŶ oƌdeƌ to seleĐt oƌ sĐƌeeŶ foƌ the desiƌed tƌait. The ideŶiied 
iŵpƌoǀed ǀaƌiaŶts ĐaŶ theŶ ďe used as staƌiŶg poiŶt foƌ aŶotheƌ iteƌaioŶ, uŶil the 
desiƌed peƌfoƌŵaŶĐe is ƌeaĐhed ďǇ the eǀolǀed pƌoteiŶ. 
”oth a random and a targeted approach provide valuable solutions for diferent problemsǱ 
While directed mutagenesis allows more eicient screening with smaller libraries, the 
introduction of random mutations ǻfor example using error-prone PCRǼ is able to identify 
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new sites with an inluence on performance.[ŗŗř] Recent reviews for the advances of directed 
evolution are regularly reported, for example by L“NE and SEELIG,[ŗŗŘ] or DEN“RD et al.[ŗŗŗ] “n 
increasingly popular approach is the use of uncanonical, or non-natural amino acids, to 
expand natureȂs Řř building blocks to even more functionalities.[ŗŗŚ,ŗŗś] Computational 
methods can support the experimental eforts by either rationalizing the efects observed in 
hit mutants or inding new promising residues. For example, docking studies followed by 
molecular dynamics simulations can ind the optimal position of a given substrate inside an 
enzyme pocket, visualizing interactions with the surrounding side chains and the 
backbone.[ŗŗŜ–ŗŗŞ] “ diferent approach uses the transition state of the conversion instead of 
substrates as a starting point for redesigning enzymes.[ŗŗş] With these methods combined, the 
resulting variants with their new properties have been changing industry and 
medicine,[ŗŖş,ŗŘŖ–ŗŘŘ] for example allowing selective conversions on a large scale, or modifying 
drug propertiesǱ since ŘŖŗř, more than half of the insulin doses prescribed in Germany are 
modiied, either for longer half-life or quicker response.[ŗŘř]  
 
ϭ.Ϯ.Ϯ CǇtoĐhƌoŵes PϰϱϬ 
“mong the best studied enzymes is the large family of cytochrome PŚśŖ enzymes ǻCYPsǼ, 
which get their name from the characteristic absorption band at ŚśŖ nm that stems from the 
CO-complex of their reduced prosthetic heme-b group. They are not only involved in the 
biosynthesis of steroids, terpenes, alkaloids, lavonoids and vitamins, but also responsible for 
the biggest part of drug metabolism in humans and the breakdown of environmental 
pollutants.[ŗŘŚ] Of particular interest to synthetic organic chemistry is their ability to catalyze a 
variety of reactions, including epoxidation of C=C double bonds, N-oxidation, deamination, 
dehalogenation, and N-, O- and S-dealkylation.[ŗŘś] Recently, a PŚśŖ enzyme was found to be 
able to catalyze bimolecular phenol coupling reactions.[ŗŘŜ] The most common CYP-catalyzed 
reactions, however, are C-H activations of spŘ and spř hybridized carbon atoms, leading to 
epoxidation or hydroxylation. They have many applications in the chemical, pharmaceutical 
and environmental sectors,[ŗŘś] biotechnology,[ŗŘŝ–ŗřŖ] and more recently in medicine, e.g. for 
the development of MRI probes ǻmagnetic resonance imagingǼ.[ŗřŗ,ŗřŘ] “cross species, they 
show a surprising degree of structural similarity, especially in the cofactor and substrate 
binding regions, even though overall sequence conservation in outlying regions is low.[ŗřř,ŗřŚ] 
CYPs used to be categorized into two classesǲ while class I depends on an N“DǻPǼH 
ferredoxin reductase as an electron source, class II CYPs partner up with an F“D- and FMN-
containing N“DPH-dependent cytochrome PŚśŖ reductase ǻCPRǼ. However, the continuous 
discovery of diferent redox mechanisms in CYPs showed that these categories are by no 
means suicient, leading to further diferentiation. H“NNEM“NN et al. kept diferences in 
domain topology of the electron shutling mechanism as a criterion, but reined the system to 
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determine ten PŚśŖ classes I-X.[ŗřś] They difer in the reducing cofactor ǻN“DH, N“DPH or 
none at allǼ, in the number of subunits involved ǻup to threeǼ and whether some or all of the 
domains are present as a distinct enzyme or fused together. “nother factor which is not part 
of this classiication scheme is their solubilityǱ while bacterial PŚśŖs are mostly present in the 
cytosol, their eukaryotic counterparts are usually membrane-bound. 
To beter harness the wide reaction space of PŚśŖs, a range of test reactions and activity 
assays have been published. The depletion of the cofactor N“DPH can be directly followed 
photometrically,[ŗřŜ] allowing a good basis for kinetic estimations. For activity screens 
however, this slow progress is not suicient, and TSOTSOU et al. modiied the assay for higher 
throughput in microtiter plates ǻMTPsǼ.[ŗřŝ] Increased sensitivity can be achieved with an 
assay based on the dealkylation of p-nitrophenoxycarboxylic acid derivatives ǻpNC“sǼ, 
under formation of p-nitrophenolate, which can be detected by absorption at ŚŗŖ nm.[ŗřŞ] This 
was also adapted for whole cells, rendering lysis steps obsolete.[ŗřş] For the investigation of 
reactions similar to the ones catalyzed by human PŚśŖs, indole oxidation with indigo 
formation has proven to be a good estimate, allowing a colorimetric read-out of colonies.[ŗŚŖ] 
ICśŖ values for PŚśŖs or inhibitor strength can be investigated using coumarin-based 
luorescence assays.[ŗŚŗ,ŗŚŘ] Fluorescence assays based on the dealkylation of allyloxyresoruin 
allow activity and ainity screenings in MTPs or via continuous-low, but no direct analysis 
of other substrates.[ŗŚř] To determine exact values for turnover or product speciicity, mostly 
chromatographic methods like gas chromatography ǻGCǼ or high performance liquid 
chromatography ǻHPLCǼ are being used.  
 
The Đase of CYPϭϬϮAϭ ;PϰϱϬBMϯͿ 
The irst described PŚśŖ enzyme with fused redox subunits is the lavocytochrome PŚśŖ”Mř 
ǻCYPŗŖŘ“ŗǼ, a self-suicient and soluble faty acid hydroxylase from Bacillus megaterium.[ŗŚŚ] 
This particularly interesting class VIII fusion system carries its own FMN/F“D reductase 
domain,[ŗŚś] and thus only depends on the presence of its cofactors, N“DPH and oxygen.  
”ecause of its solubility and self-suiciency, PŚśŖ”Mř has been intensely studied, and 
recombinant expression was achieved by WEN and FULCO in ŗşŞŝ.[ŗŚŜ] Various eforts over 
the course of almost three decades have shown that it is an immensely valuable and versatile 
candidate for enzyme engineering and directed evolution, yielding highly active and 
selective mutants for diferent applications.[ŗŚŝ] Its similarity to human PŚśŖs also make it a 
valuable tool for medicinal chemists.[ŗŚŞ] General overviews can be found by WHITEHOUSE,[ŗŚş] 
GUENGERICH,[ŗśŖ] REN“ULT,[ŗśŗ] and MCINTOSH.[ŗśŘ]  
Figure ŗ-Ŝ shows a structural model. In its active form, PŚśŖ”Mř is present as a dimer ǻPŚśŖ 
subdomain only, panel “Ǽ.[ŗśř] Since there is no published full structure of all subunits, panel 
”Ǽ shows a potential model of the monomer, which was created by aligning PŚśŖ”Mř and its 
FMN domain with a homologue. Together with its oxidase and FMN/F“D subdomains the 
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monomer amounts to a size of ŗŗş kDa. The narrow connection between FMN and F“D acts 
as a hinge region, allowing the enzyme to change between an open and closed conformation, 
thus enabling electron transfer.[ŗśŚ] 
 
Figure ϭ-ϲ.  Model of PϰϱϬBMϯ, a Đlass VIII oǆidoƌeduĐtase. AͿ DiŵeƌizaioŶ is ŶeĐessaƌǇ foƌ oǆǇgeŶase 
aĐiǀitǇ ;PDB-ID ϭBVY[ϭϱϱ]Ϳ; BͿ PoteŶial ŵodel of the thƌee suďdoŵaiŶs. The PϰϱϬ aŶd FMN 
suďuŶit of BMϯ ;gƌeeŶ aŶd puƌple, ƌespeĐiǀelǇ; PDB-ID ϭBVYͿ ǁeƌe aligŶed ǁith the FAD 
suďdoŵaiŶ of a Ǉeast–huŵaŶ NADPH ĐǇtoĐhƌoŵe PϰϱϬ ƌeduĐtase ;ďlue, PDB-ID ϯFJO[ϭϱϲ]Ϳ 
aloŶg theiƌ FMN doŵaiŶ. RepƌoduĐed iŶ aŶalogǇ to AIGRAIN et al.[ϭϱϰ] 
Tackling the persisting challenge[ŗśŝ] of eiciently controlling selectivity in CYPs, the REETZ 
lab recently reported the regio- and stereoselective hydroxylation of many diverse substrates, 
including small-functionalized molecules,[ŗśŞ] tetralones,[ŗśş] acyloins,[ŗŜŖ] and steroids,[ŗŜŗ,ŗŜŘ] 
while other groups expanded the reaction range to terpenes.[ŗŜř,ŗŜŚ] Since the natively used 
cofactor N“DPH decomposes quickly in aqueous solution and is rather expensive, there are 
eforts towards the development of alternative electron sourcesǱ Changing the recognition 
site towards beter acceptance of N“DH,[ŗŜś] or replacing the reductase domain by 
photoactive metal complexes,[ŗŘş,ŗŜŜ] an organic photosensitizer,[ŗŜŝ] or electrochemical 
reduction,[ŗŜŞ,ŗŜş] are only a few examples. 
 
MeĐhaŶisŵ  
Despite the wide range of transformations they catalyze, the model reaction of PŚśŖ 
oxygenases still is the formal insertion of one oxygen atom into a CH-bond. The overall 
mechanism is shown in Figure ŗ-ŝ. The oxidation process in CYPs occurs at a cysteine-bound 
prosthetic heme group, whose active iron center is present in its low-spin ferric form in the 
resting state of the enzyme ǻŗǼ. Upon binding of the substrate ǻŘǼ, the iron changes from a 
low- to high-spin electronic coniguration, and is subsequently reduced to its ferrous state 
ǻřǼ. The nicotinamide cofactor N“DPH ǻor N“DHǼ is utilized as an electron source. 
Molecular oxygen binds to the iron ǻŚǼ, and undergoes reductive scission. In the process, the 
center is again reduced, and after the uptake of two protons, the oxygen-oxygen bond is 
cleaved. One oxygen atom is released as a water molecule, forming the green ferryl-oxo 
intermediate ȃCompound IȄ ǻŝǼ with its oxidized ironǻIVǼ center. This state responsible for 
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the actual conversion step had long been elusive, and could only be isolated and 
characterized in ŘŖŗŖ by RITTLE and GREEN.[ŗŝŖ] Hydrogen atom transfer from the substrate 
yields Compound II ǻŞǼ, which then transfers its hydroxyl group to the substrate radical in a 
rebound mechanism. Thus, the ferric iron state is regenerated ǻşǼ, allowing the oxidized 
product to dissociate and be replaced by water, returning the enzyme to its resting 
state ǻŗǼ.[ŗŝŗ]  
 
Figure ϭ-ϳ.  CatalǇiĐ ĐǇĐle of ŵoŶo-oǆidaioŶ ďǇ CYPs. The suďstƌate ƌeplaĐes ǁateƌ upoŶ ďiŶdiŶg to 
the aĐiǀe site ǁith its heŵe gƌoup. UŶdeƌ ƌeduĐioŶ ďǇ NADPH, a dioǆǇgeŶ ŵoleĐule is 
Đleaǀed aŶd oŶe atoŵ liďeƌated as ǁateƌ, ǁhile the otheƌ is tƌaŶsfeƌƌed to the suďstƌate iŶ 
a ƌadiĐal ƌeďouŶd ŵeĐhaŶisŵ.  
Three shunt pathways exist, cuting through the catalytic cycle. Two of these undermine the 
eiciency of substrate turnoverǱ a superoxide anion can be released after the irst reduction 
step ǻautooxidation shuntǼ, or Compound I can be reduced, releasing the bound oxygen 
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atom as water ǻoxidase shuntǼ, in both cases without any reaction with the substrate. 
However the third pathway, termed peroxidase shunt, allows to generate compound I 
directly from hydrogen peroxide, without the need for other cofactors. There have even been 
eforts to increase the feasibility of this shunt to completely replace the additional oxidizing 
agent and drive product formation purely with HŘOŘ.[ŗŝŘ]  
 
Figure ϭ-ϴ.  Possiďle eleĐtƌoŶ tƌaŶsfeƌ pathǁaǇs iŶ PϰϱϬBMϯ ďetǁeeŶ ŵoŶoŵeƌs aŶd suďdoŵaiŶs. AͿ 
ĐƌossiŶg ŵoŶoŵeƌs ďetǁeeŶ FMN aŶd PϰϱϬ doŵaiŶs; BͿ ĐƌossiŶg ŵoŶoŵeƌs ďetǁeeŶ FAD 
aŶd FMN doŵaiŶs; CͿ eǆpeƌiŵeŶtal appƌoaĐh foƌ the iŶǀesigaioŶ of the pathǁaǇ usiŶg 
tǁo ŵutaŶts ǁith eitheƌ aŶ iŶaĐiǀated FMN oƌ PϰϱϬ doŵaiŶ. 
The electronic mechanism has long been debated, with three main pathways being discussed 
ǻcf. Figure ŗ-ŞǼǱ The irst is the intra-monomer electron transfer ǻdashed linesǼ, from F“D via 
FMN to hemeǲ but although never fully ruled out, this cannot be the only option, since 
mutants with one inactivated domain ǻFMN or heme, as in case CǼ can regain catalytic 
activity upon co-incubation.[ŗŝř,ŗŝŚ] This left two options to cross between monomers, either 
from FMNŗ to hemeŘ ǻcase “Ǽ, or from F“Dŗ to FMNŘ ǻcase ”Ǽ. Further studies were able to 
show conclusively that the most likely mechanism involves an electron transfer along F“Dŗ-
FMNŗ-hemeŘ ǻcase “Ǽ.[ŗŜś] 
In any case, the transfer across multiple centers requires the orchestrated interaction of 
various sites, making the process vulnerable to side reactions. These leakage or uncoupling 
processes can occur anywhere on the way from the F“D to the heme center, or inside the 
catalytic cycle ǻshunt pathways, see aboveǼ. Since especially mutants are often prone to 
higher leak rates,[ŗŝś] this parameter together with the overall coupling eiciency, are 
important parts of cytochrome characterization and have been intensely studied.[ŗŝŜ] 
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ϭ.ϯ Dƌug DeliǀeƌǇ 
The irst question in drug development is undoubtedly the activity towards the target, 
closely followed by the need to rule out side efects. However, the next important problem to 
be solved is always how to get the drug into the body, and to its site of action. “ lot of drugs 
would pass right through the body if given orally, either without being taken up because of 
low bioavailability or because they are deactivated by digestion. If they do make their way 
into the blood stream, they irst pass through the liver, where most of the enzymes are 
produced that are responsible for the decomposition of complex compounds – PŚśŖs among 
the most important – so that a high percentage of drugs is already inactivated before they 
can reach their target. Depending on where the drugȂs inal site of action is located, there can 
be additional obstacles, for example cell membranes or the blood brain barrier. Some other 
efects have to be considered, even once the drug has successfully entered the bloodstream, 
which can be detrimental for its activity, ranging from kidney iltration, uptake by 
phagocytes, or aggregation with serum proteins, to premature enzymatic degradation.[ŗŝŝ,ŗŝŞ] 
 
Figure ϭ-ϵ.  AspeĐts of dƌug deliǀeƌǇ. AƌouŶd the ĐeŶtƌal aspeĐt of adŵiŶistƌaioŶ, the taƌget issue 
;letͿ, the Ŷatuƌe of the ĐoŵpouŶd ;topͿ aŶd the ŵoleĐulaƌ deliǀeƌǇ sǇsteŵ ;ďotoŵͿ aƌe 
eƋuallǇ iŵpoƌtaŶt foƌ suĐĐessful tƌeatŵeŶt. 
To address these issues in cases where the pure drug is not efective enough, diferent 
methods have been developed to overcome these issues. The ideal delivery system has a 
range of characteristic featuresǱ it has to be stable in dosage form, protect the active 
ingredient until it arrives at the site of action, control localization and release, while 
minimizing toxicity and side efects. “t the same time, it has to be biodegradable, and of 
course should be cheap and easy in its preparation. This important but multi-faceted 
problem is recognized by the scientiic community, and as a result, a vast amount of research 
is being conducted on this ield from very diferent perspectives – chemistry, biology, 
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medicine, pharmacy, physics, or material sciences. For every drug and its purpose, the 
delivery system has to be tailored to suit the particular needs of the aliction and the patient, 
which is the main reason for ever ongoing developments in the area. Reviews covering the 
topic of drug delivery in general are available for example by CROMMELIN,[ŗŝş] M“RTINHO[ŗŞŖ] 
or K“P“RISSIDES.[ŗŞŗ] The most common approaches can be classiied according to diferent 
principles, which are equally important for medical treatment ǻcf. Figure ŗ-şǼ. Most obvious 
for the patient is the mechanism of administration, with diferent options available, 
depending on the targeted tissue ǻe.g. oral, subcutaneous, transdermal, intravenous, 
pulmonary, or intraocularǼ. The chemical nature and molecular weight of the drug has a 
large inluence on stability and distribution in the body – a small organic molecule will 
behave inherently diferent from nucleic acids or a protein. Thus, the packing of the drug on 
a molecular level has to be tailored accordingly, options ranging from pure solutions via 
encapsulation to antibody-tagging. Table ŗ-ŗ gives on overview over diferent methods with 
examples, some of which will be addressed in more detail below. 
 
Taďle ϭ-ϭ.  Oǀeƌǀieǁ aŶd ĐoŵpaƌisoŶ of difeƌeŶt dƌug deliǀeƌǇ ĐoŶĐepts. 
VesiĐle Class/ 
Method Pƌo CoŶ Eǆaŵples RefeƌeŶĐes 
Pƌodƌugs 
speĐiiĐallǇ tailoƌed, 
tuŶiŶg of phǇsiĐo-
ĐheŵiĐal pƌopeƌies 
oŶlǇ suitaďle foƌ sŵall 
ŵoleĐules, usuallǇ less 
staďle thaŶ paƌeŶt 
ĐoŵpouŶds 
AspiƌiŶ, FiŶgoliŵod; 
eŶhaŶĐed soluďilitǇ 
aŶd uptake, eǆtƌa 
fuŶĐioŶs 
CLAS[ϭϴϮ] 
MiĐelles 
iŵpƌoǀed ĐiƌĐulaioŶ 
iŵe, use of EPR efeĐt, 
loǁeƌed toǆiĐitǇ 
suďjeĐt to eƋuiliďƌiuŵ – 
dissoluioŶ of ŵiĐelles, 
iŶteƌaĐioŶ ǁith pƌoteiŶs 
Đis-PlaiŶ NISHIYAMA[ϭϴϯ] 
Liposoŵes 
tuŶaďle phǇsiĐo-
ĐheŵiĐal pƌopeƌies, 
fuŶĐioŶalitǇ, Đheap 
loǁ eŶĐapsulated load, 
iŶstaďilitǇ iŶ 
ďloodstƌeaŵ, ďuƌst 
ƌelease, side efeĐts 
siRNA deliǀeƌǇ, 
ƌesuliŶg iŶ hepaiĐ 
geŶe sileŶĐiŶg 
SEMPLE[ϭϴϰ] 
PolǇŵeƌiĐ 
NaŶopaƌiĐles 
tuŶaďle, loǁ iŶteƌ-
aĐioŶ ǁith pƌoteiŶs, 
pƌoteĐioŶ of Đaƌgo 
sloǁ ďiodegƌadaioŶ 
ĐǇtostaiĐ ageŶt 
ViŶoƌelďiŶe agaiŶst 
ďƌeast ĐaŶĐeƌ 
BAHADORI[ϭϴϱ] 
PolǇeleĐtƌolǇte 
Capsules 
tuŶaďle, easǇ addiioŶ 
of fuŶĐioŶal eleŵeŶts 
foƌ taƌgeiŶg oƌ ƌelease 
ĐoŶtƌol 
toǆiĐitǇ, loǁ 
ďioĐoŵpaiďilitǇ/ 
degƌadaďilitǇ, pƌoteiŶ 
iŶteƌaĐioŶ 
aŶigeŶ deliǀeƌǇ DE KOKER[ϭϴϲ] 
Viƌal VeĐtoƌs 
self-asseŵďlǇ, 
difeƌeŶtlǇ sized 
paĐkiŶg ŵoleĐules, 
eǀolǀed foƌ deliǀeƌǇ 
iŵŵuŶe ƌeaĐioŶ 
depeŶdiŶg oŶ eǆpƌessed 
aŶigeŶs 
deliǀeƌǇ of a ziŶĐ 
phthaloĐǇaŶiŶe foƌ PDT MA
[ϭϴϳ] 
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ϭ.ϯ.ϭ Pƌodƌugs 
The most straightforward way to implement improvements to a drug, from a chemistȁs point 
of view, is to modify the actual drug on a molecular level, creating a prodrug which is 
metabolically converted into its active form by the body itself, by either ataching a caging 
group or using a precursor compound. The prodrug strategy is quite common, with a market 
share of ŗś% in ŘŖŖş,[ŗŞŞ] since it allows to improve a wide array of properties. The following 
examples ǻcf. Scheme ŗ-ŗǼ are only a small glance at the available range of options, but a 
recent comprehensive review was published by CL“S et al.[ŗŞŘ]  
 
SĐheme ϭ-ϭ.  Eǆaŵples foƌ pƌodƌugs ǁith difeƌeŶt ĐhaŶges to ĐƌuĐial paƌaŵeteƌs. EŶhaŶĐed ŵoieies 
Đoŵpaƌed to theiƌ paƌeŶt ĐoŵpouŶds aƌe highlighted. 
“ major issue to be addressed is often solubility or permeability, as in the case of Ceftaroline 
fosamil, an antibiotic against resistant dermal infections.[ŗŞş]  Fingolimod was adapted to be 
activated by the body instead of sufering inactivation, and alleviates multiple sclerosis upon 
phosphorylation.[ŗşŖ] Gabapentin enacarbil, prescribed against restless leg syndrome, was 
optimized for uptake by directly addressing transporters.[ŗşŗ] Even targeting to tissues is 
possible at this level, by tailoring metabolic mechanisms as with acyl esters of Ganciclovir, 
which are an ophthalmic antiviral agent. Probably the most common prodrug, and a 
compound that seldom comes to mind, is Aspirin, which adds a secondary function with an 
additional groupǱ Salicylate by itself only has an analgesic efect. ”ut the common derivative 
is a lot more potent, adding anti-inlammatory and antipyretic properties. It can covalently 
transfer an acetyl residue to cyclooxygenase ǻCOXǼ, which is used for prostaglandin 
biosynthesis, thus irreversibly inhibiting the enzyme, and releasing salicylate in the 
process.[ŗşŘ] 
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ϭ.ϯ.Ϯ NaŶopaƌiĐles 
However, the efect of a small side chain can diminish when added to a larger drug. For this 
reason, larger packaging systems based on nanoparticles are being developed.  
The term covers a large family of complex structures ǻcf. Figure ŗ-ŗŖǼ, and basically the only 
aspect they have in common is their size, which lies between ŗ and ŗŖŖ nm. The simplest 
ones are inorganic nanoparticles, small spheres of uniform composition of metals, salts or 
silica. More elaborate versions include deined alloys or core-shell structures. Nanoparticles 
made from lipids can have two major shapes, depending on the synthesis conditionsǱ single-
layered micelles and double-layered liposomes. If polymers are used, especially in the case of 
block-copolymers, complex formations can be achieved through diferences in 
hydrophobicity. Hollow structures or spheres of polymer matrix, in which drugs can be 
embedded, or also rod-like shapes, are possible. Polyelectrolytes can be used to create 
layered hollow capsules, which are easily modiied by embedding further functional groups 
inside the outer membrane. “n especially versatile material is carbon, which can form 
diferent ordered structures in addition to spherical nanoparticles, like tubes, cones, or 
fullerenes. “dopted from nature are virus particles, which typically consist of several 
hundreds to thousands of protein molecules that self-assemble to form a hollow scafold 
packaging the viral nucleic acid. These can be emptied and used to deliver various cargoes. 
“ll of these can be tuned by composition and synthesis conditions, or be modiied 
afterwards by ataching functional groups or ligands to their surface. Hybrid particles from 
diferent classes can also be formed, often with a layered structure. Due to the immensely 
active research in the ield of applying nanoparticles for medical uses, a large number of 
review articles on the topic is published every year. Recent examples have been published by 
COOPER,[ŗşř] SUN[ŗşŚ] or LEE.[ŗşś] 
The simplest nanoparticles that can be used for drug delivery purposes are micelles, which 
consist of a single lipid layer and can keep hydrophobic molecules inside. In one example, 
cis-Platin loaded micelles showed longer circulation in blood compared with the free drug, 
and improved accumulation in the tumor when tested on mice with a human lung cancer 
xenograft.[ŗŞř] “ bit larger, but made from similar compounds, are liposomes. They are 
already quite common and approved for various treatments.[ŗşŜ] “n example of a very 
successful application of liposomes is the stable nucleic acid lipid particle ǻSN“LPǼ, which 
can for example be used to deliver strands of small interfering RN“s ǻsiRN“Ǽ, with a speciic 
sequence designed to silence a liver gene.[ŗŞŚ] Instead of lipids, larger constructs like polymers 
can be used for self-assembling nanoparticles. Since there is a plethora of monomers to 
choose from, polymeric particles are easily tunable and have been used for a wide range of 
drug types, from DN“ to metal complexes. In comparison with liposomes, they are more 
stable and not in equilibrium with monomers, which makes it less likely for them to interact 
with plasma proteins while giving them an even longer half-life. Their dense packing also 
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protects their cargo against outer inluences like changes of pH value or reactive oxygen 
species. Their long half-life can pose problems in terms of biodegradability, but tailored 
polymers are already addressing this issue.[ŗşŝ] Vinorelbine, an anti-mitotic chemotherapy 
drug that is used against some types of cancer, showed improved ICśŖ values in a polymer 
formulation.[ŗŞś] Charged polyelectrolytes can be used in addition to neutral polymers. They 
are wrapped around a template, layer-by-layer with opposite charges, before the core is 
dissolved. The choice of electrolytes determines the properties, but other modiications can 
be introduced into the layers and add diferent functions. Unfortunately, their surface charge 
can put them in danger of interacting with serum proteins.[ŗşŞ] They have been used to 
deliver antigens for vaccination to dendritic cells.[ŗŞŜ]  
 
Figure ϭ-ϭϬ.  ClassiiĐaioŶ of ŶaŶopaƌiĐles ďased oŶ theiƌ stƌuĐtuƌe aŶd ŵateƌials. 
 
“s always in science, nature already had the idea of using nanoparticles for cellular delivery 
long before us – we call them viruses. They have been shown to allow dissassembly by pH 
changes, emptying of the original cargo, and closing them again around other compounds, 
like hydrophobic drugs or oligonucleotides. For example, a zinc phthalocyanine was packed 
inside, which generates reactive oxygen species upon irradiation.[ŗŞŝ]  
The delivery of proteins and enzymes is an especially formidable challenge, due to the size 
and various sensitivity issues. However, various approaches have been reported, including 
chitosan-[ŗşş] or silica nanoparticles[ŘŖŖ], modiied nanocapsules,[ŘŖŗ] or again virus-based 
methods.[ŘŖŘ] Conjugation to polymers has been suggested to allow oral application of certain 
enzymes.[ŘŖř]. “ recent review for therapeutic delivery focusing on protein-based 
nanoparticles was published by HERRER“ ESTR“D“ et al.[ŘŖŚ] 
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ϭ.ϯ.ϯ TaƌgeiŶg  
Targeting a drug to its site of action is not a new concept – it dates back to the early ŘŖth 
century, when P“UL EHRLICH managed to develop a cure for syphilis that selectively 
atacked Treponema pallidum inside its human hostǱ[ŘŖś] Salvarsan was the irst chemical 
compound rationally selected by screening and chosen for the treatment of a speciic 
pathogen. His dream was what he called Zauberkugel ǻmagic bulletǼ in reference to an opera, 
where a man makes a pact with the devil for a bullet that will automatically ind its target, so 
he could win his task and marry his bride. EHRLICH wanted the same for his researchǱ to ind 
one treatment that could selectively kill all pathogens without having any side efects. Even 
today, it does not seem likely that this will ever be possible, but progress has been made with 
selectively targeting certain tissues by ataching ligands to the drug or a vesicle that can be 
recognized by certain cells. Targeting not only to the right tissue but also to the right 
compartments inside cells is crucial for the activity of the treatment ǻcf. Figure ŗ-ŗŗǼ.  
 
Figure ϭ-ϭϭ.  SuďĐellulaƌ taƌgets iŶ a eukaƌǇoiĐ Đell. 
“n acid-labile drug for example will be degraded rapidly if it is delivered to the lysosome, 
and a transcriptional inhibitor cannot fulil its task if it does not reach the nucleus. For this 
reason, it depends again on the mechanism of action and the nature of the drug to determine 
which kind of targeted delivery should be chosen. 
“ lot of this research is being conducted with regard to cancer, which is the number Ř death 
cause in developed countries, second only to heart diseases. The special properties of vessels 
nourishing tumors are very useful, opening a door for medical chemistsǱ Tumors and also 
inlamed tissue often show an unnaturally high permeability of the vasculature. 
Macromolecular drugs with a long circulating half-life can accumulate here, depending on 
the biophysicochemical properties. Especially tumors often lack functional lymphatic 
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drainage, so that once arrived, the macromolecules will stay in the tissue for prolonged 
times. This is called the enhanced permeability and retention efect, short EPR.[ŗŝŞ,ŘŖŜ] This so-
called passive targeting relies on the native characteristics of the target tissue to accumulate 
the drug. “ctive targeting, on the contrary, adds a structure to the compound or delivery 
vesicle that can only be recognized by certain cells through selective interaction with 
receptors, and thus enhances the uptake. This can only be achieved after the compound has 
reached the tissue in question. ”oth methods can be beautifully combined, especially since 
the modiication of nanoparticles with their modular build is quite easy. Review articles have 
been published by ”ERTR“ND,[ŘŖŝ] “RI“S,[ŘŖŞ] or N“R“NG.[ŘŖş] Table ŗ-Ř gives an overview over 
diferent methods.  
 
Taďle ϭ-Ϯ.  Oǀeƌǀieǁ of taƌgeiŶg ŵethods aŶd eǆaŵples foƌ theiƌ appliĐaioŶ. 
LigaŶd 
Class/ 
Method 
Pƌo CoŶ Eǆaŵple RefeƌeŶĐes 
Sŵall 
MoleĐules sŵall, Đheap, ƌoďust litle speĐiiĐitǇ 
folate-ŵediated deliǀeƌǇ 
of aŶiĐaŶĐeƌ dƌugs LICCIARDI
[ϮϭϬ] 
MoŶoĐloŶal 
AŶiďodies 
;MaďͿ 
high speĐiiĐitǇ 
laƌge, Đoŵpleǆ, 
eǆpeŶsiǀe, shoƌt half-
life, IŵŵuŶe ƌeaĐioŶs 
possiďle 
aŶiďodǇ dƌug 
ĐoŶjugates alƌeadǇ used 
iŶ ŵediĐiŶe 
FIRER[Ϯϭϭ] 
Pepides/ 
PƌoteiŶs 
speĐiiĐ, sŵall, loǁ 
iŵŵuŶogeŶiĐitǇ, staďle, 
easǇ sǇŶthesis, liďƌaƌǇ 
teĐhŶiƋues estaďlished 
possiďle iŶteƌaĐioŶs 
ǁith otheƌ pƌoteiŶs 
tƌaŶsfeƌƌiŶ-liŶked 
DoǆoƌuďiĐiŶ ŁUBGAN[ϮϭϮ] 
Aptaŵeƌs 
seleĐiǀe, tailoƌed ;SELEXͿ, 
suitaďle foƌ all sizes of 
taƌgets, easǇ sǇŶthesis aŶd 
ŵodiiĐaioŶ, ƌapid issue 
peŶetƌaioŶ 
degƌadaďle ďǇ 
RNases  aŶd DNases  
;ĐaŶ ďe oǀeƌĐoŵe ǁith 
eǆpaŶded alphaďet  
-> toǆiĐitǇ?Ϳ 
aptaŵeƌs ďiŶdiŶg 
thƌoŵďiŶe, ďioiŶ, 
ĐoĐaiŶe 
NIX[Ϯϭϯ] 
NEVES[Ϯϭϰ] 
LONG[Ϯϭϱ] 
ReŵotelǇ 
CoŶtƌolled 
SǇsteŵs 
spaial aŶd/oƌ teŵpoƌal 
ĐoŶtƌol, ŵoŶitoƌiŶg, 
adapiǀitǇ to situaioŶ 
eǆpeŶsiǀe eƋuipŵeŶt foƌ 
tƌeatŵeŶt, ĐoŶiŶed to 
ŵagŶeiĐ ield shape 
ŵagŶeiĐ ŶaŶopaƌiĐles, 
light tƌiggeƌed ƌelease 
DEL PINO[Ϯϭϲ] 
OCHS[Ϯϭϳ] 
 
Folic acid for example is a water soluble vitamin, which is essential for nucleotide 
biosynthesis and one-electron transfer reactions. For this reason, the corresponding folate 
receptor is highly overexpressed in many malignant tissues. The receptor keeps its high 
ainity for it even after derivatization via its ·-carboxylic acid group and folate can thus be 
used to target these tissues. LICCI“RDI et al. reported the development of a formulation to 
deliver hydrophobic antitumor drugs bound in polymeric nanoparticles.[ŘŗŖ] One efect of 
ϭ    IŶtƌoduĐioŶ  
_________________________________________________ 
 
 
 
| Ϯϯ 
folate as a targeting ligand is the subcellular adressation to a recycling center instead of a 
lysosome, which reduces the risk of premature degradation of the active compound. 
“nother class with higher molecular weight are antibodies – they have been used as drugs 
on their own for some decades, but they are also valuable as targeting agents, and some 
formulations are already in use or in clinical studies.[Řŗŗ] The problem is that they are complex 
and expensive, show a short half-life, and sometimes lead to immune reactions.[ŘŗŞ] For this 
reason, antibody fragments are studied, but other proteins and peptides are also promising 
possibilities.  
“ diferent, but highly speciic class of compounds are aptamers. They are either DN“- or 
RN“-oliconucleotides, which fold into unique conformations depending on their sequence, 
and can be tailored to selectively identify almost any compound, from small molecules to 
large proteins.[Řŗř–Řŗś] “n important tool for their development is called SELEX ǻsystematic 
evolution of ligands by exponential enrichmentǼ, a screening technique that depends on 
iterations of ampliication from a large combinatorial library.[Řŗş] More than ŘŖŖ aptamers 
have already been isolated and can be used as targeting ligands in nanoparticle drug 
delivery. The implications for chemical biology of aptamers in general and this technique in 
particular have been pointed out repeatedly.[ŘŘŖ,ŘŘŗ] 
Not quite drug-targeting in the sense used above, but too important to leave unmentioned, 
are so-called gene-targeting techniquesǱ 
“ntisense oligonucleotides[ŘŘŘ,ŘŘř] or siRN“s[ŘŘŚ] ǻas briely mentioned aboveǼ can be used to 
regulate protein expression by either directly blocking mRN“s or recruiting cell-internal 
degradation machinery. “ recent comprehensive review on the topic covering current 
clinical developments was published by MCCLOREY and WOOD.[ŘŘś]  
The very promising, more radical gene-targeting technique CRISPR/Cas has been developed 
recently, which allows the introduction of stable, heritable changes into an organismȂs 
genome.[ŘŘŜ] Originally, the mechanism is used as a defense strategy against viral DN“, 
providing bacteria with acquired immunity. The process is based on programmable 
nucleases like Casş, which rely on CRISPR RN“s ǻclustered regularly interspaced short 
palindromic repeatsǼ to guide them to their target sequence. Modifying these guide-RN“s 
allows the targeted exchange of a sequence in any genomic location, resulting in a versatile 
gene editing method.[ŘŘŝ] With this unique ability to permanently alter genes in a living 
organism, potential cures for genetic diseases may soon be within reach, although further 
research and ethical debates are irst necessary. “n international summit of leading scientists 
was held in late ŘŖŗś, with formal ethical guidelines to be expected in ŘŖŗŜ.[ŘŘŞ] In the 
meantime, research on the topic is moving fast, and a large number of current reviews can be 
found across the life sciences. General overviews were published for example by DOUDN“ & 
CH“PENTIER[ŘŘş] or HSU et al.[ŘřŖ] 
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“part from the last cases, these are all possible ways to atach some type of ligand to the 
drug or the vesicle, so that it might arrive at the right place. The other option is external 
control, where the physician can choose where to deliver the drug inside the body and at 
what time to release it. “n interesting approach is the use of magnetic nanoparticles, which 
can be steered by an external magnetic ield. In a report by DEL PINO et al., magnetic 
nanoparticles were loaded with siRN“ for gene silencing, and added to a low reactor with 
cultured GFP-expressing HeLa cells.[ŘŗŜ] When a magnet was brought close to the setup, the 
particles accumulated there, and caused only cells in proximity to shut down their GFP 
synthesis. 
In a diferent strategy, light can be used to trigger the release of cargo. For this application, 
gold nanoparticles are embedded in the shell of polyelectrolyte capsules. They can be excited 
by IR light of a certain wavelength, and the plasmonic vibrations of the particles will then 
heat the shell in a sharply deined area, breaking the capsule and releasing its content. This 
has been demonstrated by P“R“KȂS group, who showed that they can open two diferent 
kinds of capsules sequentially, releasing an enzyme and its substrate and follow the reaction 
by luorescence microcopy.[Řŗŝ] Since in photodynamic therapy, irradiation is already used 
routinely, it would be comparatively easy to implement this kind of reaction in everyday 
treatments. 
With ever more methods being developed, there are virtually no limits on the possible 
delivery and targeting combinations that can be developed from the diferent approaches 
mentioned above, all catering to diferent speciic aspects of the cargo in question. “ general 
overview on active drug release systems was published by KIRYUKHIN et al.,[Řřŗ] while WEISER 
et al. are focusing on limitations and models of the ield.[ŘřŘ]  
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Ϯ OďjeĐiǀe     
This thesis focuses on the development of an enzyme-based, catalytic bioorthogonal system 
for the activation of caged compounds in vivo, using a modular toolbox ǻcf. Figure Ř-ŗǼǱ at the 
core of the concept are small-molecules ǻe.g. dyes, probes or pro-drugsǼ that can be 
inactivated by caging with a tailored protection group ǻ“Ǽ. These will be activated using a 
catalyst ǻ”Ǽ, which we intend to develop for the eicient turnover in a physiological 
environment.  
Ultimately, we envision to establish a targeted delivery system ǻCǼ as a carrier of the catalyst 
to its intended site of action, so that the method can be used within living cells or organisms. 
This endeavor can be split into three separate steps, which are described in detail below. 
 
Figure Ϯ-ϭ.  CoŶĐept of the ďiooƌthogoŶal eŶzǇŵaiĐ aĐiǀaioŶ of Đaged ĐoŵpouŶds. The suďstƌate AͿ 
is aĐiǀated ďǇ uŶĐagiŶg, a ƌeaĐioŶ ǁhiĐh is ĐatalǇzed ďǇ aŶ eŶgiŶeeƌed eŶzǇŵe BͿ. 
DeliǀeƌǇ sǇsteŵ CͿ ďƌiŶgs the ĐatalǇst iŶside the Đell to its iŶteŶded site of aĐioŶ. 
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Initially, protection groups have to be identiied, ideally featuring 
bioorthogonality, which means that the protection group is 
completely stable in the biological environment and is cleaved 
eiciently and selectively solely by the engineered enzyme of 
choice. We chose diferent ether groups as alcohol protection 
groups, since they are particularly stable under physiological 
conditions, but can be cleaved by some family members of 
cytochrome PŚśŖ monooxygenases ǻcf. Figure Ř-ŘǼ. “n adjacent 
methylene group of the substrate is subjected to oxygen insertion, 
yielding an intermediate hemiacetal. This chemical species is hydrolytically unstable and 
undergoes spontaneous decomposition in aqueous media, liberating the reactivated target 
molecule R-OH, which carries a free hydroxyl group and exhibits for example luorescence 
and/or bioactivity ǻorangeǼ. The protecting moiety ǻPG, blueǼ is released with an aldehyde 
functional group.  
 
Figure Ϯ-Ϯ.  MeĐhaŶisŵ of the etheƌ-depƌoteĐioŶ ƌeaĐioŶ ĐatalǇzed ďǇ PϰϱϬ ŵutaŶts. The iŶseƌioŶ of 
a siŶgle oǆǇgeŶ atoŵ at the ŵethǇleŶe gƌoup Đƌeates aŶ uŶstaďle heŵi-aĐetal, ǁhiĐh iŶ 
tuƌŶ uŶdeƌgoes spoŶtaŶeous hǇdƌolǇsis iŶ aƋueous ŵedia. 
Choosing the right substituents for the protection group, we hypothesize that they are not 
recognized as substrates by natural enzymes but only by engineered CYPs. To further 
minimize the efort and simplify product analysis, a direct luorescence read-out will be 
used. Caged luorophores will be synthesized, using diferent protection groups, and these 
will be tested as substrates for the enzyme variants.  
 
Given the performance issues typically observed in 
chemically or light-induced uncaging reactions, 
[ŗŞ,řŝ,Śś] our goal is to use an engineered 
ȃbioorthogonal enzymeȄ instead, to keep any 
interference with the cellular environment to a 
minimum. For the development of the biocatalyst, a collaboration with the REETZ lab with 
their long expertise in protein engineering provides the necessary knowledge. The creation 
of mutant libraries by directed evolution can be achieved much faster now than only a few 
years ago, due to advances in methodologies[ŗŜŘ] and systematic reduction of unnecessary 
work, for example by using reduced alphabets.[ŗŗŖ] Nevertheless, it is in everybodyȂs interest 
to get as much as possible out of the work involved in the creation of libraries and 
collections. Our plan, therefore, is to screen already existing libraries of evolved PŚśŖ”Mř 
variants for our diferent, formerly unintended application. This allows the reduction of both 
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time and money spent, especially since in the case of collections statistically occurring 
duplicates are already ruled out.  
 
Once the deprotection system is working, 
we plan to implement a microparticle-based 
delivery system in collaboration with the 
P“R“K lab. “ range of examples for protein 
delivery to mammalian cells exist,[Řřř–Řřś] and 
OCHS et al. have previously published 
examples of encapsulation and triggered release.[Řŗŝ] The modular build of these capsules 
readily allows the ine-tuning of their properties. The stability of the biocatalyst under 
diferent conditions will be investigated, so that the delivery system can be adapted to its 
needs. 
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ϯ Results aŶd DisĐussioŶ   
ϯ.ϭ Suďstƌate SǇŶthesis 
For proof-of-principle studies, the well-known luorescent dye luorescein ǻŗǼ was used as 
parent compound for the design of suitable caged substrates to be deprotected by PŚśŖ”Mř 
mutants. 
In solution, luorescein is present as a complex mixture of seven prototropic forms. [ŘřŜ] “t pH 
values around ř, the non-luorescent spiro-lactone form is most abundant ǻleft in Scheme 
ř-ŗǼ, while at higher pH values above ŝ the highly luorescent dianion is the only species 
ǻrightǼ. The compound can be ixed in its spiro form by alkylation of both hydroxyl groups, 
thus suppressing luorescence.  
 
SĐheme ϯ-ϭ.  pH-DepeŶdeŶt eƋuiliďƌiuŵ ďetǁeeŶ the Đoloƌless spiƌo-laĐtoŶe ;letͿ aŶd the luoƌesĐeŶt 
diaŶioŶiĐ speĐies ;ƌightͿ of luoƌesĐeiŶ. AlkǇlaioŶ of the hǇdƌoǆǇl gƌoups ĐaŶ loĐk the 
ĐoŵpouŶd iŶ its spiƌo foƌŵ, thus suppƌessiŶg luoƌesĐeŶĐe. 
The choice of protection groups is crucial to the success of the concept, so a small selection of 
diferent options was chosen as a starting pointǱ allyl and propargyl, since similar positions 
are known to be favored in hydroxylation reactions by PŚśŖ”Mř but not by other 
cytochromes.[Řřŝ–Řřş] “lkynes are also known to act as suicide inhibitors on some PŚśŖs,[ŘŚŖ,ŘŚŗ] 
which could help to put higher demands on the enzyme, thus reducing the risk of uncaging 
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by natural variants. Following a recent study by RUFF et al. who used coumarin derivatives 
as PŚśŖ probes,[ŘŚŘ] benzyl was selected as a third alternative.  
Fluorescein derivatives were obtained via a WILLI“MSON ether synthesis, following a 
protocol by R“J“SEK“R et al.[ŘŚř] Reaction conditions are shown in Scheme ř-ŘǱ First, the 
luorophore was deprotonated with potassium carbonate in dimethyl formamide ǻDMFǼ, 
before a primary alkyl bromide carrying the protection group was added to the reaction 
mixture to yield the desired ether via an SNŘ reaction in moderate yields. Enough substrate 
for the following screening procedures was obtained, so that no optimization of the synthesis 
was performed.  
 
SĐheme ϯ-Ϯ.  SǇŶthesis of luoƌesĐeiŶ dietheƌs ϭa-ϭĐ ǀia WILLIAMSON etheƌ sǇŶthesis. Ateƌ depƌotoŶaioŶ 
ǁith ĐaƌďoŶate, the hǇdƌoǆǇl gƌoups aƌe Đoupled to the ĐoƌƌespoŶdiŶg ďƌoŵide iŶ aŶ SNϮ 
ƌeaĐioŶ. IŶ the Đase of the pƌopaƌgǇl suďsitueŶt, side pƌoduĐts ϭa’ aŶd ϭa’’ of the 
alkǇlaioŶ ƌeaĐioŶ ǁeƌe oďseƌǀed. 
In the case of the propargyl caging group, side products were observed, which can be 
atributed to the reaction with only one equivalent of bromide resulting in the formation of 
the corresponding mono-ether, and the reaction of the acid moiety instead of one hydroxyl 
group, leading to the ether-ester derivative. In contrast to the colorless diether, both 
byproducts are colored and show luorescence, albeit at lower intensity than the parent 
compound. Derivatives can readily be separated by lash column chromatography over 
silica.   
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ϯ.Ϯ SĐƌeeŶiŶg Method  
ϯ.Ϯ.ϭ CoŶĐept 
The screening method was adapted for analysis by luorescence from known protocols. [ŗŜŗ] 
For the substrate reaction, a cofactor recycling system is employed, generating N“DPH in 
situ from N“DP+, with glucose dehydrogenase ǻGDHǼ as a catalyst and glucose as reducing 
agent, as shown in Figure ř-ŗ.[ŘŚŚ] Not only does this routine lower the cost by preventing the 
need to handle the unstable and expensive compound N“DPH, but this system also ensures 
a continuous supply of the cofactor in the reaction mix, allowing higher overall turnover and 
increased signal intensities.  
 
Figure ϯ-ϭ.  CofaĐtoƌ ƌeĐǇĐliŶg sǇsteŵ foƌ the iŶ situ geŶeƌaioŶ of NADPH, foƌ PϰϱϬBMϯ-ĐatalǇzed 
depƌoteĐioŶ ƌeaĐioŶs. NADP+ is ĐoŶǀeƌted to NADPH ďǇ GDH, uŶdeƌ oǆidaioŶ of 
D-gluĐose. The ĐofaĐtoƌ ĐaŶ theŶ ďe used ďǇ PϰϱϬBMϯ foƌ the hǇdƌoǆǇlaioŶ of suďstƌates. 
Changing the analysis method from chromatography to luorometry in this case highly 
reduces cost and workload of the screening, since time-consuming steps such as extraction, 
iltration and chromatographic separation are replaced by simply transferring the reaction 
mix into a black lat-botom şŜ-well microtiter plate ǻMTPǼ and measuring either spectra or 
single-point results. To ind the best conditions for analysis, emission and excitation spectra 
of the parent compound were measured, maxima determined and a suitable cut-of ilter 
identiied. These setings were used in all following experiments, and are shown in Table ś-ŗ. 
To identify the most suitable working concentrations of enzyme and substrates, test reactions 
were carried out on substrates ŗa-c with ŗŗ puriied mutants ǻincluding the wild type, wtǼ 
and lysates of a small collection containing řŘ variants from a diferent project, which were 
available at the REETZ lab ǻFigure ř-Ř, mutant names are either derived from their changed 
amino acid sites or are numbered according to their original project IDǼ. First, enzyme 
concentrations of ŗŖ µM and ŗŖŖ nM were tested at substrate concentrations of ŗ mM and 
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ŗŖ µM. These irst tests showed that, on one hand, solubility of the substrate was an issue due 
to precipitation at ŗ mM, limiting working concentrations to ŗŖŖ µM, and on the other hand 
that it was not necessary to run reactions at high enzyme concentrations. Transferred to 
lysate reactions and tested on the small one-plate collection, this allows a ŗǱŗŖ dilution of 
lysate and thus the screening of multiple substrates from one batch. Immediately, the 
prevalence of derivative ŗa becomes apparent, especially in the more active mutants. 
 
Figure ϯ-Ϯ.  Results of the pƌe-sĐƌeeŶ of luoƌesĐeiŶ deƌiǀaiǀes ϭa-Đ usiŶg ϭϭ puƌiied eŶzǇŵes at 
ϭϬϬ ŶM ;let, ϭϬ µM suďstƌateͿ aŶd a sŵall test ĐolleĐioŶ of ϯϮ ǀaƌiaŶts ;ƌight, lǇsate 
ƌeaĐioŶ of ϭϬϬ µM suďstƌateͿ. Top paŶels shoǁ oǀeƌall iŶteŶsitǇ, ďotoŵ paŶels illustƌate 
ƌelaiǀe suďstƌate seleĐiǀitǇ. ReaĐioŶs ǁeƌe Đaƌƌied out iŶ Bufeƌ I folloǁiŶg staŶdaƌd 
ĐoŶdiioŶs. 
This optimized procedure not only saves time, but also makes the comparison of results 
obtained from the same batch much more reliable, since errors due to changing levels in 
protein expression are eliminated. “dditionally, the deprotection reaction is extremely fast, 
reducing reaction times to şŖ min instead of the ŘŚ h often applied in PŚśŖ”Mř reactions. With 
shorter incubation times, volume changes due to evaporation of the bufer are minimized, 
again leading to lower errors in the screening process.  
 
Figure ϯ-ϯ.  SĐheŵaiĐ ƌepƌeseŶtaioŶ of the opiŵized sĐƌeeŶiŶg pƌoĐess, fƌoŵ glǇĐeƌol stoĐk to 
suďstƌate ƌeaĐioŶ. No fuƌtheƌ ǁoƌkup is ŶeĐessaƌǇ ďefoƌe luoƌoŵetƌiĐ aŶalǇsis. 
Figure ř-ř gives an overview over the inal screening procedure. Library glycerol stocks were 
used to inoculate over-night cultures. “fter incubation, an aliquot was transferred to a new 
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vessel containing expression medium with IPTG. Expressed cells were washed with 
potassium phosphate bufer ǻKPiǼ, and could then either be frozen and stored until further 
use, or directly resuspended in lysis bufer. “fter incubation, cell debris was pelleted by 
centrifugation and the supernatant ǻlysateǼ was transferred to a new vessel containing 
reaction bufer I. “fter şŖ min, the reaction was inished and could be analyzed 
luorometrically. 
 
ϯ.Ϯ.Ϯ Liďƌaƌies 
In order to obtain variant libraries for screening, one can either go through the process of 
creating a new library for a speciically tailored collection, or use an existing library, 
reducing the amount of work necessary for irst results. In accordance with the First Law of 
Directed Evolution ǻȃYou get what you screen forȄǼ,[ŘŚś] we chose to screen two variant 
libraries available at the REETZ lab, which had been constructed speciically for enhanced 
regio- and stereoselectivity in the course of other studies. 
              
Figure ϯ-ϰ. PYMOL[Ϯϰϲ] ƌeŶdeƌiŶgs of PϰϱϬBMϯ ǁt iŶ a Đo-ĐƌǇstallized stƌuĐtuƌe ǁith N-palŵitoǇlglǇĐiŶe 
;PDB-ID ϭJP)[Ϯϰϳ]Ϳ, as full ǀieǁ ;letͿ aŶd zooŵ iŶto the aĐiǀe site ;ƌightͿ. Highlighted aƌe 
the pƌostheiĐ heŵe gƌoup ;ƌedͿ aŶd aŵiŶo aĐid ƌesidues taƌgeted iŶ SABRINA’s ColleĐioŶ 
;ďlueͿ, the MegaSite liďƌaƌǇ ;oƌaŶgeͿ, oƌ ďoth ;gƌeeŶͿ. The suďstƌate is shoǁŶ iŶ ďlaĐk. 
 
S“”RIN“Ȃs Collection created by S“”RIN“ HOE”ENREICH[ŗŜŗ,ŗŜŘ,ŘŚŞ] comprises triplicates of ca. 
ŗśŖ deined variants ǻlist see “ppendix ŗŗǼ arranged in MTPs, which were used for steroid 
hydroxylation. The second library, termed MegaSite, contains ŗŖ MTPs of unsequenced 
variants ǻunpublished work by C“RLOS G. “CEVEDO-ROCH“Ǽ, where ive residues were 
randomized to four diferent amino acids. Their respective positions inside the active pocket 
are shown in Figure ř-Ś. Details regarding library creation and targeted sites are described in 
Chapter ś.Ś.Ř, page şŗ. 
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The bacterial strain used here for the inducible expression of proteins in E. coli is ”LŘŗ-
GoldǻDEřǼ, which carries the gene for Tŝ polymerase via the phage DEř. Expression of the 
polymerase is under regulation by a lacUVś promoter, allowing controlled induction with 
IPTG or lactose. The gene for PŚśŖ”Mř is introduced to the bacteria either on the vector 
pRSFDuet ǻNovagenǼ or pETMŗŗ ǻEM”LǼ, together with a kanamycin resistance as a 
selection marker. In some cases, a His-tag for easier puriication and a TEV restriction site for 
removal of the tag are included with PŚśŖ”Mř. ”oth genes are regulated by a Tŝ promoter that 
is only transcribed by Tŝ polymerase, thus practically eliminating expression until induction 
is performed. Figure ř-ś shows a plasmid map of pRSFDuet, including all motifs and 
sequencing primers. 
 
Figure ϯ-ϱ.  VeĐtoƌ ŵap of pRSFDuet-ϭ as used foƌ ĐƌeaioŶ of the MegaSite liďƌaƌǇ, iŶĐludiŶg all pƌiŵeƌ 
sites. OpioŶal His-tag foƌ puƌiiĐaioŶ aŶd TEV ƌestƌiĐioŶ site aƌe iŶĐluded iŶ the 
ƌepƌeseŶtaioŶ. 
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ϯ.ϯ SĐƌeeŶiŶg Results 
ϯ.ϯ.ϭ FluoƌesĐeŶĐe Read-out 
The examination of these over ŗŖŖŖ mutants against substrates ŗa-c showed that only few 
mutants are able to convert the allyl diether ŗb with medium activity, while no mutants were 
found to cleave the benzyl derivative ŗc. However, a number of enzyme mutants displayed 
remarkably high activity towards the cleavage of the propargylic diether ŗa. The plate 
exhibiting the highest signal is shown in Figure ř-Ŝ. These results are particularly 
noteworthy since alkynes are known to act as suicide inhibitors, irreversibly inactivating 
CYPs by alkylation of the heme group in their active center.[ŘŚŖ,ŘŚŗ,ŘŚş] However, some of the 
mutants from this study seem to be able to overcome this threat. Generally, results from 
S“”RIN“ȂS collection were much lower due to a diferent plasmid with lower copy numbers 
and thus lower expression levels, so they had to be assessed separately. 
 
Figure ϯ-ϲ.  Eǆaŵple of sĐƌeeŶiŶg ƌesults foƌ MegaSite plate No. ϳ, iŶdiĐaiŶg aĐiǀitǇ ;top paŶelͿ aŶd 
ƌelaiǀe seleĐiǀitǇ ;ďotoŵ paŶelͿ. HoƌizoŶtal liŶes iŶdiĐate ďaĐkgƌouŶd iŶteŶsitǇ ;ƌedͿ aŶd 
the ŵiŶiŵuŵ aĐiǀitǇ thƌeshold that ǁas Đhosed foƌ geŶeiĐ seƋueŶĐiŶg ;gƌeeŶ, ƌesults Đf. 
AppeŶdiǆ ϲͿ. ReaĐioŶs ǁeƌe Đaƌƌied out iŶ Bufeƌ I ǁith lǇsate at a iŶal suďstƌate 
ĐoŶĐeŶtƌaioŶ of ϭϬϬ µM. 
Those mutants from the MegaSite library showing signals higher than ŘŖŖŖ au ǻrepresented 
by the green threshold line in Figure ř-ŜǼ, which means roughly ŘŖ-fold increased activity 
over the wild type, as well as the six most active enzymes from S“”RIN“Ȃs collection, were 
combined to a new plate of ŚŞ variants ǻpresent in duplicatesǼ and sent for sequencing to 
G“TC to identify and conirm their mutations.  
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ϯ.ϯ.Ϯ SeƋueŶĐe AŶalǇsis 
Genetic sequencing was performed by the company G“TC, using two sets of primers to 
cover the relevant parts of the gene. The resulting sequences were aligned with the wild type 
sequence in ”ioEdit ŝ.Ř.Ŗ to determine mutations present in the isolated variants, as collected 
in Table ŝ-ŗ, “ppendix Ŝ.  
Upon analyzing the sequence traces, it became clear that some mutants had been isolated up 
to four times. The diferences in their performance between entries are due to varying 
expression levels in the culture. For further experiments, the most active stock was used. “ 
new collection plate was assembled, containing the řř diferent hit variants from this study, 
as well as hits from other projects, the empty vector and the wt as controls ǻdetails see 
“ppendix ŗŘǼ. Reproducibility of the results for this collection plate can be seen in Figure ř-ŝ, 
showing good correlation across diferent times and experimenters. 
 
Figure ϯ-ϳ.  Results foƌ the depƌoteĐioŶ ƌeaĐioŶ of ϭa as deteƌŵiŶed ďǇ luoƌesĐeŶĐe assaǇ oŶ the 
ŵiǆed ϵϲeƌ ĐolleĐioŶ plate ;ŵutaŶt details Đf. AppeŶdiǆ ϭϮͿ. Hit ǀaƌiaŶts fƌoŵ this pƌojeĐt 
aƌe highlighted. RepƌoduĐiďilitǇ is shoǁŶ oǀeƌ iŵe aŶd difeƌeŶt eǆpeƌiŵeŶteƌs ;the data 
ƌoǁ deŶoted N.N. ǁas geŶeƌated ďǇ NATHALIE NETTͿ. ReaĐioŶs ǁeƌe Đaƌƌied out iŶ Bufeƌ I 
ǁith lǇsate at a iŶal suďstƌate ĐoŶĐeŶtƌaioŶ of ϭϬϬ µM usiŶg the NADPH ƌeĐǇĐliŶg sǇsteŵ 
desĐƌiďed iŶ Figuƌe ϯ-ϭ. 
Overall the most prominent example was mutant TFFIS ǻmutations RŚŝT/SŝŘF/“ŞŘF/ 
FŞŝI/LŚřŝSǼ, reliably showing almost twice as much activity as any other mutant in the lysate 
reaction. It shows a strong preference for the activation of the propargylic diether ŗa over ŗb 
ǻweak activationǼ or ŗc ǻno activationǼ. In contrast, wild type ǻwtǼ PŚśŖ”Mř does not activate 
any of the derivatives, demonstrating a compelling degree of selectivity across the mutants. 
The mutant which gave the highest overall signal in the irst screening, TSFIS ǻcf. Figure ř-ŜǼ, 
showed lower apparent selectivity than TFFIS, and did not conirm its activity in repetitions 
with the collections plate, prompting us to exempt this apparent false positive from further 
studies. To be able to obtain quantitative results, the most promising hit mutants were 
puriied ǻcf. Chapter ř.ś.ŗ, page ŚřǼ. 
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ϯ.ϰ Suďstƌate ModiiĐaioŶ aŶd OpiŵizaioŶ 
ϯ.ϰ.ϭ ModiiĐaioŶs of the PƌopaƌgǇl PƌoteĐioŶ Gƌoup 
To further investigate the propargylic protection group, N“TH“LIE NETT prepared a second 
generation of substrates during her master thesis,[ŘśŖ] comprising of three additional 
derivatives ŗd-f ǻcf. Scheme ř-řǼ. The necessary bromides were prepared in an “PPEL 
reaction from their corresponding alcohols. Fluorescein derivatives were then synthesized in 
a WILLI“MSON ether synthesis following the same reaction conditions as described in 
Chapter ř.ŗ, page Řş. 
 
SĐheme ϯ-ϯ.  SeĐoŶd geŶeƌaioŶ luoƌesĐeiŶ deƌiǀaiǀes oďtaiŶed ǀia WILLIAMSON etheƌ sǇŶthesis as 
shoǁŶ iŶ SĐheŵe ϯ-Ϯ. FoƌŵallǇ, a ǀaƌiaioŶ of the pƌopaƌgǇl pƌoteĐioŶ gƌoups ǁas 
iŶtƌoduĐed. 
 
ϯ.ϰ.Ϯ CouŵaƌiŶ Deƌiǀaiǀes 
 
SĐheme ϯ-ϰ. CouŵaƌiŶ deƌiǀaiǀes sǇŶthesized foƌ depƌoteĐioŶ ƌeaĐioŶs to iŶǀesigate the appliĐaďilitǇ 
of the pƌeǀiouslǇ used pƌoteĐioŶ gƌoups foƌ difeƌeŶt suďstƌates. 
Encouraged by the results based on luorescein derivatives, a third generation of substrates 
derived from two coumarin luorophores ǻŘ and řǼ was investigated. Ś-Methylumbelliferone 
Ř is an established drug used in bile therapy[Řśŗ] and has recently been under intense 
investigation for its activity as an anti-cancer agent efective against various cancer types.[ŘśŘ–
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ŘśŜ] Its ethers are closely related to a known probe for CYP levels in clinical samples.[Řśŝ] The 
second compound, ř-carboxycoumarin ř, is a known substrate for similar reactions catalyzed 
by PŚśŖ variants.[ŗŚŖ,ŘŚŘ,ŘśŞ] Particularly, derivative řc has previously been reported for 
deprotection reactions by PŚśŖ”Mř,[ŘŚŘ] and is therefore a useful reference for the evaluation of 
screening results.  
Their propargylic ether derivatives ǻŘa and řaǼ were prepared, as well as the respective Ř-
butynyl ǻŘd and řdǼ and benzyl ǻŘc and řcǼ ethers. “fter positive results with these 
protection groups were obtained, further modiications were made to substituent c, to 
investigate sterical and electronic inluences on the deprotection reactions of resulting Śth 
generation compounds řg, h and i.  
 
SǇŶthesis of UŵďellifeƌoŶe Deƌiǀaiǀes 
 
SĐheme ϯ-ϱ. SǇŶthesis of uŵďellifeƌoŶe deƌiǀaiǀes Ϯa, Đ aŶd d ǀia WILLIAMSON etheƌ sǇŶthesis. Ateƌ 
depƌotoŶaioŶ ǁith ĐaƌďoŶate, the hǇdƌoǆǇl gƌoups aƌe Đoupled to the ĐoƌƌespoŶdiŶg 
ďƌoŵide iŶ aŶ SNϮ ƌeaĐioŶ. 
In analogy to the luorescein derivatives and following literature known methods,[Řśş] methyl 
umbelliferone was alkylated via a WILLI“MSON ether synthesis. In comparison to the 
synthesis of luorescein derivatives, the solvent was changed from DMF to acetone. Lower 
temperature and reduced equivalents of the reagents were employed. Due to no competing 
sites, a much cleaner reaction was observed. The resulting products were puriied by 
crystallization from ethyl alcohol to yield a white solid. Reaction conditions are shown in 
Scheme ř-ś. 
 
SǇŶthesis of CaƌďoǆǇĐouŵaƌiŶ Deƌiǀaiǀes 
The synthesis of the unprotected ř-CCE ř was carried out via a one-step synthesis according 
to a procedure by RUFF et al. ǻcf. Scheme ř-ŜǼ.[ŘŚŘ] Ř,Ś-Dihydroxybenzaldehyde reacted with 
diethyl malonate in methanol in a KNOEVEN“GEL-like reaction catalyzed by morpholine and 
acetic acidǱ an “LDOL reaction is followed by elimination of water and decarboxylation, 
ultimately leading to the formation of an intramolecular γ-lactone. The crude product was 
recrystallized from methanol to remove traces of byproducts, such as trans-coumarinic acid, 
yielding the unprotected coumarin as a pure colorless solid.  
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SĐheme ϯ-ϲ. SǇŶthesis of the uŶpƌoteĐted ĐaƌďoǆǇ-ĐouŵaƌiŶ ϯ iŶ a KNOEVENAGEL ĐoŶdeŶsaioŶ ƌeaĐioŶ. 
For the following alkylation via WILLI“MSON ether synthesis, two possible conditions were 
employed ǻScheme ř-ŝǼ. Method I followed the conditions previously described for parent 
compounds ŗ and Ř. In the second route,[ŘŚŘ] the unprotected compound was treated with 
sodium hydride in toluene as a irst step, allowing the isolation of the corresponding sodium 
salt ř-Na, before it was reacted with the desired bromides in DMF.  
 
SĐheŵe ϯ-ϳ. Tǁo ŵethods foƌ the pƌepaƌaioŶ of etheƌ-pƌoteĐted ϯ-CCE deƌiǀaiǀes ďǇ WILLIAMSON 
etheƌ sǇŶthesis. Method I folloǁs the saŵe oŶe-pot appƌoaĐh as desĐƌiďed ďefoƌe foƌ 
deƌiǀaiǀes of ĐoŵpouŶds ϭ aŶd Ϯ, ǁhile Method II takes a tǁo-step appƌoaĐh ǁith 
iŶteƌŵediate isolaioŶ of the ĐoƌƌespoŶdiŶg sodiuŵ salt. 
Method I tended to yield slightly higher amounts of the raw product, while Method II gave a 
cleaner reaction, making puriication easier. In both cases, lash chromatography over silica 
aforded the pure derivatives řa, b, c, d, g, h and i. Parts of this work were carried out by 
N“TH“LIE NETT[ŘśŖ], CHRISTI“N SPRINGER,[ŘŜŖ] LIS“ ENGELS”ERGER, KERSTIN M“RK, JULIUS 
WINKLER and J“NOSCH KETTLER.  
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In case of the chiral compound řg, chiral resolution was determined. Unfortunately, the 
chiral center in the protection group racemized during the reaction, most likely during the 
synthesis of the bromide, so that the enantiomers had to be resolved via chiral reversed 
phase HPLC for chirality dependent analyses. HPLC traces showing the purity before and 
after enantiomeric resolution are shown in Figure ř-Ş, conditions are described in Table ś-Ś.  
 
Figure ϯ-ϴ.  HPLC tƌaĐes of Đhiƌal ƌesoluioŶ of eŶaŶioŵeƌs ϯg, ďefoƌe ;ďlaĐkͿ aŶd ateƌ seŵi-
pƌepaƌaiǀe puƌiiĐaioŶ ǀia HPLC ;oƌaŶge: ;RͿ-ϯg; gƌeeŶ: ;SͿ-ϯgͿ. SepaƌaioŶ ǁas ĐoŶduĐted 
oŶ a CHIRALPAK IB ĐoluŵŶ usiŶg MeCN : Ϭ.ϭ% TFA/HϮO as solǀeŶts, folloǁiŶg gƌadieŶt IV as 
desĐƌiďed iŶ Taďle ϱ-ϰ, page ϳϮ. 
 
ϯ.ϰ.ϯ SĐƌeeŶiŶg Results of Suďstƌate GeŶeƌaioŶs II-IV 
“ graphic representation of the results for substrate generations II-IV is shown in Figure ř-ş. 
The distinct suitability of the propargylic protection group was conirmed by experiments 
with Řnd generation alkyne derivatives ŗd-f. Whereas a large number of PŚśŖ”Mř mutants 
display weak activity for the Ř-butynyl diether ŗd, no active mutants could be found for the 
alkynes ŗe and ŗf. For this reason, investigations towards those protection groups were 
discontinued. The advantage of řrd and Śth generation substrates based on coumarin is that 
they carry only one protection site, rendering kinetics calculations less complex. The 
disadvantage of these derivatives, however, is that they have their emission maximum in the 
range of the cofactor N“DPH, so that a large luorescence background impedes the 
evaluation of the libraries. Nevertheless, we were able to identify hit mutants by subtracting 
the background from measurements. Parts of these screening experiments were carried out 
by N“TH“LIE NETT ǻřa, c, dǼ,[ŘśŖ] CHRISTI“N SPRINGER ǻřg, iǼ[ŘŜŖ] and LIS“ ENGELS”ERGER ǻřb, 
hǼ. Overall, mutant WMV ǻRŚŝW/“ŞŘM/FŞŘVǼ displayed extremely high activity towards the 
benzylic ethers Řc and řc, whereas mutant MŖŗ ǻRŚŝL/FŞŝV/LŗŞŞQ/EŘŜŝV/GŚŗśSǼ[ŗş] showed 
to be capable of selectively activating the propargylic ethers Řa and řa. These were 
subsequently puriied by K“TJ“ KRÄLING ǻcf. Chapter ř.ś.ŗ, page ŚřǼ. 
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Figure ϯ-ϵ.  AĐiǀitǇ of PϰϱϬBMϯ ŵutaŶts toǁaƌds difeƌeŶt Đaged ĐoŵpouŶds aƌƌaŶged iŶ aŶ MTP 
foƌŵat ;ϵϲ saŵplesͿ. FluoƌesĐeiŶ- ϭa-f ;gƌeeŶͿ aŶd ĐouŵaƌiŶ-ďased suďstƌates ;Ϯa, Đ, d, ƌed 
aŶd ϯa, Đ, d, ďlueͿ ǁeƌe used foƌ liďƌaƌǇ sĐƌeeŶiŶg. FluoƌesĐeŶĐe iŶteŶsiies aƌe Ŷoƌŵalized 
to the loǁest/highest ǀalues iŶĐluded iŶ the plates, ďƌighteƌ Đoloƌs shoǁiŶg higheƌ aĐiǀitǇ 
;foƌ oƌigiŶal ǀalues see AppeŶdiǆ ϴͿ. Figuƌe adapted ateƌ ouƌ puďliĐaioŶ ǁith peƌŵissioŶ 
fƌoŵ JOHN WILEY & SONS LTD.[ϭ] 
Coumarin derivate řb, carrying an allyl group, was not converted eiciently by any screened 
mutant. The same is true for pyridinyl derivative ři, which is probably due to inhibitionǱ it is 
possible for the substrate to coordinate to the iron core via its nitrogen atom, as is known for 
imidazoles.[ŘŜŗ] Quite actively, but with very low selectivity, a large number of mutants from 
S“”RIN“Ȃs collection ǻdata not shownǼ converted derivative řh. Low selectivity, however, is 
not beneicial to this endeavor, so investigations with regard to this compound was 
abandoned.  
For an outlook towards the design of suitable protection groups, the chiral compound řg was 
used to test for enantioselectivity in our libraries ǻcf. Figure ř-ŗŖǼ. In a irst step, the racemic 
compound was screened, directly comparing it with earlier results of řd. Some very 
promising mutants were found, albeit most of them also converted řd. The most active ones 
were selected, and used for reactions with the enantio-pure derivatives řgǼ. It became clear 
that a general preference for ǻSǼ-řg prevailed in all but one selected mutant. Noteworthy is 
the inverted selectivity upon changing only two residuesǱ mutant LFF“ 
ǻRŚŝL/SŝŘF/“ŞŘF/FŞŝ“Ǽ behaves like the majority of tested mutants, while LFFF“ 
ǻRŚŝL/SŝŘF/“ŞŘF/FŞŝ-/LŚřŝ“Ǽ exhibits a preference for ǻRǼ-řg.  
These results are very promising, and found mutants could be used as a starting point for 
future engineering eforts. However, no extended investigation of Śth generation results was 
possible in the given timeframe. Future docking studies and modiications towards chiral 
protection groups could deinitely help improve the selectivity of the uncaging system. 
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Figure ϯ-ϭϬ.  Results of the lǇsate ƌeaĐioŶ of difeƌeŶt ŵutaŶts toǁaƌds eŶaŶioŵeƌs ϯg. All ďut oŶe 
tested ŵutaŶt ;LFFFAͿ faǀoƌ the S-eŶaŶioŵeƌ. Top paŶels shoǁ oǀeƌall iŶteŶsitǇ, ďotoŵ 
paŶels illustƌate ƌelaiǀe seleĐiǀitǇ. ReaĐioŶs ǁeƌe Đaƌƌied out iŶ Bufeƌ I ǁith lǇsate at a 
iŶal suďstƌate ĐoŶĐeŶtƌaioŶ of ϭϬϬ µM. 
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ϯ.ϱ MutaŶt ChaƌaĐteƌizaioŶ 
ϯ.ϱ.ϭ PuƌiiĐaioŶ aŶd CoŶĐeŶtƌaioŶ DeteƌŵiŶaioŶ 
For enzyme puriication, large scale expression cultures were grown in T” medium 
containing kanamycin. The bacteria were washed with bufer, resuspended and lysed by 
sonication. The lysate was cleared by centrifugation and iltration before puriication. Since 
most hit mutants did not contain a His-tag, these enzymes were puriied over a series of 
chromatographic steps, starting with a manually operated anion exchange column by 
increasing the concentration of KCl, followed by a desalting column using HEPES bufer, a 
second anion exchange column, and last a gel iltration column. The sample was 
concentrated by ultracentrifugation after each step, and the bufer replaced to KPi after the 
last column. In case of His-tagged proteins, the raw extract was puriied by ainity 
chromatography ǻNi-NT“Ǽ and eluted by gradually increasing the competitor concentration 
in the bufer. Generally, imidazole is used for this step, but in the case of PŚśŖs, it can 
deactivate the enzyme by coordinating to the iron core of the active site, so that histidine was 
used here instead. In both cases, the sample was then divided into aliquots, frozen in liquid 
nitrogen and stored at -ŞŖ°C until further use. 
 
Figure ϯ-ϭϭ.  CoŶĐeŶtƌaioŶ deteƌŵiŶaioŶ of PϰϱϬBMϯ. ShoǁŶ aƌe aďsoƌpioŶ speĐtƌa of the ƌeduĐed 
eŶzǇŵe, aǀeƌaged oǀeƌ thƌee ŵeasuƌeŵeŶts ǁith ;gƌeeŶͿ aŶd ǁithout addiioŶ of CO 
;oƌaŶgeͿ, as ǁell as the ĐalĐulated difeƌeŶĐe speĐtƌuŵ ;puƌpleͿ.  
Enzyme concentration was determined using an established method based on spectroscopic 
measurements of the corresponding CO-heme complexes, allowing to distinguish intact 
active sites from inactivated ones.[ŘŜŘ] Unlike in the literature procedure, no additives for the 
bufer were needed in this case, since we used a puriied, soluble protein, which is not 
membrane bound and not derived from tissue samples.  
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“ diluted solution of the protein is divided into diferent cuvetes, half of which are 
saturated with CO-gas, while the other serve as controls. The gas binds to the ferrous iron 
core of the active site, inducing an increase of the absorption band at ŚśŖ nm. To make sure 
all iron centers are in their reduced ferrous oxidation state, all cuvetes are treated with 
sodium dithionite, before measuring spectra or single point absorption at three wavelengths. 
Protein rendered inactive by loss of its axial cysteine ligand from the iron center experiences 
a hypsochromic shift, and can be tracked by measuring absorption at ŚŘř nm. “s a general 
background for the presence of other PŚśŖ enzymes, a reference measurement at ŚşŖ nm is 
used. This can be particularly useful when measuring concentrations from tissue samples. 
For analysis of the data, non-CO reference values are subtracted from the values of CO-
treated samples to yield a diference spectrum ǻcf. Figure ř-ŗŗǼ, and the concentration of 
active and inactive enzyme can be calculated using the molar extinction coeicients of 
şŗ,ŖŖŖ M-ŗ ∙ cm-ŗ at ŚśŖ nm and Śŗ,ŖŖŖ M-ŗ ∙ cm-ŗ at ŚŘř nm, respectively. Table ř-ŗ shows 
concentrations of puriied PŚśŖ”Mř mutants. Their original screening data towards diferent 
substrates is collected in “ppendix ŝ. 
 
Taďle ϯ-ϭ.  DeteƌŵiŶed ĐoŶĐeŶtƌaioŶs foƌ all puƌiied ŵutaŶts. 
Screen 
Mutant 
Name 
Library/Entry Substrate 
His- 
Tag 
Concentration 
[µM] 
 wt+His  - - + 97.7 
 wt  - - - 24.4 
 wt  - - - 91.5 
Gen I 
TFFIS MS -03-7C 1a, 1d - 15.5 
TFFIS MS -05-A12 1a, 1d - 17.3 
Gen II 
YFM-WEI-A SC -05-70 1d + 13.6 
PC-A SC -05-34 1d + 29.2 
Gen III 
M01 96er -08 2a - 13.5 
M11  96er -12 2a - 18.7 
WMV 96er -17 2c, 3c -   2.4 
LV 96er -05 3c - 121.6 
WWV-MQ’ 96er -55 3d + 42.0  
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ϯ.ϱ.Ϯ HPLC AŶalǇsis 
For the analysis of possible side products and quantiication of turnover for kinetic 
calculations, analytical HPLC methods were developed.  
Qualitaiǀe 
First, separation conditions were establishedǱ Due to the polarity of the compounds, reversed 
phase HPLC is the method of choice. Separation of substrates and reaction products is 
possible using a CŗŞ or CŞ column and diferent gradients of acetonitrile and Ŗ.ŗ% 
triluoroacetic acid ǻTF“Ǽ in water ǻcf. Chapter ś.ŗ.Ś, page ŝŖǼ.  
 
Figure ϯ-ϭϮ. HPLC tƌaĐes of luoƌesĐeiŶ ;letͿ aŶd uŵďellifeƌoŶe deƌiǀaiǀes ;ƌightͿ. SepaƌaioŶ ǁas 
ĐoŶduĐted oŶ a ƌeǀeƌsed-phase Cϭϴ ĐoluŵŶ usiŶg MeCN : Ϭ.ϭ% TFA/HϮO as solǀeŶts, 
folloǁiŶg gƌadieŶt I ;let paŶelͿ as desĐƌiďed iŶ Taďle ϱ-ϰ, page ϳϮ oƌ at isoĐƌaiĐ ĐoŶdiioŶs 
;ϱϬ:ϱϬ, ƌight paŶelͿ. 
 
QuaŶitaiǀe 
For quantiication by HPLC, concentration calibration curves of luorescein substrates were 
prepared of direct dilutions and extracts ǻcarried out in triplicates, cf. “ppendix ś, Figure 
ŝ-ŘǼ. “ll dilution series show linear correlation of peak area vs. concentration in the working 
range, and closing in on ǻŖ|ŖǼ for all substrates apart from free luorescein, where a y-ofset 
of Śŝř m“U ∙ s is observed. ”elow ŗŖ µM, error bars tend to grow beyond ŗŖ%. Measure-
ments are prone to solvent change, since samples diluted in water instead of MeCN 
generally show a lower signal by an average of ŘŚ% ǻdenoted by ȃxȄ in the graphǼ. Therefore, 
dilution in the same solvent is mandatory for comparison of results. The next step is the 
comparison of these data with extracted samples. 
To determine the best extraction method, diferent solvents were tested on derivatives of 
substrate ŗ and Ř ǻFigure ř-ŗřǼ. Extraction was carried out ř times, the organic phases 
combined, evaporated, and the residue redissolved in acetonitrile prior to analysis. Overall, 
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ethyl acetate proved to be the best choice, retaining the best ratio between diferent 
derivatives. Especially in the case of luorescein derivatives this is not a trivial task, due to 
the increased polarity of the products, which strongly inluences extraction from aqueous 
phase. 
     
Figure ϯ-ϭϯ. EǀaluaioŶ of eǆtƌaĐioŶ solǀeŶts oŶ luoƌesĐeiŶ uŶd uŵďellifeƌoŶe deƌiǀaiǀes. SepaƌaioŶ 
ǁas ĐoŶduĐted oŶ a ƌeǀeƌsed-phase Cϭϴ ĐoluŵŶ usiŶg MeCN : Ϭ.ϭ% TFA/HϮO as solǀeŶts at 
isoĐƌaiĐ ĐoŶdiioŶs  of ϳϬ% ;let paŶelͿ oƌ ϱϬ% aĐetoŶitƌile ;ƌight paŶelͿ. The peak deŶoted 
ǁith aŶ asteƌisk is due to uŶideŶiied ǁateƌ-soluďle ĐoŵpoŶeŶts. 
“dditionally, diferent extraction processes were tested with luorescein derivatives. When 
comparing diferent automated and manual extraction methods ǻdetails cf. Chapter ś.ŗ.Ś, 
page ŝŗǼ, it becomes clear that a large diference in eiciency is observed. Only for the 
butynyl diether ŗd can equal results be obtained, at around ŝŖ% of the intensity of the direct 
dilution. Even though percentages for the other substrates are even lower, especially in the 
robot-method, the automation of the results is an immense advantage both in terms of time 
and reliability. Therefore it is sensible to use the robot for all further extraction steps to keep 
the error as low as possible. 
Dilution series were extracted with the robot ǻcf. “ppendix ś, Figure ŝ-řǼ, and indeed show a 
linear correlation of peak area vs. concentration, albeit at larger errors than the direct 
measurements. So even though extraction is not complete, the results clearly show the ability 
to estimate the total amount of compounds present in solution. 
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Figure ϯ-ϭϰ. EǀaluaioŶ of eǆtƌaĐioŶ ŵethods, Ŷoƌŵalized to the oďseƌǀed ĐoŶĐeŶtƌaioŶs iŶ 
ĐoƌƌespoŶdiŶg iǆed diluioŶ ŵeasuƌeŵeŶts. The let paŶel eŵphasizes ǀaƌǇiŶg degƌees of 
eǆtƌaĐioŶ ĐoŵpleteŶess aĐƌoss the deƌiǀaiǀes, ǁhile the ƌight paŶel aĐĐeŶtuates the 
difeƌeŶĐe ďetǁeeŶ ŵethods. SepaƌaioŶ ǁas ĐoŶduĐted oŶ a ƌeǀeƌsed-phase Cϭϴ ĐoluŵŶ 
usiŶg MeCN : Ϭ.ϭ% TFA/HϮO as solǀeŶts, folloǁiŶg gƌadieŶt I ;let paŶelͿ as desĐƌiďed iŶ 
Taďle ϱ-ϰ, page ϳϮ. CoƌƌespoŶdiŶg peak aƌeas ǁeƌe theŶ Ŷoƌŵalized to the ǀalue 
ŵeasuƌed foƌ aŶalǇsis of a soluioŶ ǁith kŶoǁŶ ĐoŶĐeŶtƌaioŶ ;gƌaǇͿ. 
 
ϯ.ϱ.ϯ BioĐheŵiĐal AŶalǇsis 
“fter puriication, the most prominent mutants were characterized biochemically using 
deined enzyme concentrations and the same reaction conditions used for the screening 
procedure ǻcf. Chapter ś.Ŝ.Ř, p. şŝǼ. 
 
Relaiǀe AĐiǀitǇ 
”y controlling the enzyme concentration, it was possible to cancel out diferences in 
expression levels present in lysates, allowing the direct comparison of our most promising 
hit mutants as shown in Figure ř-ŗś. In the case of substrate ŗa, the most active mutant TFFIS 
yields a śŘ-fold higher luorescence response than the wt. None of the other hits was able to 
convert any of the luorescein substrates. While the highly active mutant WMV converted all 
coumarin-derived substrates ǻŘa, Řc, řc, and řdǼ, the more selective mutant MŖŗ showed 
activity towards substrates Řa and Řc only, at about Ś-fold higher than the wt. This means 
that compounds even with very similar core structures can be diferentiated by certain 
mutants, but this gain in selectivity comes with an activity penalty, e.g.Ǳ WMV shows ŗŜ-fold 
higher activity than MŖŗ towards substrate řd. Previous reports for řc[ŗŞc] using other PŚśŖ”Mř 
mutants achieved only a ŝ-fold increase at similar concentrations in a diferent bufer[Řŗ] after 
one round of random directed evolution, which difers from our library mutants where the 
active site was targeted using recommended guidelines.[ŘŘ]  
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Figure ϯ-ϭϱ.  IŶ vitƌo ĐhaƌaĐteƌizaioŶ. EŶzǇŵaiĐ aĐiǀitǇ of PϰϱϬBMϯ hit ŵutaŶts toǁaƌds Đaged 
ĐoŵpouŶds, Ŷoƌŵalized to the laƌgest oďseƌǀed luoƌesĐeŶĐe ƌespoŶse foƌ eaĐh suďstƌate 
;oƌigiŶal data: Đf. AppeŶdiǆ ϵͿ. ReaĐioŶs ǁeƌe Đaƌƌied out iŶ Bufeƌ I, geŶeƌallǇ folloǁiŶg 
staŶdaƌd ĐoŶdiioŶs at iŶal ĐoŶĐeŶtƌaioŶs of Ϭ.ϭ µM aŶd ϭϬϬ µM foƌ eŶzǇŵe aŶd 
suďstƌate, ƌespeĐiǀelǇ. Figuƌe ƌepƌoduĐed fƌoŵ ouƌ puďliĐaioŶ ǁith peƌŵissioŶ fƌoŵ JOHN 
WILEY & SONS LTD.[ϭ] 
To further investigate the reaction, real time luorescence analysis of the reaction of TFFIS 
with ŗa was conducted ǻFigure ř-ŗŜǼ, in which the mono-deprotection of ŗa was revealed. 
The observation was later easily conirmed by HPLC analysis, as shown below in Figure 
ř-ŗŞ.  
 
Figure ϯ-ϭϲ. Real-iŵe luoƌesĐeŶĐe ŵoŶitoƌiŶg of the ƌeaĐioŶs TFFIS/ϭa. The ƌeaĐioŶ ǁas Đaƌƌied out 
iŶ Bufeƌ I, folloǁiŶg staŶdaƌd ĐoŶdiioŶs at iŶal ĐoŶĐeŶtƌaioŶs of Ϭ.ϭ µM aŶd ϭϬϬ µM foƌ 
eŶzǇŵe aŶd suďstƌate, ƌespeĐiǀelǇ. CoŵpleioŶ of the ƌeaĐioŶ is oďseƌǀed ateƌ Đa. 
ϰϬ ŵiŶ ;stage ϭ, gƌeeŶͿ. FuŶĐioŶalitǇ of the eŶzǇŵe ǁas ĐheĐked ďǇ a seĐoŶd addiioŶ of 
suďstƌate ;stage Ϯ, ƌedͿ, aŶd NADPH ;stage ϯ, oƌaŶgeͿ. A seĐoŶd addiioŶ of eŶzǇŵe ;stage 
ϰ, ďlueͿ shoǁed soŵe ĐoŶǀeƌsioŶ, ďut sigŶiiĐaŶtlǇ loǁeƌ thaŶ ďefoƌe, poiŶiŶg toǁaƌds aŶ 
iŶaĐiǀaioŶ of PϰϱϬBMϯ. 
“ two-step deprotection should be visible in the luorometric trace, with a irst, smaller 
increase in signal intensity, since the mono-ether is less luorescent than free luorescein, 
which would only be generated in a second deprotection step. To gain some insight into 
what caused the reaction to stop, more substrate was added, but to no avail. Therefore, either 
the enzyme was inactivated or the cofactor was depleted, meaning the recycling system had 
failed. To distinguish between those two possibilities, N“DPH was added to the system, 
again resulting in no change in luorescence. This conirmed that enzymatic activity had been 
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afected. “dding more enzyme to the reaction resulted in some turnover, but not at the full 
previously observed activity, suggesting that something in solution was afecting the 
enzyme after a certain number of turnovers. However, no further investigations were 
conducted in this study as to what the inhibitory efect might be. 
 
SeleĐiǀitǇ aŶd OƌthogoŶalitǇ  
”y choosing highly selective catalysts, it may be possible to have two independent reactions 
in the same system without interference from one another, which could reveal possibilities 
for further applications. Not only could this be of advantage in bio-imaging,[ŘŜř] but also for 
classical organic synthesis of complex molecules, where the independent cleavage of 
diferent protection groups is of great importance. Therefore, to determine the orthogonality 
of diferent mutants towards each other, their behavior in a mixed system was investigated. 
Real-time monitored reactions containing two enzymes added simultaneously or 
successively were conducted under standard reaction conditions in bufer I, towards 
substrate ŗa at a concentration of ŗŖŖ µM. Similar measurements with coumarin-based 
substrates were not possible because of the interference of N“DPH luorescence.  
 
Figure ϯ-ϭϳ.  OƌthogoŶalitǇ test ǁith difeƌeŶt ŵutaŶts iŶ the Đase of suďstƌate ϭa.  Both eŶzǇŵes ǁeƌe 
eitheƌ added at the saŵe iŵe ;ďlaĐk liŶesͿ oƌ suĐĐessiǀelǇ ;Đoloƌed liŶes, addiioŶ iŵe 
ŵaƌked ďǇ aƌƌoǁsͿ. Let: TFFIS aŶd MϬϭ; Right: TFFIS aŶd WMV. The TIFFIS/MϬϭ paiƌ 
shoǁs eǆpeĐted oƌthogoŶalitǇ, ǁheƌeas the data of the TFFIS/WMV paiƌ pƌoǀides eǀideŶĐe 
foƌ the foƌŵaioŶ of ŵiǆed diŵeƌs ǁith ĐhaŶged ĐatalǇiĐ pƌopeƌies. ReaĐioŶs ǁeƌe 
Đaƌƌied out iŶ Bufeƌ I, geŶeƌallǇ folloǁiŶg staŶdaƌd ĐoŶdiioŶs at a iŶal suďstƌate 
ĐoŶĐeŶtƌaioŶs ϭϬϬ µM. The iŶal eŶzǇŵe ĐoŶĐeŶtƌaioŶ ǁas Ϭ.ϭ µM foƌ TFFIS aŶd MϬϭ, aŶd 
Ϭ.Ϭϭ µM foƌ WMV, to aĐĐouŶt foƌ the difeƌeŶĐe iŶ peƌfoƌŵaŶĐe.  
This mixed approach was found to work well in vitro for some combinations of PŚśŖ”Mř 
mutants ǻcf. Figure ř-ŗŝ, left panelǼ, where activity is only seen when the corresponding 
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mutant TFFIS suitable for substrate ŗa is added to the reaction mix, as expected. The 
observation does not change when MŖŗ is present, which does not show activity for 
substrate ŗa.  However, this is not true for every combination of mutants. In the example of 
WMV, depicted on the right panel of Figure ř-ŗŝ, higher activity is achieved when both 
enzymes are mixed, exceeding the activity of the active mutant by itself. This observation 
could be atributed to the particularly complex case of PŚśŖ”Mř, which is only active as a 
dimer and thus subject to cooperative changes in substrate turnover. The activity gain could 
be due to conformational changes, but more likely is a result of the electron transfer pathway 
bridging both monomers,[ŘŜŚ] so one mutant would take over substrate conversion while the 
other excels at cofactor turnover. Therefore, it is recommended that the behavior of every 
pair of suitable mutants be tested carefully in regard to the properties of mixed PŚśŖ”Mř 
systems for future projects based on the concept of orthogonality. 
 
KiŶeiĐ Paƌaŵeteƌs 
For further applications, characterization of the kinetic parameters of the found mutants is of 
importance. “ combination of two methods was used as a basis for kinetic evaluationǱ 
photometric analysis of N“DPH consumption allowed the tracking of changes in cofactor 
concentration in real time, while HPLC analysis of products, as described in Chapter ř.ś.Ř, p. 
Śś, was used for endpoint quantiication of products.  
 
Leak- and Consumption Rate 
First, the leak rate ǻLRǼ was determined. This value describes the amount of cofactor that is 
used by the enzyme in absence of a substrate. Upon addition of enzyme to a N“DPH 
solution in bufer, the depletion can be directly followed. The observed change of absorption 
over time ǻΔA/ΔtǼ was used to calculate the change of N“DPH concentration ΔĐ, following 
L“M”ERT-”EERȂs law ǻEq. ŗǼ, where ε is the extinction coeicient and d is the cuvete 
diameter. This value ΔĐNADPH was then normalized by the concentration of enzyme ĐBMϯ, to 
yield the amount of cofactor consumed by one mole of enzyme per time ǻEq. ŘǼǱ 
   ܣ =  � ∙ ܿ ∙ ݀     (1) 
    ܮ� =  ∆�ಿಲ����ಳಾ3 ∙ �       ;ϮͿ 
The N“DPH consumption rate ǻCRǼ is determined in the same way, albeit in the presence of 
substrate. These reactions are followed until the slope latens to a horizontal line, marking 
the end of turnover.  
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Product Formation Rate 
Using HPLC analysis of extracts obtained from inished CR measurements ǻcf. Figure ř-ŗŞǼ, 
the overall product formation rate ǻPFRǼ can be determined according to known 
protocols.[ŗŜŗ] Since as described above, we observed diferences in extraction eiciency, it 
would be most useful in future work to use such a correlation as a basis for calculations. 
However, to keep this study comparable to earlier works, the same established method was 
used for determining kinetic characteristics, where all substrate/product integrals are added 
to determine the assumed ŗŖŖ% mark, and fractions thereof are calculated accordingly for 
the individual compounds.  
 
Figure ϯ-ϭϴ.  HPLC tƌaĐes of ƌeaĐioŶs as used foƌ ƋuaŶiiĐaioŶ. Hit ŵutaŶts aƌe shoǁŶ iŶ gƌeeŶ, ĐleaƌlǇ 
shoǁiŶg pƌoduĐt foƌŵaioŶ – iŶ Đase of suďstƌate ϭd, ŵoŶo-depƌoteĐted luoƌesĐeiŶ ϭd’ is 
foƌŵed ďǇ ŵutaŶt TFFIS ;letͿ. WMV ;ƌightͿ shoǁs total ĐoŶǀeƌsioŶ of suďstƌate ϯd. No 
ĐoŶǀeƌsioŶ oĐĐuƌs iŶ ǁt ƌeaĐioŶs ;oƌaŶgeͿ. GƌeǇ laŶes shoǁ a ĐoŶtƌol of ĐheŵiĐallǇ 
sǇŶtheized deƌiǀaiǀes. The suďstaŶĐe ŵaƌked * is aŶ uŶideŶiied ĐoŵpouŶd pƌeseŶt iŶ 
all eŶzǇŵe ƌeaĐioŶs, iŶdepeŶdeŶt of the suďstƌate. SepaƌaioŶ ǁas ĐoŶduĐted oŶ a 
ƌeǀeƌsed-phase Cϭϴ ĐoluŵŶ usiŶg MeCN : Ϭ.ϭ% TFA/HϮO as solǀeŶts, folloǁiŶg gƌadieŶt I 
as desĐƌiďed iŶ Taďle ϱ-ϰ, page ϳϮ.  
Multiplying the observed conversion ǻ%CǼ with the initial substrate concentration ĐS and 
dividing by the reaction time tR, normalized to the concentration of enzyme, yields the 
amount of product formed per mole enzyme over time ǻcf. Eq. řǼ. 
   ܲܨ� =  %�∙ �ೄ�ಳಾ3 ∙ �ೃ    (3) 
 
Coupling Eiciency 
To determine coupling eiciency ǻCEǼ, a measure of the catalytic eiciency describing the 
ratio of cofactor used for product formation, the overall N“DPH consumption rate ǻCRtotǼ 
over the full reaction time was irst determined following Eq. ŗ and Ř, to then calculate the 
CEǱ 
 ܥܧ =  ��������    ǻŚǼ 
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Turnover Number 
“n important measure for catalytic performance is the turnover number ǻTONǼ, describing 
the number of substrate molecules converted per molecule of catalyst. Since the 
measurements described above were limited by the total amount of cofactor present, the 
TON was determined using the N“DPH recycling system ǻ”ufer IIǼ. “fter the reaction was 
inished, products were extracted and analysed by HPLC to calculate the conversion %C as 
described above. Multiplying %C with the initial substrate concentration ĐS and dividing by 
the concentration of enzyme, yields the maximum amount of product formed per mole 
enzyme. 
   �ܱܰ =  %�∙ �ೄ�ಳಾ3     (5) 
 
MICHAELIS-MENTEN Kinetics 
Classical MICH“ELIS-MENTEN kinetics were analyzed by determining initial reaction rates as 
described above for diferent substrate concentrations ĐS, then linearly ploted as a function 
of ĐS ǻcf. Figure ř-ŗşǼ. In the case of substrate ŗa, a direct approach for following substrate 
conversion was used and the reaction analysed in real time via luorescence. 
    � =  ����  ∙ �ೄ�ಾ+�ೄ     (6) 
   �ܿ�� =  ����ܿܤܯ3    (7) 
 
Figure ϯ-ϭϵ.  MICHAELIS-MENTEN plots foƌ TFFIS ǁith ϭa ;letͿ aŶd WMV ǁith ϯd ;ƌightͿ. At loǁeƌ 
ĐoŶĐeŶtƌaioŶs ;gƌeǇ data poiŶtsͿ, the high leak ƌate of WMV ǁithout suďstƌate iŶteƌfeƌes 
ǁith the ŵeasuƌeŵeŶt.  
The program ORIGIN was used for non-linear curve iting to match the MICH“ELIS-MENTEN 
Equation ǻŜǼ, where vŵaǆ is the maximum reaction velocity at saturation substrate concentra-
tion and KM is the MICH“ELIS constant ǻdescribing substrate concentration at half maximum 
velocityǼ. Knowing the enzyme concentration, the enzymatic turnover number or catalytic 
constant, kĐat, can be determined and used to calculate the catalytic eiciency kĐat/KM ǻEq. ŝǼ. 
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Results 
The results of determined kinetic parameters are summarized in Table ř-Ř. In the case of 
substrate ŗa, the most active mutant TFFIS yields a śŘ-fold higher luorescence response than 
the wt, corresponding to a turnover number ǻTONǼ of ŚŘś. MICH“ELIS-MENTEN parameters 
of KM and kĐat were determined to be ř.ŝ µM and Ŗ.ŘŜ s-ŗ, respectively ǻkĐat/KM = ŝŖ.ř mM-ŗ  s-ŗǼ. 
None of the other hits was able to convert any of the luorescein substrates. ”y far the highest 
performance is shown by mutant WMV, which shows full substrate conversion already at a 
low enzyme concentration of Ŗ.Ŗŗ µM with remarkable MICH“LIS-MENTEN values of 
KM = ŝ.Ř µM, kĐat = śśŖ s-ŗ, and kĐat/KM = ŝ.Ŝ ∙ ŗŖŚ mM-ŗ  s-ŗ against substrate řd. This respectively 
translates into a turnover number over śŖŖŖ ǻassay limitǼ, an excellent value that is seldom 
reported for PŚśŖ”Mř mutants.[ŗŚŝ] However, another important parameter for CYP enzymes 
besides turnover and activity is their leak rate. The WMV-mutant was found to have the 
highest leak rate, resulting in the wasting of valuable resources ǻN“DPHǼ if left without the 
opportunity to use them productively. Still, about ŗś and Řŗ% of the N“DPH electrons are 
directed to product formation in the case of TFFIS and WMV, respectively.  
 
Taďle ϯ-Ϯ.  BioĐheŵiĐal ĐhaƌaĐteƌizaioŶ of difeƌeŶt PϰϱϬBMϯ ŵutaŶts. GiǀeŶ aƌe ǀalues foƌ leak ƌate 
;LRͿ, NADPH ĐoŶsuŵpioŶ ƌate ;NͿ, pƌoduĐt foƌŵaioŶ ƌate ;PFRͿ, ĐoupliŶg eiĐieŶĐǇ ;CEͿ, 
tuƌŶoǀeƌ Ŷuŵďeƌ ;TONͿ, ĐatalǇiĐ ĐoŶstaŶt kĐat, MiĐhaelis ĐoŶstaŶt KM, aŶd ĐatalǇiĐ 
eiĐieŶĐǇ kĐat/KM. 
Mutant Substrate LR N PFR CE TON kcat  KM kcat/KM 
TFFIS¤ 1a^ 620 861 131 15% 425 0.26 3.7 70.3 
wt¤  106 182 * * * * * * 
WMV§ 3d~ 26608 18643 3845 21% >5000 549.8 7.2 ϳ.ϲ∙ϭϬ4 
wt¤  106 81 * * * * * * 
M01¤ 2a^ 119 81 3 4% 47 * * * 
Leak ƌate aŶd NADPH ĐoŶsuŵpioŶ ƌate aƌe giǀeŶ iŶ µŵol NADPH ∙ µŵol BMϯ-ϭ ∙ ŵiŶ-ϭ aŶd ǁeƌe 
ĐalĐulated as iŶiial ƌates oǀeƌ ϭϬs iŶ pƌeseŶĐe of ϭ% DMF. PƌoduĐt foƌŵaioŶ ƌate is giǀeŶ iŶ µŵol ∙ µŵol 
BMϯ-ϭ ∙ ŵiŶ-ϭ. The MICHAELIS ĐoŶstaŶt KM is giǀeŶ iŶ µŵol ∙ L-ϭ, kĐat iŶ s-ϭ aŶd kĐat/KM iŶ ŵŵol ∙ L-ϭ ∙ s-ϭ. 
ReaĐioŶs ǁeƌe Đaƌƌied out iŶ Bufeƌ I oƌ II ;foƌ TONͿ at eŶzǇŵe ĐoŶĐeŶtƌaioŶs of Ϭ.ϭ µM ;¤Ϳ oƌ Ϭ.Ϭϭ µM ;§Ϳ 
aŶd ŵaǆiŵuŵ suďstƌate ĐoŶĐeŶtƌaioŶs of ϭϬϬ µM ;^Ϳ oƌ ϱϬ µM ;~Ϳ. EŶtƌies ŵaƌked * Đould Ŷot ďe 
deteƌŵiŶed due to loǁ aĐiǀitǇ. 
While the highly active mutant WMV activated all coumarin-derived substrates ǻŘa, Řc, řc, 
and řdǼ, the more selective mutant MŖŗ showed activity towards substrates Řa and Řc only, 
at about Ś-fold higher than the wt ǻTON = ŚŝǼ. This means that compounds even with very 
similar core structures can be diferentiated by various mutants, but this gain in selectivity 
comes with an activity penalty, as discussed above ǻpage ŚŝǼ. 
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ϯ.ϱ.ϰ CoŶsideƌaioŶ of IŶdiǀidual Site IŶlueŶĐes  
For a beter understanding of the observed selectivities, it is sensible to combine in silico 
models and empirical data. Therefore, docking and molecular dynamics ǻMDǼ simulations of 
the three most interesting variants TFFIS, WMV and MŖŗ with their respective substrates ǻŗa, 
řd and ŘaǼ were performed by RICH“RD LONSD“LE.[ŗ] Mutations were introduced in silico to 
the wt crystal structure ǻPD”-ID ŗ”Uŝ[ŘŜś]Ǽ, and the simulations led to stable binding modes 
of the substrates in their corresponding mutants close enough to enable hydroxylation by the 
oxidizing iron-oxo species ǻCompound IǼ. These results are shown in Figure ř-ŘŖ, and can be 
compared with literature-known data on the inluence of mutations at certain sites, a lot of 
which have been reviewed by WHITEHOUSE et al.,[ŗŚş] while key mutations have been pointed 
out by ”UTLER et al.[ŘŜŜ] 
     
 
Figure ϯ-ϮϬ. IŶ siliĐo ƌesults. DoĐkiŶg poses foƌ ;aͿ suďstƌate ϭa iŶ TFFIS, ;ďͿ suďstƌate ϯd iŶ WMV aŶd 
;ĐͿ suďstƌate Ϯa iŶ MϬϭ. Highlighted aƌe the oǆidized pƌostheiĐ heŵe gƌoups ;ƌedͿ, 
suďstƌate ;gƌeeŶͿ aŶd ŵutated ƌesidues ;oƌaŶge: Rϰϳǆ, ďlue: FϴϳǆͿ. 
TFFIS shows a change at position SŝŘF ǻyellowǼ, where a small polar residue is replaced by a 
bulky one. This position is known to dramatically afect stereoselectivity, so we can expect 
this radical change to have an inluence on substrate binding.[ŘŜŝ] “nd indeed, it forms a π-
stacking interaction with the substrate, ixing it in proximity to the iron core to allow 
conversion. Likewise, substrate binding is known to be inluenced via direct or water-
mediated hydrogen bonds by changes of LŚřŝ to polar residues.[ŗřŘ] However, serine here 
does not show any apparent direct interaction in the docked structure. 
ϯ     Results aŶd DisĐussioŶ 
_________________________________________________ 
 
 
 
| ϱϱ 
In the case of WMV, the substrate can enter deep into the active site, positioning the 
protection group closely to the heme, which can account for the extremely fast turnover 
observed in the kinetics measurements. “dditionally, substrate positioning of řd is 
facilitated by a hydrogen bond between the carbonyl oxygen and SŝŘ. 
LŗŞŞ, which is mutated in MŖŗ, is located on the F-helix of the enzyme. This structure, 
together with the G-helix, can inluence substrate admission,[ŗřŜ,ŘŜŞ,ŘŜş] because they cover the 
active site and are able to restrict or grant access in a sliding mechanism.  Mutations at EŘŜŝ, 
also present in MŖŗ, can be expected to interfere both with substrate binding and proton 
shutling, by disturbing a highly conserved hydrogen bond patern. However, changing it for 
valine in the case of this mutant can reportedly improve coupling eiciencies for some 
substrates.[ŘŝŖ]  
“ll three mutants have changes of RŚŝ and FŞŝ in common, and especially the later shows a 
patern of being replaced by a small hydrophobic residue ǻvaline or isoleucine, blueǼ. It is 
known that FŞŝ is close to the substrate in the active site,[ŗřŜ,ŘŜş,Řŝŗ] restricting access to the iron 
core, especially in the case of bulky substrates. It is also highly conserved in naturally 
occurring homologues, but changing it to alanine can reportedly inluence selectivity. [ŗŚş] Our 
found mutants do not show alanine, but similar changes to small hydrophobic residues 
ǻisoleucine for TFFIS and valine for both WMV and MŖŗǼ. RŚŝ, on the other hand is the only 
charged residue in the binding pocket, and crucial for substrate binding and ainity, often 
appearing in a mutation dyad with Yśŗ.[ŘŜŞ,ŘŜş,Řŝŗ–Řŝř]  Here we cover a wide range of mutations 
ǻorangeǼ, from small, polar protic threonine in TFFIS, favoring luorescein substrates, over 
small, hydrophobic leucine in MŖŗ to large, hydrophobic tryptophan in WMV. The later two 
are most puzzling, since the smaller, supposedly less restrictive residue is present in the 
more selective mutant. That is a clear reminder that individual residues can never account 
for the observed performance of an enzyme, but that it is important to look at the bigger 
picture. 
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ϯ.ϲ ReaĐioŶs iŶside LiǀiŶg Cells 
For the investigation of the deprotection system as a means for possible prodrug activation, 
the implementation into living cells is an important milestone. TFFIS/ŗa was used as 
deprotection system for all following experiments, unless otherwise stated. 
 
ϯ.ϲ.ϭ HeLa Cells 
“ cervical cancer cell line isolated in ŗşśŗ and named HeLa after the original donor 
HENRIETT“ L“CKS, was used here.[ŘŝŚ] ”eing the irst stable human cell line that allowed 
culturing over multiple generations, it is widely used across various scientiic ields. 
However, it should be noted that due to changes in chromosome numbers and diferent 
additional mutations obtained over the years, the comparability with healthy human tissue is 
debated. Nevertheless, HeLa cells are still an invaluable tool for investigations in vivo, not 
least because their genome has been sequenced,[Řŝś] but also because their behavior has been 
extensively studied, allowing direct comparisons with diferent indings and between 
research groups. 
First of all, cytotoxicity of the substrate had to be ruled out, by subjecting the cells to the 
compound and comparing their activity in a photometric resazurin conversion assay. The 
experiments carried out by MIKH“IL ZYUZIN conirmed no changes in cell viability at 
substrate  concentrations ranging from ŗŖŖ nM to ŗŖŖ µM ǻcf. Figure ř-ŘŗǼ.  
 
Figure ϯ-Ϯϭ.  CǇtotoǆiĐitǇ of suďstƌate ϭa agaiŶst HeLa Đells, ǁith DMF aŶd DMSO as Đo-solǀeŶts, as 
deteƌŵiŶed ǀia a ƌesazuƌiŶ luoƌesĐeŶĐe assaǇ. AdheƌeŶt Đells ǁeƌe iŶĐuďated ǁith ǀaƌǇiŶg 
ĐoŶĐeŶtƌaioŶs of the suďstƌate ;Ϭ.ϭ-ϭϬϬ µMͿ foƌ ϳ h ďefoƌe tƌeatŵeŶt ǁith ƌesazuƌiŶ, aŶd 
the sigŶal ǁas Ŷoƌŵalized to a ĐoŶtƌol of Đells tƌeated ǁith the saŵe Đo-solǀeŶt ďut Ŷo 
suďstƌate. 
 
ϯ     Results aŶd DisĐussioŶ 
_________________________________________________ 
 
 
 
| ϱϳ 
DiƌeĐt TƌaŶsfeĐioŶ 
For a irst straightforward qualitative estimation of the deprotection performance inside a 
living system, commercially available kits allow the direct transfection of cells. This can be 
done by either using the pure protein or mRN“, which is then used as a translation template 
by the cellȂs protein synthesis machinery. “nother option is microinjection, which eliminates 
the need of additional reagents. “ll three methods were investigated. 
 
Puriied Protein 
The puriied protein was transfected using the commercially available kit TUR”OFECT.[ŘŝŜ] The 
enzyme is irst mixed with the transfection agent to allow complex formation. Then the cells 
are treated with the mix and incubated for complex uptake. Upon addition of substrate stock 
solution to the cells, very low activity of luorescence was observed along with considerable 
cytotoxicity ǻcf. Figure ř-ŘŘǼ. Experiments were carried out in collaboration with MIKH“IL 
ZYUZIN. 
      
Figure ϯ-ϮϮ.  TƌaŶsfeĐioŶ of HeLa Đells ǁith puƌiied TFFIS usiŶg TURBOFECT at Ϭ.ϴ ;letͿ aŶd ϭ.ϲ ʅL/ʅg 
pƌoteiŶ ;ƌightͿ. ToǆiĐitǇ of the tƌeatŵeŶt is easilǇ ǀisiďle ďǇ the ƌouŶd shape of the Đells, 
iŶdiĐaiŶg detaĐhŵeŶt fƌoŵ the plate, aŶd the foƌŵaioŶ of ǀesiĐles. 
Two diferent complexation ratios were tested, Ŗ.Ş or ŗ.Ŝ µL/µg of the agent per total protein. 
Cells are dead in both cases, and at increased contrast setings low luorescence can be seen 
at the lower concentration, while at higher TUR”OFECT ratio the cells are surrounded by a 
number of TUR”OFECT-TFFIS particles. Toxicity of the treatment is easily visible by the 
formation of vesicles and the round shape of the cells, indicating detachment from the plate. 
To investigate the cause of this toxicity, the cells were observed over time upon incubation 
with the complex, and after the addition of the substrate ǻcf. Figure ř-ŘřǼ. The samples 
showed no diference regarding the incubation time with the reagent, but after addition of 
the substrate apoptosis was quickly induced in all of the cells. Since substrate toxicity had 
been ruled out, the reason for the apoptosis of transfected cells has to be atributed to a 
diferent efect. “ possible explanation is the sudden activation of the enzyme upon addition 
of substrate, and the following N“DPH depletion, which might cause too much stress for the 
cells. Possible solutions are the optimization of the enzyme amount delivered to each cell, to 
allow a regeneration of the intracellular N“DPH pool while the reaction is taking place. 
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Figure ϯ-Ϯϯ.  Apoptosis of HeLa Đells upoŶ addiioŶ of suďstƌate ϭa ateƌ TURBOFECT tƌaŶsfeĐioŶ of TFFIS. 
 
mRNA 
To overcome enzyme deactivation after delivery to lysosomes, a diferent approach was 
made to transfect HeLa cells with the corresponding mRN“. Experiments were carried out 
by JO“NN“ REJM“N. The general method involves the linearization of plasmid DN“, 
followed by in vitro transcription. The mRN“ was subjected to the addition of a poly-“ tail, 
to increase its lifetime inside the cell. It is then transfection into HeLa cells in a process 
similar to protein transfection, using LIPOFECT“MINE.[Řŝŝ]  
    
Figure ϯ-Ϯϰ.  TƌaŶsfeĐioŶ of HeLa Đells ǁith ŵRNA eŶĐodiŶg foƌ TFFIS, usiŶg LIPOFECTAMINE ;let: 
luoƌesĐeŶĐe ĐhaŶŶel, ƌight: ďƌight ieldͿ. The tƌeatŵeŶt is toǆiĐ foƌ the Đells ;ƌouŶd shape, 
foƌŵaioŶ of ǀesiĐlesͿ. This has to ďe atƌiďuted to this paƌiĐulaƌ ŵRNA, siŶĐe a ĐoŶtƌol 
ǁith GFP did Ŷot shoǁ aŶǇ toǆiĐitǇ ;data Ŷot shoǁŶͿ. 
 
Unfortunately, the achieved luorescent activity was extremely low, and some toxicity was 
observed. Since a control experiment using the same method, but mRN“ coding for GFP, the 
toxicity might be due to the protein itself or to the use of bacterial mRN“. To determine 
which of these, it is suggested to clone the gene to a human vector. However, this approach 
was not followed any further during the course of this project. 
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ϯ.ϲ.Ϯ EŶĐapsulaioŶ 
Ultimately, delivery of the protein to mammalian cells was planned via encapsulation into 
polyelectrolyte microparticles, which can be taken up via endocytosis and then opened by 
irradiation.[ŘŝŞ] The P“R“K group has experience with this procedure, and MIKH“IL ZYUZIN 
worked on the adaptation of the synthesis for the PŚśŖ”Mř system.  
Pƌe-Tests 
In a irst step, the enzyme was subjected to a range of diferent conditions to investigate its 
stability in the process of encapsulation. Previously published studies[Řŝş,ŘŞŖ] already showed 
the susceptibility of the protein to bufer components and environmental conditions, 
showing the importance of these experiments. 
 
Additives 
The performance of the enzyme in presence of diferent additives used in capsule synthesis 
was tested at standard conditions in ”ufer IIǱ Total PŚśŖ”Mř-concentration was kept at 
Ŗ.ŗ µM, and the reactions were carried out using N“DPH instead of the GDH recycling 
system, to prevent interactions of the additives with GDH from inluencing the results. To 
evaluate the activity of the enzyme in cell-like environment, HeLa lysate was also used 
instead of reaction bufer for one reaction. Results are shown in Figure ř-Řś. 
 
Figuƌe ϯ-Ϯϱ.  StaďilitǇ of TFFIS iŶ pƌeseŶĐe of difeƌeŶt addiiǀes, Ŷoƌŵalized to the sigŶal iŶ KPi ďufeƌ. 
ReaĐioŶs ǁeƌe Đaƌƌied out iŶ Bufeƌ II folloǁiŶg staŶdaƌd ĐoŶdiioŶs at iŶal ĐoŶĐeŶtƌaioŶs 
of Ϭ.ϭ µM aŶd ϭϬϬ µM foƌ eŶzǇŵe aŶd suďstƌate, ƌespeĐiǀelǇ.  
Diferent bufer systems ǻKPi, P”SǼ are not an issue, neither are all tested polyelectrolytes. 
Some of them ǻP“H, PSSǼ even increase enzyme activity. HeLa lysate prepared using the 
detergent Triton X ŗŖŖ deactivates the protein, while lysate prepared by a cycle of freeze and 
thaw leads to higher luorescent responses. Native proteins do not seem to be the cause, so 
that one possible explanation could be the presence of cell-derived N“DPH in the lysate, 
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because higher cofactor concentration is directly related to product formation. Unfortunately, 
medium, especially with serum, diminishes enzymatic activity. The biggest issue can be seen 
in reactions with sodium carbonate or calcium chloride solutions, which reduce activity 
almost completely. ”oth tested transfection agents are safe, with PULSIN seemingly being the 
beter choice. 
 
pH-Stability 
Since PŚśŖ”Mř is known to be pH sensitive,[ŗŚś,ŘŞŗ] performance of TFFIS was tested at diferent 
pH values by RO”ERT GIESSM“NN. “ primary screen showed loss of function between pH Ś 
and ś, so that a detailed, time dependent proile could be determined ǻcf. Figure ř-ŘŜǼ. ”elow 
a pH of Ś.ś, the enzyme is inactivated irreversibly. Time-dependent stability also decreases 
with falling pH values, so that a pH of Ś.Ŗ the enzyme starts deteriorating quickly after ca. 
ŘŖ min. This can pose a particular problem for intracellular delivery, since many transfection 
methods irst direct their cargo to endosomes, which are often acidiied by the cell to become 
lysosomes with a pH below ś.[ŘŞŘ]  
 
Figure ϯ-Ϯϲ.  StaďilitǇ of TFFIS at difeƌeŶt pH ǀalues aĐƌoss a ǁide ƌaŶge of Ϯ-ϭϬ ;letͿ, aŶd iŶ a iŵe 
depeŶdeŶt aŶalǇsis of a Ŷaƌƌoǁ ƌaŶge of ϰ-ϱ ;ƌightͿ. ReaĐioŶs ǁeƌe Đaƌƌied out at pH ϳ 
ateƌ iŶĐuďaioŶ of the eŶzǇŵe at the speĐiied pH foƌ ϲϬ ŵiŶ oƌ the speĐiied aŵouŶt of 
iŵe. ReaĐioŶs ǁeƌe Đaƌƌied out iŶ Bufeƌ I folloǁiŶg staŶdaƌd ĐoŶdiioŶs at iŶal 
ĐoŶĐeŶtƌaioŶs of Ϭ.ϭ µM aŶd ϭϬϬ µM foƌ eŶzǇŵe aŶd suďstƌate, ƌespeĐiǀelǇ. 
Ionic Strength 
“nother important factor in enzymatic activity is ionic strength, known to afect 
dimerization in PŚśŖ”Mř, which is necessary for the enzyme to be active.[ŘŜŚ] This parameter 
can also afect reaction rates.[ŘŞř] Thus, the performance of TFFIS in potassium and sodium 
phosphate bufers was analyzed at varying ionic strength between ŗŖŖ mM and ŗ mM. 
Even though potassium seems to be the preferred cation for the enzyme, its performance in 
sodium is still very good and a litle less prone to efects from dilution ǻcf. Figure ř-Řŝ, top 
panelǼ. Recommended ionic strength is above řŖ mM. 
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Figure ϯ-Ϯϳ.  AĐiǀitǇ test of TFFIS. Let paŶel: AĐiǀitǇ ateƌ suďjeĐiŶg the eŶzǇŵe to difeƌeŶt 
ŵeĐhaŶiĐal distuƌďaŶĐes foƌ ǀaƌǇiŶg aŵouŶts of iŵe. ReaĐioŶs ǁeƌe Đaƌƌied out iŶ 
Bufeƌ I. Right paŶel: aĐiǀitǇ iŶ pƌeseŶĐe of difeƌeŶt ĐaioŶs at ǀaƌǇiŶg ioŶiĐ stƌeŶgth. 
ReaĐioŶs ǁeƌe Đaƌƌied out iŶ aŶalogǇ to Bufeƌ II. All ƌeaĐioŶs folloǁed staŶdaƌd 
ĐoŶdiioŶs at iŶal ĐoŶĐeŶtƌaioŶs of Ϭ.ϭ µM aŶd ϭϬϬ µM foƌ eŶzǇŵe aŶd suďstƌate, 
ƌespeĐiǀelǇ.  
 
Mechanical Disturbance 
The original capsule synthesis protocol requires agitation both by vortex and sonication. For 
this reason, the endurance of TFFIS was tested after subjecting it to mechanical disturbance 
for times from ŗ-ŗś min. Vortexing for ś min already reduces activity by around śŖ%, while 
sonication is safe even for prolonged periods of time and should thus be favored ǻcf. Figure 
ř-Řŝ, botom panelǼ. 
 
ModiiĐaioŶ of Capsule SǇŶthesis 
“fter stability studies ǻcf. Figure ř-ŘŞǼ showed incompatibility of the enzyme with various 
methods and compounds used in capsule synthesis, modiications were made to diminish 
these detrimental efects. The general approach is shown in Figure ř-Řş. First, a calcium 
carbonate template is precipitated from solution, and then coated in a layer-by-layer 
technique with alternating layers of anionic and cationic polyelectrolytes. 
Once the desired thickness of the wall is reached, the inner core is dissolved using EDT“ as a 
calcium chelating agent. Incorporation of the protein can occur either at the irst step ǻco-
precipitationǼ or after removal of the template ǻpost-loadingǼ. Neither method yielded loaded 
capsules with active enzyme, no mater whether bufered solutions or diferent mixing 
methods were applied. Diferent approaches for the preparation of loaded templates were 
followed. However, no active capsules could be synthesized so that this means of delivery 
could not be pursued any further.      
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Figure ϯ-Ϯϴ.  StaďilitǇ of TFFIS duƌiŶg difeƌeŶt steps of Đapsule sǇŶthesis. ReaĐioŶs ǁeƌe Đaƌƌied out iŶ 
Bufeƌ II folloǁiŶg staŶdaƌd ĐoŶdiioŶs at iŶal ĐoŶĐeŶtƌaioŶs of Ϭ.ϭ µM aŶd ϭϬϬ µM foƌ 
eŶzǇŵe aŶd suďstƌate, ƌespeĐiǀelǇ. 
 
Figure ϯ-Ϯϵ.  SĐheŵaiĐ desĐƌipioŶ of Đapsule sǇŶthesis. SoluioŶs of sodiuŵ ĐaƌďoŶate aŶd ĐalĐiuŵ 
Đhloƌide aƌe ĐoŵďiŶed aŶd ŵiǆed, foƌŵiŶg a iŶelǇ distƌiďuted pƌeĐipitate. These paƌiĐles 
aƌe used as teŵplates foƌ a laǇeƌ-ďǇ-laǇeƌ appƌoaĐh. TƌeatŵeŶt of the Đoƌes is alteƌŶated 
ďetǁeeŶ aŶioŶiĐ aŶd ĐaioŶiĐ polǇŵeƌs, uŶil the desiƌed thiĐkŶess is ƌeaĐhed. The Đoƌe 
ĐaŶ theŶ ďe dissolǀed usiŶg EDTA as a ĐalĐiuŵ Đhelate ageŶt. 
 
ϯ.ϲ.ϯ EsĐheƌiĐhia Đoli 
In order to investigate general enzymatic performance inside living systems, bacterial cells 
were used as a host, analogous to previous results by RUFF et al.[ŘŚŘ] In collaboration with 
N“TH“LIE NETT, E. coli expressing diferent variants were treated with substrates, and 
product formation was analyzed either by luorescence microscopy ǻmeasurements by FELIX 
DEMPWOLFFǼ or luorometrically.[ŗ] For TFFIS/ŗa, the resulting signal was easily monitored 
under a luorescence microscope, as shown in Figure ř-řŖ. However, the other tested 
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substrates could not be monitored in that way, since background luorescence was too high 
for good contrast imaging. Instead, the supernatants were removed, the cells washed and 
lysed, before luorometric analysis using a plate-reader. The results are shown in Figure ř-řŗ, 
and show clearly that the reaction takes places in the case of all corresponding hit 
mutant/substrate pairs, but is counteracted by active transport of the product from the cells 
into the supernatant. Only cells carrying TFFIS keep the majority of the uncaged luorophore 
inside.  
 
Figure ϯ-ϯϬ.  Liǀe Đell eǆpeƌiŵeŶts. E. Đoli eǆpƌessiŶg TFFIS ;topͿ shoǁ a high luoƌesĐeŶĐe sigŶal ateƌ 
tƌeatŵeŶt ǁith suďstƌate ϭa, iŶdiĐaiŶg suĐĐessful depƌoteĐioŶ. No sigŶiiĐaŶt sigŶal leǀel 
is oďseƌǀed iŶ the ǁt ;ďotoŵͿ. ShoǁŶ aƌe luoƌesĐeŶĐe ĐhaŶŶel ;letͿ, opiĐal ĐhaŶŶel 
;ŵiddleͿ aŶd oǀeƌlaǇ of ďoth ĐhaŶŶels ;ƌightͿ. SĐale ďaƌs iŶdiĐate Ϯ µŵ. Figuƌe adapted 
ateƌ ouƌ puďliĐaioŶ ǁith peƌŵissioŶ fƌoŵ JOHN WILEY & SONS LTD.[ϭ] 
 
Figure ϯ-ϯϭ.  Results of luoƌesĐeŶĐe ƌead-out of supeƌŶataŶts aŶd lǇsates of ǁhole Đell ƌeaĐioŶs. 
SigŶals aƌe Ŷoƌŵalized to the ŵaǆiŵuŵ aĐiǀitǇ oďseƌǀed foƌ the ĐoƌƌespoŶdiŶg 
luoƌophoƌe iŶ this assaǇ, Ŷegaiǀe sigŶals aƌe due to uŶƌelated suďstaŶĐes pƌeseŶt iŶ 
ŵediuŵ oƌ lǇsate ;oƌigiŶal data see AppeŶdiǆ ϭϬͿ. 
TFFIS 
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ϰ SuŵŵaƌǇ aŶd Outlook   
Caged compounds have been successfully applied in various ields from chemical biology to 
medicinal chemistry. For their activation, two main approaches are usedǱ ataching a photo-
labile substituent, which can be cleaved by irradiationǲ or using the target organismȂs own 
enzymes to remove the group, usually atached via an ester- or amide bond. However, those 
options sufer from certain disadvantagesǱ The former method often relies on tissue-
damaging UV light, and is necessarily conined to the proximity of the light source.[12,35] The 
later approach, on the other hand, does not allow any control over the time and site of 
activation at all. “ solution might be the use of artiicial catalysts in combination with 
bioorthogonal protecting groups, but classical metal catalysts are easily deactivated in a 
cellular environment.[44,45] Fortunately, nature provides us with an invaluable alternative – 
enzymes are biocatalysts, evolved for selectivity and perfectly adapted to physiological 
conditions. For that reason, they have been extensively used in medicine and industry.[78,88] 
However, sometimes their native functionality is not enough for speciic applications, giving 
rise to the lourishing ield of protein engineering that allows us to tailor enzymes to our 
needs.[109,111,112]  
“nother growing area of research is the controlled delivery and release of a compound 
inside an organism or even to subcellular destinations. The most versatile option for large 
biomolecules like a protein are probably nanoparticles, which allow a large range of 
variation in their composition and can for example be tagged with antibodies for tissue 
targeting.[284] Thus, we reasoned that engineered enzymes could expand the toolbox of 
bioorthogonal chemistry by selectively catalyzing the cleavage of an artiicial protection 
group in vivo, and that nano- or microparticles could be used to deliver the biocatalyst to its 
site of action. Speciically, we intended to use caged luorophores for this proof-of-concept 
study, to be activated by engineered PŚśŖ”Mř variants available in the REETZ lab, and 
transported into living cells after encapsulation in collaboration with P“R“KȂs group. 
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SĐheme ϰ-ϭ.  Oǀeƌǀieǁ oǀeƌ sĐƌeeŶed ŵodel ĐoŵpouŶds aŶd theiƌ ƌespeĐiǀe hit ŵutaŶt. Fiƌst aŶd 
seĐoŶd geŶeƌaioŶ ĐoŵpouŶds aƌe luoƌesĐeiŶ deƌiǀaiǀes ;ϭͿ, ǁheƌeas thiƌd geŶeƌaioŶ 
oŶes aƌe ďased oŶ ĐouŵaƌiŶs ;Ϯ aŶd ϯͿ. Fuƌtheƌ iŶlueŶĐes ǁeƌe iŶǀesigated usiŶg fouƌth 
geŶeƌaioŶ pƌoteĐioŶ gƌoups. Coloƌ Đodes foƌ suďstƌates deƌiǀed fƌoŵ paƌeŶt ĐoŵpouŶds 
ϭ ;gƌeeŶͿ, Ϯ ;ƌedͿ aŶd ϯ ;ďlueͿ aƌe used thƌoughout this studǇ. Figuƌe adapted ateƌ ouƌ 
puďliĐaioŶ ǁith peƌŵissioŶ fƌoŵ JOHN WILEY & SONS LTD.[ϭ] 
“s alcohol protection groups, we chose non-native ethers. In the irst stage of the project, 
three luorescein diethers ǻGeneration I, cf. Scheme Ś-ŗ for an overview over all tested 
substratesǼ were successfully synthesized. ”ased on known protocols,[ŗŜŗ] a luorescence-
based medium throughput bioassay was developed ǻcf. Figure ř-řǼ. Existing libraries and 
collections of engineered cytochrome PŚśŖ”Mř variants expressed in E. coli ǻa total of over 
ŗŖŖŖ variantsǼ, which were available from the REETZ lab from previous studies,[ŗŜŗ,ŗŜŘ,ŘŚŞ] were 
screened for activity in regard to deprotection of these three substrates. The propargyl 
derivative ŗa proved to be the most suitable option for this luorophore. “fter the screening 
progress, hit variants with unknown mutations were sent for sequencing, and the mutation 
sites identiied. Duplicates were removed, and the mutations of řř remaining hit variants 
collected ǻTable ŝ-ŗǼ. Positions of the mutations in the active site are shown in Figure ř-ŘŖ. 
The most active mutant is TFFIS, which was puriied alongside the wild type for further 
characterization. Glycerol stocks of active variants, together with others that showed 
promising activity in diferent projects ǻREETZ groupǼ were combined in a collection plate ǻcf. 
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“ppendix ŗŘǼ to reduce screening efort in the following stages. Results and reproducibility 
for the conversion of ŗa are shown in Figure ř-ŝ. 
In the second stage of the project ǻGeneration IIǼ, modiications were introduced at the 
propargyl residue of the substrate, to test if an improvement in activity could be achieved, 
but for luorescein no beter protection group was found.[ŘśŖ] Notably, the most active mutant 
was again TFFIS for the closest related derivative that only difered in a methyl group 
ǻbutynyl diether ŗdǼ. Furthermore, diferent luorescent substrates derived from coumarin 
were protected with the now established protection groups ǻGeneration IIIǼǱ methyl 
umbelliferone ǻŘǼ, a drug used in bile therapy,[Řśŗ] and a literature known substrate for similar 
reactions, ř-carbyxycoumarin ethyl ester ǻřǼ.[ŘŚŘ] Their similar core structure can pose a 
problem for selectivity, since the most active mutant WMV is able to reliably activate both 
benzyl derivatives Řc and řc. However, it was possible to ind mutants that are able to 
distinguish them ǻMŖŗǼ, albeit at a lower level of activity. They could be used as starting 
point for directed engineering to reach beter performance. “nother set of protection groups 
ǻGeneration IVǼ was used to investigate the inluence of sterical, electronical, and chiral 
diferences on the deprotection reaction. One interesting aspect was the sensitivity to stereo-
information, ofering a valuable opportunity to ine-tune selectivity in future designs of 
caging groups. 
“fter the screening, it was possible to assemble activity proiles like the example shown in 
Figure ř-ş. For every tested parent compound at least one suitable pair of protection group 
and enzyme was successfully identiied in the end, and the corresponding proteins were 
expressed in a larger culture and puriied for further characterization. First, the enzyme 
concentration was determined to eliminate diferences in expression levels that appear in 
lysate assays. “fterwards, a range of kinetic characteristics and MICH“ELIS-MENTEN 
parameters were measured, highlighting the large diferences in performance that are 
present between mutants. “ beter understanding on the inluence of the involved mutated 
residues was achieved by combining empirical data from literature known studies with 
theoretical investigations in docking/MD experiments. “n interesting aspect is added by an 
experiment with two diferent enzymatic reactions in the same system, which showed that it 
is possible to create fully orthogonal PŚśŖ/protection group pairs, but that the issue of mixed 
dimers has to be closely monitored in such cases ǻcf. Figure ř-ŗŝǼ. 
To investigate the behavior of the system under the conditions present in encapsulation 
procedures, TFFIS/ŗa was used as a reliable model reaction and tested against a multitude of 
diferent inluencesǱ stability against additives and chemicals, changes of pH values, ionic 
strength, and mechanical disturbance. Unfortunately, it was not possible in the given 
timeframe to modify the encapsulation protocol suiciently, so that no functional loaded 
capsules could be prepared and delivered to mammalian cells. Tests with commercially 
available techniques to transfect HeLa cells either directly with the protein or the 
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corresponding mRN“ showed only weak activity while at the same time exhibiting a certain 
level of toxicity.  
However, the reaction was successfully implemented inside living E.coli with all tested 
substrates, proving the enzyme active in a cellular environment and thus representing an 
encouraging support for the general concept ǻcf. Figure ř-řŖǼ.  
CoŶĐlusioŶ 
In summary, a system for the enzymatic bioorthogonal uncaging of small organic molecules 
was successfully developed. “ range of caged luorophores carrying ether protection groups 
were synthesized, which can be cleaved selectively by diferent identiied PŚśŖ”Mř mutants, 
without the immediate need for mutagenesis experiments. “ll identiied pairs of enzyme and 
protection group were fully characterized, and the inluence of mutations was rationalized 
based on empirical and theoretical studies. External inluences on the performance were 
examined. Furthermore, it is shown that carefully selected enzyme pairs are able to perform 
orthogonally in the same system. The scope of diferent transfection methods into 
mammalian cells was investigated. Finally, the activity of the PŚśŖ”Mř biocatalysts inside 
living bacterial cells was proved, and the indings were published and can be accessed at 
“NGEW“NDTE CHEMIE[Ř] and its international edition.[ŗ] 
Outlook 
The reported results pave the way for future applications of enzyme-mediated deprotection 
reactions, which can be used in medicinal chemistry, for the activation of prodrugs at the 
target location. In chemical biology, carefully selected orthogonal reactions could be used as 
general tools, or for cellular probes of diferent compounds, which then result in distinct 
signals, e.g. for imaging purposes. “nother possible use could be the application in crucial 
steps of organic synthesis, where tailored orthogonal protection groups have a long history 
in the production of structurally complex compounds. Combined approaches merging 
chemical and biological synthesis are a much valued concept.[ŘŞś,ŘŞŜ] 
To further increase the performance and versatility, it could be promising to transfer the 
concept to a diferent system, possibly by choosing a smaller, less complex enzyme that 
works without the need for a cofactor. Lipases for example are a well-studied class of 
enzymes, with a long history of engineering, the results of which are listed in an online 
database.[ŘŞŝ]  
To address the challenge of protein delivery, other options apart from polyelectrolyte 
capsules could be investigated. One approach by SÁNCHEZ-SÁNCHEZ et al. uses virus-like 
particles to deliver a functional PŚśŖ”Mř variant into the cytosol of living cancer cells for prodrug 
activation.[ŘŖŘ] “ collaboration with their group is currently being established to combine this 
approach with our enzymatic deprotection system. 
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ϱ EǆpeƌiŵeŶtal Paƌt    
ϱ.ϭ AŶalǇiĐal EƋuipŵeŶt 
ϱ.ϭ.ϭ NMR SpeĐtƌosĐopǇ 
NMR spectra were measured at room temperature on a ”RUKER “V“NCE řŖŖ system ǻŗH-
NMR resonanceǱ řŖŖ.ŗ MHz, ŗřC-NMR resonanceǱ ŝś.ŗ MHzǼ, equipped with an autosampler 
”“CS-ŜŖ and analyzed using MESTRENOV“ VŜ.Ŗ.Ř software.  
Chemical shifts are given in ppm on the δ scale, and were determined after calibration to the 
residual signals of the solvents, which were used as an internal standard.[ŘŞŞ,ŘŞş]  
CDClř  ŗHǱ δ = ŝ.ŘŜ ppm ŗřCǱ δ = ŝŝ.ŗŜ ppm  
DMSO-dŜ ŗHǱ δ = Ř.śŖ ppm ŗřCǱ δ = řş.śŘ ppm  
“ceton-dŜ ŗHǱ δ = Ř.Ŗś ppm ŗřCǱ δ = ŘŖŜ.ŘŜǲ Řş.ŞŚ ppm 
Coupling constants J are given in Herz and were calculated by the program. Multiplicities of 
the signals are assigned as observed in the spectra, not according to theoretical expectations. 
They are denoted as followsǱ s = singlet, m = multiplet, d = doublet, t = triplet, q = quartet. 
“ssignment of the signals was performed based on coupling constants, ŘD spectra ǻCOSYǲ 
HMQCǼ or comparison with literature known compounds. 
 
ϱ.ϭ.Ϯ Mass SpeĐtƌoŵetƌǇ 
Mass spectrometric analysis of the compounds was performed by members of the service 
department of the PHILIPPS-UNIVERSITÄT M“R”URG. HR-ESI mass spectra were acquired 
with an LTQ-FT Ultra mass spectrometer ǻTHERMO FISHER SCIENTIFICǼ. Ionic masses are 
given in units of m/z for the isotopes with the highest natural abundance. 
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ϱ.ϭ.ϯ FluoƌoŵetƌiĐ aŶd SpeĐtƌophotoŵetƌiĐ MeasuƌeŵeŶts 
Photometric absorption analyses were measured on a J“SCO V‐ŜśŖ spectrophotometer 
equipped with a P“C‐ŝŚř Peltier temperature control unit and analyzed using 
SPECTR“M“N“GER VŘ software or ORIGIN ŘŖŗś. Fluorescence measurements were performed 
in black şŜ-well lat botom plates on a MOLECUL“R DEVICES SpectraMax Mś using SOFTM“X 
Pro Vś.Ř software and analyzed using ORIGIN ŘŖŗś. The setings used for the detection of 
diferent substrate classes are shown in Table ś-ŗ. 
 
Taďle ϱ-ϭ.  SeiŶgs foƌ luoƌesĐeŶĐe ƌead-out of difeƌeŶt suďstƌate Đlasses, deteƌŵiŶed fƌoŵ theiƌ 
ƌespeĐiǀe eǆĐitaioŶ aŶd eŵissioŶ ŵaǆiŵa. 
Substrate Class 
 Excitation Wavelength 
ʄex [nm] 
Emission Wavelength 
ʄem [nm] 
Cut-off filter 
ʄCO [nm] 
Fluorescein 1 490 520 515 
Methylumbelliferone 2 370 450 420 
Carboxycoumarin 3 400 440 420 
Linearity in the observed ranges of fluorescence was confirmed for all fluorophores (cf. Figure 7-1). 
 
ϱ.ϭ.ϰ HPLC MeasuƌeŵeŶts 
HPLC AŶalǇsis of ReaĐioŶs 
HPLC analyses were performed on an “GILENT ŗŘŖŖ system equipped with a quaternary 
pump, autosampler, column oven and variable wavelength detector ǻŘŘŖ nmǼ and analyzed 
using CHEMST“TION ”Ŗř.Ŗŗ software. 
Run conditions are shown in Table ś-Ř. “ll separations were performed at řŖ°C, on a 
reversed-phase CŗŞ column ǻ“GILENT Eclipse XDŞ-CŗŞ, d = Ś.Ŝ mm, l = ŗśŖ mm, particle size 
ś µmǼ in MeCN Ǳ Ŗ.ŗ% TF“/HŘO with ŗś µL injection volume. Retention times for all 
derivatives are given in Table ś-ř and an example chromatogram for a typical reaction of 
TFFIS on substrate ŗa is shown in Figure ř-ŗŞ. 
 
Taďle ϱ-Ϯ.  HPLC ĐoŶdiioŶs foƌ aŶalǇsis of ƌeaĐioŶ pƌoduĐts iŶ MeCN : Ϭ.ϭ% TFA/HϮO, at a loǁ ƌate of 
ϭ.ϱ ŵL/ŵiŶ. 
Tiŵe  
 [ŵiŶ] GƌadieŶt I GƌadieŶt II 
Ϭ  
ϳ  
ϭϱ  
ϮϬ  
ϮϮ  
ϯϬ-ϳϬ 
ϯϬ-ϳϬ 
ϲϬ-ϰϬ 
ϲϬ-ϰϬ 
ϯϬ-ϳϬ 
ϱϬ-ϱϬ 
ϱϬ-ϱϬ 
ϳϬ-ϯϬ 
ϱϬ-ϱϬ 
ϱϬ-ϱϬ 
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Taďle ϱ-ϯ.  ReteŶioŶ iŵes foƌ suďstƌate deƌiǀaiǀes as deteƌŵiŶed fƌoŵ the ĐoŶdiioŶs desĐƌiďed iŶ 
Taďle ϱ-Ϯ, GƌadieŶt I. 
CoŵpouŶd  ReteŶioŶ Tiŵe /ŵiŶ 
Aƌea foƌ ϭϬϬ µM 
/ŵAU*s 
FluoƌesĐeiŶ ϭ ϴ.ϳ ϴϬϯϬ 
PƌopaƌgǇl Dietheƌ ϭa ϭϴ.ϭ ϭϬϬϯϯ 
PƌopaƌgǇl MoŶoetheƌ  ϭϰ.ϳ ϲϭϵϬ 
CaƌďoǆǇĐouŵaƌiŶe ϯ ϯ.ϭ ϭϬϱϯ 
ButǇŶǇl Etheƌ ϯd ϭϯ.ϵ ϭϬϲϭ 
BeŶzǇl Etheƌ ϯĐ ϭϲ.ϵ ϭϭϰϬ 
MethǇluŵďellifeƌoŶe Ϯ Ϯ.ϳ ϱϴϮ 
PƌopaƌgǇl Etheƌ Ϯa ϭϬ.ϳ ϲϵϯ 
 
CaliďƌaioŶ Cuƌǀes 
For a calibration curve using integrated HPLC signals, DMF stocks of luorescein derivatives 
in concentrations ranging from ŗŖ to Ŗ.ŗ mM were diluted ŗŖŖ-fold, either in water or MeCN. 
MeCN-tests were carried out in triplicates. The solutions were prepared in a NUNC round-
botom PP şŜ-well plate in a total volume of ŘŖŖ µL ǻwater, added one by one using a manual 
pipeteǼ or ŘŖŘ µL ǻMeCN, added in rows of Ŝ using a manual Ş-channel pipeteǼ, then sealed 
with a NUNC rubber lid that can be perforated by the HPLC autosampler. Gradient II was 
used for all runs on the same machine. Tested substrates were ŗ, ŗa, ŗaȁ, and ŗd.  
CoŶĐeŶtƌaioŶ Tests 
Extraction tests were carried out ǻresults cf. Chapter ř.ś.Ř, page Śś, Figure ϯ-ϭϰǼǱ Substrates 
and product stocks of substrates and luorescein in concentrations ranging from ŗŖ to Ŗ. 
ŗ mM were diluted ŗŖŖ-fold in bufer in deep well plates, to yield a total volume of śŖŖ µL. 
These were extracted using the TEC“N Pipeting robot. “fter the irst addition of ŘŖŖ µL 
EtO“c and centrifugation for ŗŖ min at ŚŖŖŖ rpm, ~śŖ µL of the organic phase were 
transferred to a NUNC round botom PP şŜ-well plate, and a second extraction step ǻŗśŖ µLǼ 
followed. Organic phases were combined, and evaporated under air overnight. 
Redissolution in řŖŖ µL MeCN was achieved using an Ş-channel pipete, and plates were 
immediately sealed with a NUNC rubber lid. Samples were prepared in triplicates. 
For evaluation of the extraction method and reproducibility, samples of śŖŖ µL at a 
concentration of ŗŖŖ µM were extracted manuallyǱ 
ŗ. copying the robot-procedure exactly ǻR, RobotǼ 
Ř. copying the robot-procedure, but adding a step of thorough mixing by pipeting 
before each centrifugation step ǻM, MixǼ 
ř. extracting twice with śŖŖ µL EtO“c, combining org. phases ǻřŖŖ+śŖŖ µLǼ, and 
redissolving in śŖŖ µL MeCN ǻśŖŖǼ 
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EŶaŶioŵeƌiĐ SepaƌaioŶ 
Separation conditions are shown in Table ś-Ś. “nalytical measurements were performed at 
řŖ°C on a D“ICEL CHIR“LP“K I” column ǻd = Ś.Ŝ mm, l = ŘśŖ mm, particle size ś µmǼ using 
gradient IV, and separation of the enantiomers for isolation was performed on a semi-
preparative version of the same column ǻd = ŗŖ mm, l = ŘśŖ mm, particle size ś µmǼ using 
gradient III. Example chromatograms are shown in Figure ř-Ş, page ŚŖ. 
 
Taďle ϱ-ϰ.  HPLC ĐoŶdiioŶs foƌ eŶaŶioŵeƌiĐ ƌesoluioŶ iŶ MeCN : Ϭ.ϭ% TFA/HϮO. 
Tiŵe GƌadieŶt III Tiŵe GƌadieŶt IV 
[ŵiŶ] loǁ: ϯ ŵL/ŵiŶ [ŵiŶ] loǁ: ϭ ŵL/ŵiŶ 
Ϭ 
ϱϬ 
ϲϬ 
ϳϬ 
ϰϱ-ϱϱ 
ϱϬ-ϱϬ 
ϱϬ-ϱϬ 
ϰϱ-ϱϱ 
Ϭ 
Ϯϳ 
Ϯϵ 
ϯϵ 
ϰϱ-ϱϱ 
ϱϮ-ϰϴ 
ϰϱ-ϱϱ 
ϰϱ-ϱϱ 
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ϱ.Ϯ Bufeƌs aŶd StoĐk SoluioŶs 
Media and chemicals for bacteria were ordered from FLUK“ and ROTH. High-purity water 
was generated from the instituteȂs deionized water supply using a TK“ MICROL“” water 
puriication system. 
LB-Mediuŵ ;LǇsogeŶǇ BƌothͿ 
Tryptone     ŗŖ g 
Yeast Extract     ś g 
NaCl      ŗŖ g 
Water was added to a total volume of ŗŖŖŖ mL, components mixed until dissolved. The pH 
was then adjusted to ŝ before sterilization by autoclaving.   
TB-Mediuŵ ;TeƌƌiiĐ BƌothͿ 
Tryptone     ŗŘ g 
Yeast Extract     ŘŚ g 
Glycerol     Ś mL 
Water was added to a total volume of şŖŖ mL, components mixed until dissolved, then 
sterilized by autoclaving. ”efore use, ŗŖŖ mL of phosphate salt solution was added ǻsee 
belowǼ. 
Phosphate Salts foƌ TB-Mediuŵ ;ϭϬǆͿ 
KŘHPOŚ Trihydrate    ŗŜŚ.ř g   ǻŝŘŖ mMǼ 
KHŘPOŚ     Řř.ŗ g    ǻŗŝŖ mMǼ 
Water was added to a total volume of ŗŖŖŖ mL, components mixed until dissolved, then 
sterilized by autoclaving.  
Poǁeƌ Miǆ ;ϭϬϬǆͿ 
Glycerol      ŚŖ%  
Glutamate      saturated   in ŗŖŖ mM KPi, pH ŝ.Ś 
Components were mixed and sterilized by autoclaving. 
TƌaŶsiioŶ TƌaĐe Metal Miǆ ;TTM-Miǆ, ϭϬϬϬǆͿ 
Protocol modiied from STUDIER et al.[ŘşŖ] by KILLE.[ŘŚŞ] 
FeClř ∙ Ŝ HŘO      Ŝŝś.ŝś mg   ǻśŖ mMǼ  
CaClŘ      ŗŗŖ.şş mg   ǻŘŖ mMǼ  
MnSOŚ ∙ HŘO      ŞŚ.śŗ mg   ǻŗŖ mMǼ  
ZnSOŚ ∙ ŝ HŘO     ŗŚř.ŝŝ mg   ǻŗŖ mMǼ  
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CoClŘ ∙ Ŝ HŘO      Řř.ŝş mg   ǻŘ mMǼ  
CuClŘ ∙ Ř HŘO      ŗŝ.Ŗś mg   ǻŘ mMǼ  
NiClŘ ∙ Ŝ HŘO      Řř.ŝŝ mg  ǻŘ mMǼ  
NaŘMoOŚ ∙ Ř HŘO    ŘŚ.ŗş mg   ǻŘ mMǼ  
Hř”Oř      Ŝ.ŗŞ mg   ǻŘ mMǼ  
con. HCl      řŗŘ.ś µL  
The inal volume was adjusted with puriied water to śŖ mL. 
TB-Mediuŵ ;TeƌƌiiĐ BƌothͿ ǁith Phosphate Salts foƌ PϰϱϬBMϯ EǆpƌessioŶ 
T”-Medium     şŖŖ mL 
Phosphate Salts     ŗŖŖ mL 
Power Mix      ŗŖ mL 
TTM-Mix      ŗ mL 
Kanamycin     ŗ mL 
ϭϬǆ Phosphate Bufeƌ ;KPiͿ ϭ M, pH ϳ.ϰ  
KŘHPOŚ Trihydrate    ŗŜŖ g    
KHŘPOŚ     ŚŖ.ş g    
Water was added to a total volume of ŗŖŖŖ mL, components mixed until dissolved, then the 
pH value was conirmed using a pH meter and adjusted with KOH or HCl if necessary. 
Phosphate Bufeƌ ;KPiͿ ϭϬϬ ŵM, pH ϳ.ϰ 
ŗŖx Phosphate ”ufer    ŗŖŖ mL 
Water      şŖŖ mL 
”oth components were mixed and iltered sterile prior to use. Storage at Ś°C. 
StoĐk SoluioŶs of Addiiǀes 
Individual stocks were prepared by dissolving the speciied amount of substance in watera,  
KPib ǻŗŖŖ mM pH ŝ.ŚǼ or DMFc and stored at -ŘŖ°C, with the exemption from N“DPH-stocks, 
which were freshly prepared before use. Final dilution factors for use are given. 
Kanamycina ǻKanǼ    śŖ mg/mL    xŗŖŖŖ 
Isopropyl-Ά-D-ŗ-thiogalactopyranosidea       
ǻIPTGǼ     Řř.Şř mg/mL  ǻŗŖŖ mMǼ xŗŖŖŖ 
Nicotinamide adenine dinucleotide phosphate monosodium saltb   
ǻN“DP+Ǽ    ŝŞ.ŝŚ mg/mL  ǻŗŖŖ mMǼ xŗŖŖ 
Reduced nicotinamide adenine dinucleotide phosphate tetrasodium saltb  
ǻN“DPHǼ    ŘŖ.Ŗ mg/mL  ǻŘŚ mMǼ xŗŖŖ 
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Glucose Monohydrateb   ŗŞŖ.ŗŜ mg/mL  ǻŗ MǼ  xŗŖ 
Glucose Dehydrogenaseb ǻCodexis GDH-ŗŖśǼ     
ǻGDHǼ        ŗřř U/mL xŗřř 
Substratesc        ǻŖ.Ŗŗ-ŗŖ mMǼ xŗŖŖ 
PϰϱϬ WashiŶg Bufeƌ  
Glycerol     ś%    in ŗŖŖ mM KPi, pH ŝ.Ś 
PϰϱϬ ReaĐioŶ Bufeƌ I 
Glucose      ŗŖŖ mM  in ŗŖŖ mM KPi, pH ŝ.Ś 
N“DP+     ŗ mM 
GDH      ŗ U/ml 
The N“DPH recycling system used here is described in Figure ř-ŗ. 
PϰϱϬ ReaĐioŶ Bufeƌ II 
N“DPH     řŖŖ µM   in ŗŖŖ mM KPi, pH ŝ.Ś 
BRITTON-ROBINSON Bufeƌs 
Hř”Oř      Ŗ.ŖŚ M 
HřPOŚ      Ŗ.ŖŚ M 
“cetic “cid     Ŗ.ŖŚ M 
The aqueous solution was iltered, and titrated to the desired pH value with Ŗ.Ř M NaOH. 
LǇsis Bufeƌ 
Lysozyme     ŗ mg/mL   in ŗŖŖ mM KPi, pH ŝ.Ś 
EluioŶ Bufeƌ 
KCl      ŗ M    in ŗŖŖ mM KPi, pH ŝ.Ś 
HEPES Bufeƌ 
HEPES      ŘŖ mM, pH ŝ.ś  
DEAE Bufeƌs 
”ufer “Ǳ  HEPES    ŘŖ mM, pH ŝ.ś  
”ufer ”Ǳ  HEPES    ŘŖ mM, pH ŝ.ś 
  KCl    ŗ M 
 
 
ϱ     EǆpeƌiŵeŶtal Paƌt 
_________________________________________________ 
 
 
 
 ϳϲ | 
His-Tƌap Bufeƌs 
”ufer “Ǳ NaCl    ŞŖŖ mM in ŗŖŖ mM KPi, pH ŝ.Ś 
  L-Histidine   Ř mM 
”ufer ”Ǳ L-Histidine   ŞŖ mM  in ŗŖŖ mM KPi, pH ŝ.Ś 
ϰǆ SDS RuŶŶiŶg Bufeƌ 
TRIS      Řś mM 
Glycine     ŗşŘ mM 
SDS      Ŗ.ŗ% 
SDS Saŵple Bufeƌ 
Tris/HCl     ŗŖŖ mM 
SDS      ŗŖŖ mM 
β-Mercaptoethanol    Ř mM 
Glycerol     ŚŖ% 
”romophenol ”lue    ŗ% 
SDS ResolǀiŶg Gel 
For ŗŘ gelsǱ 
“crylamide     řŘ mL   ŗŘ% in HŘO 
Tris/HCl      Ş.ŝś mL  Ŗ.ś M, pH Ş.Ś 
HŘO      ŗş.ŞŜ mL 
SDS      řśŖ µL   ŗŖ% in HŘO 
“PS      ŗŝś µL   ŗŖ% in HŘO 
TEMED     řś µL   
SDS LoadiŶg Gel 
For ŗŘ gelsǱ 
“crylamide     ś.Şř mL  ś%, HŘO 
Tris/HCl      ŘŖ mL   ŗ.ś M, pH Ŝ.Ş 
HŘO      Řŝ mL 
SDS      ŞŖŖ µL   ŗŖ% in HŘO 
“PS      ŚŖŖ µL   ŗŖ% in HŘO 
TEMED     ŚŖ µL 
SDS Gel StaiŶ 
Ethanol     śŖ%  in HŘO 
“cetic acid     ŗŖ% 
Coomassie ”rilliant ”lue   ŘśŖ mg/L  
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ϱ.ϯ Suďstƌate SǇŶthesis aŶd ChaƌaĐteƌizaioŶ 
ϱ.ϯ.ϭ GeŶeƌal Methods 
Commercially available chemicals were ordered in highest available purity from “CROS, 
MERCK, SIGM“ “LDRICH, TCI CHEMIC“LS, THERMO FISHER SCIENTIFIC and VWR, and used 
without further puriication unless otherwise speciied. “nalytical grade solvents for 
reactions and HPLC were purchased from VWR, “CROS, FISHER SCIENTIFIC or MERCK, if 
necessary dried using standard protocols.[Řşŗ] Solvents for chromatography were used from 
the instituteȂs supply after distillation. Compressed air, liquid and gaseous nitrogen were 
used from the institutes supply without further puriication. High-purity water was 
generated from the instituteȂs deionized water supply using a TK“ MICROL“” water 
puriication system. 
Chemical syntheses were performed under inert nitrogen gas atmosphere unless otherwise 
speciied, using SCHLENK technique and lasks dried by repeated heating and lushing with 
inert gas. Transfer of solvents and liquid compounds was achieved using syringes and septa. 
For analysis by thin layer chromatography ǻTLCǼ, commercially available silica gel sheets 
were used ǻ“lugram Xtra SIL G/UVŘśŚ from M“CHEREY-N“GELǼ. Detection of the substances 
was performed under UV light at wavelengths of ŘśŚ or řŜŜ nm, or by staining with a 
potassium permanganate dip. Puriication by lash column chromatography was carried out 
using silica gel ŜŖ ǻparticle size of ŚŖ-Ŝř µm, from MERCKǼ, and under increased pressure 
from the house air supply. 
 
ϱ.ϯ.Ϯ FluoƌesĐeiŶ Deƌiǀaiǀes  
 
GeŶeƌal Method foƌ PƌoteĐted FluoƌesĐeiŶ Deƌiǀaiǀes 
“dapted from R“J“SEK“R et al.[ŘŚř] potassium carbonate ǻŘ.şř g, Řŗ.Ŗ mmol, ŝ.Ŗ eqǼ and 
luorescein ǻŗ, ŗ.ŖŖ g, ř.Ŗ mmol, ŗ.Ŗ eqǼ were dissolved in DMF ǻř mLǼ and purged with 
nitrogen for ŗś min. The corresponding bromide ǻřŖ mmol, ŗŖ eqǼ was added, upon which a 
reddish precipitate formed, making stirring di cult. “n additional ~Ř mL of solvent were 
added to allow for proper stirring. The slurry was heated to ŝŖ°C and stirred overnight 
under air. The resulting mixture was diluted with ethyl acetate ǻŘś mLǼ and extracted with 
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ś% HCl ǻŘś mLǼ. The aqueous phase was washed twice with ethyl acetate. Combined organic 
phases were washed with saturated sodium bicarbonate solution and dried over sodium 
sulfate. The solvent was evaporated and the orange solid raw product puriied via column 
chromatography. 
FluoƌesĐeiŶ PƌopaƌgǇl Deƌiǀaiǀes ;ϭa, a’, a’’Ϳ 
The solid raw product was puriied via column chromatography ǻsilicaǲ DCM/MeOH śŖǱŗǼ, 
and isolated as an of-white solid ǻŜŖŖ mg, ş.Śś mmol, Śś%Ǽ. The mono-ether ŗaȂ and ether 
ester ŗaȂȂ derivatives were obtained as solid, sticky, orange side products ǻŗŘş mg, 
Ř.śŘ mmol, ŗŘ% and řřŖ mg, ř.ŝŞ mmol, ŗŞ%, respectivelyǼ.  
 
“nalytical Data for ŗa  
TLC Rf = Ŗ.Ŝş ǻDCM/MeOH śŖǱŗǼ 
Rf = Ŗ.şŗ ǻEtO“cǼ 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ Ş.ŖŘ ǻd, řJ = ŝ.Ŝ Hz, ŗH, CŗŘ-HǼ, ŝ.ŝř – ŝ.śŜ ǻm, ŘH, 
CŗŖ/ŗŗ-HǼ, ŝ.ŗŜ ǻd, řJ = ŝ.Ŝ Hz, ŗH, Cş-HǼ, Ŝ.ŞŞ ǻd, ŚJ = ŗ.ş Hz, ŘH, CŘ-HǼ, Ŝ.ŝŘ 
ǻdd, řJ = Ş.Ş, śJ = Ŗ.Ś Hz, ŗH, Cś-HǼ, Ŝ.Ŝŝ ǻdd, řJ = Ş.Ş, ŚJ = Ř.ř Hz, ŗH, CŜ-HǼ, 
Ś.ŝŘ ǻd, ŚJ = Ř.Ś Hz, ŚH, Cŗś-HǼ, Ř.śŜ ǻt, ŚJ = Ř.Ś Hz, ŘH, Cŗŝ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗŜş.Ś ǻCŗŚǼ, ŗśş.ř ǻCŗǼ, ŗśř.Ř ǻCŞǼ, ŗśŘ.ś ǻCřǼ, ŗřś.Ř ǻCŗŖǼ, 
ŗŘş.ş ǻCŗŗǼ, ŗŘş.ř ǻCśǼ, ŗŘŜ.ş ǻCŗřǼ, ŗŘś.Ř ǻCŗŘǼ, ŗŘŚ.ŗ ǻCşǼ, ŗŗŘ.ř ǻCŜ/ŚǼ, ŗŖŘ.ř 
ǻCŘǼ, Şř.Ŗ ǻCŝǼ, ŝŞ.Ŗ ǻCŗŝǼ, ŝŜ.Řş ǻCŗŜǼ, śŜ.ŗş ǻCŗśǼ ppm.  
HRMS ǻESIǼ  m/zǱ calcd. for CŘŜHŗŜOś [M+H]+Ǳ ŚŖş.ŗŖŝŜ, foundǱ ŚŖş.ŗŖŝŘ. 
 
“nalytical Data for ŗaȂ 
TLC Rf = Ŗ.ŖŖ ǻDCM/MeOH śŖǱŗǼ 
Rf = Ŗ.ŝş ǻEtO“cǼ 
ŗH-NMR  ǻřŖŖ MHzǲ “cetone-dŜǼǱ Έ ş.Ŗŝ ǻs, ŗH, CŗŚ-OHǼ, ŝ.şş ǻtd, řJ = ŝ.ś Hz, 
ŚJ = ŗ.Ŗ Hz, ŗH, CŗŘ-HǼ, ŝ.Şŗ ǻtd, řJ = ŝ.ś, ŚJ = ŗ.ř Hz, ŗH, CŗŖ-HǼ, ŝ.ŝŚ ǻtd, 
řJ = ŝ.Ś Hz, ŚJ = ŗ.ŗ Hz, ŗH, Cŗŗ-HǼ, ŝ.řŖ ǻdt, řJ = ŝ.Ŝ Hz, ŚJ = ŗ.Ŗ Hz, ŗH, Cş-HǼ, 
Ŝ.şŜ ǻt, Ś,śJ = ŗ.ś Hz, ŗH, CŘ-HǼ, Ŝ.ŝŞ ǻdd, řJ = Ř.ŗ Hz, ŚJ = Ŗ.ŝ Hz,  ŗH, CŜȂ-HǼ, 
Ŝ.ŝŝ ǻd, Ś,śJ = ŗ.Ś Hz, ŘH, Cś/ŜǼ, Ŝ.Ŝŝ ǻd, J = Ŗ.ŝ Hz, ŗH, CŘȂ-HǼ, Ŝ.ŜŚ ǻd, 
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řJ = Ř.ŗ Hz, ŗH, CśȂ-HǼ, Ś.Şş ǻd, ŚJ = Ř.Ś Hz, ŘH, Cŗś-HǼ, ř.ŗś ǻt, ŚJ = Ř.Ś Hz, ŗH, 
Cŗŝ-HǼ ppm.  
ŗřC-NMR ǻŝś MHzǲ “cetone-dŜǼǱ Έ ŗŜŖ.ř, ŗśř.ş, ŗřŜ.ŗ ǻCŗŖǼ, ŗřŖ.Ş, ŗřŖ.Ř, ŗřŖ.Ŗ, ŗŘś.Ś 
ǻCŗŘǼ, ŗŘŚ.ş ǻCşǼ, ŗŗř.ś, ŗŗř.Ś, ŗŗř.Ř, ŗŖř.Ś, ŗŖř.ř, ŗŖŘ.ŝ, ŝş.Ř, ŝŝ.Ŝ, śŜ.ŝ ǻCŗśǼ 
ppm.  
HRMS ǻESIǼ  m/zǱ calcd. For CŘřHŗŚOś [M-H]+Ǳ řŝŗ.ŖşŗŚ, foundǱ řŝŗ.ŖşŖŞ. 
 
 
“nalytical Data for ŗaȂȂ 
TLC Rf = Ŗ.ŖŖ ǻDCM/MeOH śŖǱŗǼ 
Rf = Ŗ.řş ǻEtO“cǼ 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ Ş.Řŝ ǻdd, ŗH, řJ = ŝ.Ş Hz, ŚJ = ŗ.Ř Hz, ŗH, CŗŘ-HǼ, ŝ.ŝŝ ǻtd, 
ŗH, řJ = ŝ.ś Hz, ŚJ = ŗ.ś Hz, ŗH, CŗŖ-HǼ, ŝ.Ŝş ǻtd, ŗH, řJ = ŝ.ś Hz, ŚJ = ŗ.ś Hz, 
ŗH, Cŗŗ-HǼ, ŝ.řř ǻdd, ŗH, řJ = ŝ.ś Hz, ŚJ = ŗ.ś Hz, ŗH, Cş-HǼ, ŝ.Ŗŝ ǻd, 
ŚJ = Ř.ś Hz, ŗH, CŘ-HǼ, Ŝ.şŚ ǻd, řJ = ş.Ŗ Hz, ŗH, CśȂ-HǼ, Ŝ.Şş ǻd, řJ = ş.ŝ Hz, ŗH, 
CśȂ-HǼ, Ŝ.ŞŘ ǻdd, řJ = ş.Ŗ Hz, ŚJ = Ř.ś Hz, ŗH, CŜ-HǼ, Ŝ.Ŝŗ ǻdd, řJ = ş.ŝ Hz, 
ŚJ = ŗ.Ş Hz, ŗH, CŜȂ-HǼ, Ŝ.śŝ ǻs, ŗH, CŘȂ-HǼ, Ś.ŞŖ ǻd, ŚJ = Ř.ś Hz, ŘH, Cŗś-HǼ, 
Ś.ŜŖ ǻdd, ŘJ = ŗś.ś Hz, ŚJ = Ř.Ś Hz, ŘH, CŗŞ-HǼ, Ř.Ŝŗ ǻt, ŚJ = Ř.Ś Hz, ŗH, CŘŖ-HǼ, 
Ř.řř ǻt, ŚJ = Ř.ś Hz, ŗH, Cŗŝ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗŜŚ.Ŝ, ŗŜŘ.Ŗ, ŗśş.Ŗ, ŗśŚ.ř, ŗřŚ.ŝ, ŗřř.Ř, ŗřŗ.ś, ŗřŖ.ŝ, ŗřŖ.ř, 
ŗřŖ.ŗ, ŗřŖ.Ŗ, ŗŗŞ.ř, ŗŗś.ŝ, ŗŗŚ.Ŗ, ŗŖŜ.Ŗ, ŗŖŗ.ŝ, ŝŜ.ş, ŝś.ř, śŜ.ś ǻCŗśǼ, śŘ.ş ǻCŗŞǼ 
ppm.  
HRMS ǻESIǼ  m/zǱ calcd. for CŘŜHŗŜOś [M-H]+Ǳ ŚŖş.ŗŖŝŗ, foundǱ ŚŖş.ŗŖŜŝ. 
 
 
FluoƌesĐeiŶ AllǇl Dietheƌ ;ϭďͿ 
The solid raw product was puriied via column chromatography ǻsilicaǲ hexanes/ethyl 
acetate śǱŗ → řǱŗǼ, and isolated as a colorless solid ǻśřş mg, ş.Ŗř mmol, Śř%Ǽ. 
TLC Rf = Ŗ.řŚ ǻHexǱEE řǱŗǼ 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ Ş.ŖŘ ǻd, řJ = ŝ.ŗ Hz, ŗH, CŗŘ-HǼ, ŝ.Ŝś ǻddd, řJ = ŝ.Ś Hz, 
ŚJ = ŗ.ś Hz, ŗH, CŗŖ-HǼ, ŝ.ŜŘ ǻddd, řJ = ŝ.Ś Hz, ŚJ = ŗ.Ś Hz, ŗH, Cŗŗ-HǼ, ŝ.ŗŜ ǻd, 
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řJ = ŝ.ŝ Hz, ŗH, Cş-HǼ, Ŝ.ŝŞ ǻd, ŚJ = Ř.ř Hz, ŘH, CŘ-HǼ, Ŝ.ŜŞ ǻd, řJ = Ş.Ş Hz, ŘH, 
Cś-HǼ, Ŝ.ŜŘ ǻdd, řJ = Ş.Ş Hz, ŚJ = Ř.Ś Hz, ŘH, CŜ-HǼ, Ŝ.ŖŚ ǻddt, ř,transJ = ŗŝ.ř  Hz, 
ř,cisJ = ŗŖ.ś Hz, řJ = ś.ř Hz, ŘH, CŗŜȂ-HǼ, ś.ŚŘ ǻdq, ř,transJ = ŗŝ.Ř, ŚJ = ŗ.Ŝ Hz, ŘH, 
Cŗŝ-HǼ, ś.řŗ ǻdq, ř,cisJ = ŗŖ.ś Hz, ŘJ = ŗ.Ś Hz, ŘH, Cŗŝ-HǼ, Ś.śŜ ǻdt, 
řJ = ś.ř Hz, ŚJ = ŗ.ś Hz, ŚH, Cŗś-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗŜş.ś, ŗŜŖ.Ř, ŗśř.ř, ŗśŘ.Ŝ, ŗřś.ŗ, ŗřŘ.Ş, ŗŘş.Ş, ŗŘş.Ř, ŗŘŝ.Ŗ, 
ŗŘś.ŗ, ŗŘŚ.ŗ, ŗŗŞ.ř, ŗŗŘ.ř, ŗŗŗ.Ŝ, ŗŖŗ.ş, Şř.Ś, Ŝş.Ř ppm.  
HRMS ǻESIǼ  m/zǱ calcd. for CŘŜHŘŖOś [M+H]+Ǳ Śŗř.ŗřŞş, foundǱ Śŗř.ŗřŞŚ.  
 
 
FluoƌesĐeiŶ BeŶzǇl Dietheƌ ;ϭĐͿ 
The solid raw product was puriied via column chromatography ǻsilicaǲ DCM/MeOH ŗŖǱŗǼ 
and isolated as a colorless solid ǻŗŗŝř mg, ŗś.şŜ mmol, ŝŜ%Ǽ. 
TLC Rf = Ŗ.řŖ ǻHexǱEE řǱŗǼ 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ Ş.ŖŘ ǻd, řJ = Ŝ.ş Hz, ŗH, CŗŘ-HǼ, ŝ.ŞŞ – ŝ.śř ǻm, ŘH, 
CŗŖ/ŗŗ-HǼ, ŝ.śř – ŝ.řŗ ǻm, ŗŖH, Cŗŝ-CŘŗ-HǼ, ŝ.ŗŜ ǻd, J = ŝ.ř Hz, ŗH, Cş-HǼ, 
Ŝ.ŞŚ ǻs, ŘH, CŘ-HǼ, Ŝ.Ŝş ǻs, ŚH, Cś/Ŝ-HǼ, ś.Ŗş ǻs, ŚH, Cŗś-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗŜş.ś ǻCŗŚǼ, ŗŜŖ.Ŝ ǻCŗǼ, ŗśř.ř ǻCŞǼ, ŗśŘ.Ŝ ǻCřǼ, ŗřŜ.Ś, ŗřś.ŗ 
ǻCśǼ, ŗŘş.Ş, ŗŘş.ř, ŗŘŞ.Ş, ŗŘŞ.Ś, ŗŘŝ.Ŝ, ŗŘŝ.Ŗ, ŗŘś.Ř ǻCŗŘǼ, ŗŘŚ.ŗǻCşǼ, ŗŗŘ.Ś ǻCŜǼ, 
ŗŗŗ.ŝ ǻCŚǼ, ŗŖŘ.Ŗ ǻCŘǼ, ŝŖ.ś ǻCŗśǼ ppm.  
HRMS ǻESIǼ  m/zǱ calcd. for CϯϰHϮϰOϱ [M+H]+Ǳ śŗř.ŗŝŖŘ, foundǱ śŗř.ŗŜşŝ.  
 
 
FluoƌesĐeiŶ ButǇŶǇl Dietheƌ ;ϭdͿ 
This synthesis was carried out by N“TH“LIE NETT.[ŘśŖ]  
The solid raw product was puriied via column chromatography ǻsilicaǲ DCM/MeOH śŖǱŗǼ 
and isolated as a colorless solid ǻŘśś mg, Ŗ.śŞ mmol, ŗś%Ǽ.  
TLC Rf = Ŗ.śŝ ǻDCMǱ MeOH śŖǱŗǼ 
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ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ Ş.ŖŘ ǻdd, řJ = ŝ.Ř Hz, ŚJ = ŗ.Ŗ Hz, ŗH, CŗŘ-HǼ, ŝ.ŜŚ ǻtd, 
řJ = ŝ.Ś Hz, ŚJ = ŗ.Ś Hz, ŗH, CŗŖ-HǼ, ŝ.Ŝŗ ǻtd, řJ = ŝ.Ś Hz, ŚJ = ŗ.Ř Hz, ŗH, Cŗŗ-
HǼ, ŝ.ŗŜ ǻdt, řJ = ŝ.ř Hz, ŚJ = ŗ.Ŗ Hz, ŗH, Cş-HǼ, Ŝ.ŞŜ ǻd, J = Ř.Ś Hz, ŘH, CŘ-HǼ, 
Ŝ.ŝś ǻdd, řJ = Ş.Ş Hz, ŚJ = Ř.Ś Hz, ŘH, CŜ-HǼ, Ŝ.Ŝş ǻd, řJ = Ş.Ş Hz, ŘH, Cś-HǼ, Ś.Ŝŝ 
ǻq, śJ = Ř.Ř Hz, ŚH, Cŗś-HǼ, ŗ.Şŝ ǻt, śJ = Ř.ř Hz, ŜH, CŗŞ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗŜŘ.ŝ, ŗśş.ŝ, ŗśř.Ř, ŗśŘ.Ŝ, ŗřś.ŗ, ŗŘş.Ş, ŗŘş.Ř, ŗŘŝ.Ŗ, ŗŘś.Ř, 
ŗŘŚ.ŗ, ŗŗŘ.ř, ŗŗŘ.Ŗ, ŗŖŘ.Ř, ŞŚ.Ŝ, ŝŝ.Ś, ŝř.Ŝ, śŜ.ş, ř.ş ppm.  
HRMS ǻAPCIǼ  m/zǱ calcd. for CřŞHŘŖOś [M+H]+Ǳ Śřŝ.ŗřŞř, foundǱ Śřŝ.ŗřŞŚ. 
 
 
FluoƌesĐeiŶ NoŶǇŶǇl Dietheƌ ;ϭeͿ 
This synthesis was carried out by N“TH“LIE NETT.[ŘśŖ] 
The solid raw product was puriied via column chromatography ǻsilicaǲ DCMǼ and isolated 
as a beige solid ǻřŖŜ mg, Ŗ.ŝś mmol, řś%Ǽ. 
TLC Rf = Ŗ.ŜŚ ǻDCMǼ 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ Ş.ŖŘ ǻdd, řJ = Ŝ.Ŝ Hz, ŚJ = ŗ.ř Hz, ŗH, CŗŘ-HǼ, ŝ.ŜŚ ǻm, ŘH, 
CŗŖ/ŗŗ-HǼ, ŝ.ŗŜ ǻdd, řJ = Ŝ.Ŝ Hz, ŚJ = ŗ.Ŗ Hz, ŗH, Cş-HǼ, Ŝ.Şŝ ǻdd, ŚJ = Ř.Ŗ Hz, 
śJ = Ŗ.ŝ Hz, ŘH, CŘ-HǼ, Ŝ.ŜŞ ǻm, ŚH, Cś/Ŝ-HǼ, Ś.ŝŖ ǻt, śJ = Ř.ŗ Hz, ŚH, Cŗś-HǼ, 
Ř.ŘŘ ǻddd, řJ = ŝ.ŗ Hz, śJ = Ś.ś Hz, śJ =  Ř.Ŗ Hz, ŚH, CŗŞ-HǼ, ŗ.Řŝ ǻm, ŗŜH, Cŗş-
CŘŘ-HǼ, Ŗ.ŞŜ ǻm, ŜH, CŘř-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗśş.ŝ, ŗśř.ř, ŗśŘ.Ŝ, ŗřś.ŗ, ŗŘş.Ş, ŗŘş.Ř, ŗŘŝ.ś, ŗŘŝ.ŗ, ŗŘś.Ř, 
ŗŘŚ.ŗ, ŗŗŘ.Ś, ŗŗŘ.Ŗ, ŗŖŘ.ř, Şş.Ř, Şř.ř, ŝŚ.Ś, śŝ.Ŗ, řŗ.Ś, ŘŞ.Ŝ, ŘŞ.ś, ŘŘ.ŝ, ŗŞ.ş, ŗŚ.Ř 
ppm.  
HRMS ǻAPCIǼ  m/zǱ calcd. for CřŞHŚŖOś [M+H]+Ǳ śŝŝ.ŘşŚŝ, foundǱ śŝŝ.ŘşŚş. 
 
 
FluoƌesĐeiŶ PheŶǇlpƌopaƌgǇl Dietheƌ ;ϭfͿ 
This synthesis was carried out by N“TH“LIE NETT.[ŘśŖ] 
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The solid raw product was puriied via column chromatography ǻsilicaǲ DCMǼ and isolated 
as a beige solid ǻŚřŚ mg, Ŗ.ŝŝ mmol, řŜ%Ǽ. 
TLC Rf = Ŗ.ŝŝ ǻDCMǼ 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ Ş.ŖŘ ǻdd, řJ = Ŝ.ś Hz, ŚJ = ŗ.ŗ Hz, ŗH, CŗŘ-HǼ, ŝ.ŝŖ – ŝ.śş 
ǻm, ŘH, CŗŖ/ŗŗ-HǼ, ŝ.Śŝ – ŝ.ŚŚ ǻm, ŚHǼ, ŝ.řş ǻs, ŗH, Cş-HǼ, ŝ.řŚ – ŝ.Řş ǻm, śH, 
Carom-HǼ, ŝ.ŗś – ŝ.ŖŞ ǻm, ŗH, Carom-HǼ, Ŝ.şŖ – Ŝ.Şś ǻm, ŘH, Carom-HǼ, Ŝ.Ŝś ǻd, 
ŚJ = ŗ.ŗ Hz, ŚH, Carom-HǼ, Ś.Şŝ ǻs, ŚH, Cŗś-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗŜş.ś, ŗśş.Ŝ, ŗśř.ř, ŗśŘ.Ŝ, ŗřś.ŗ, ŗřŘ.Ŗ, ŗŘş.ş, ŗŘş.ř, ŗŘş.Ŗ, 
ŗŘŞ.ś, ŗŘŝ.Ŗ, ŗŘś.Ř, ŗŘŚ.Ř, ŗŘŘ.Ř, ŗŗŘ.Ś, ŗŗŘ.Ř, ŗŖŘ.Ś, Şŝ.ş, Şř.ř, Şř.ŗ, śŝ.ŗ ppm.  
HRMS ǻAPCIǼ  m/zǱ calcd. for CřŞHŘŚOś [M+H]+Ǳ śŜŗ.ŗŜşś, foundǱ śŜŗ.ŗŜşŝ. 
 
ϱ.ϯ.ϯ MethǇl-UŵďellifeƌoŶe Deƌiǀaiǀes 
 
GeŶeƌal Method foƌ PƌoteĐted MethǇluŵďellifeƌoŶe Deƌiǀaiǀes 
The synthesis protocol was adapted from N“IK et al.[ŘşŘ] 
Methylumbelliferone ǻŘ, śŖŖ mg, Ř.ŞŚ mmol, ŗ.Ŗ eqǼ was dissolved in dry acetone ǻŗŖ mLǼ, 
and anhydrous potassium carbonate ǻś.ŜŞ mmol, Ř.Ŗ eqǼ and the corresponding bromide 
ǻś.ŜŞ mmol, Ř.Ŗ eqǼ were added. The mixture was heated to śŖ°C overnight while stirring. 
“fter cooling to room temperature, the solvent was evaporated. The residue was treated 
with ŘŖ mL of cold water, and the resulting white solid was iltered and washed with water. 
Puriication by crystallization from ś-ŗŖ mL ethanol, slowly cooling to room temperature 
overnight, yielded the product as a colorless solid. 
 
 
MethǇluŵďellifeƌoŶe PƌopaƌgǇl Etheƌ ;ϮaͿ 
The puriied product was isolated as colorless crystals ǻřŞś mg, Ŝř%Ǽ.  
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ ŝ.śř ǻd, řJ = Ş.Ŝ Hz, ŗH, Cś-HǼ, Ŝ.şŚ ǻdd, řJ = Ş.Ŝ Hz, 
ŚJ = Ř.Ŝ Hz, ŗH, CŜ-HǼ, Ŝ.şŗ ǻd, ŚJ = Ř.Ŝ Hz, ŗH, CŞ-HǼ, Ŝ.ŗŜ ǻd, ŚJ = ŗ.Ř Hz, ŗH, 
CŘ-HǼ, Ś.ŝŜ ǻd, ŚJ = Ř.Ś Hz, ŘH, Cŗŗ-HǼ, Ř.śŝ ǻt, ŚJ = Ř.Ś Hz, ŗH, Cŗř-HǼ, Ř.ŚŖ ǻd, 
ŚJ = ŗ.Ř Hz, řH, CŗŖ-HǼ ppm.  
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ŗřC-NMR  ǻŝś MHz, CDClřǼǱ Έ ŗŜŗ.Ř, ŗŜŖ.Ś, ŗśś.ŗ, ŗśŘ.Ś, ŗŘś.Ŝ ǻCśǼ, ŗŗŚ.ř, ŗŗŘ.ŝ, ŗŗŘ.ś, 
ŗŖŘ.Ř, śŜ.Ř ǻCŗŗǼ, ŗŞ.Ŝ ǻCŗŖǼ ppm.  
HRMS ǻESIǼ  m/zǱ calcd. for CŗřHŗŖOř [M+H]+Ǳ Řŗś.ŖŝŖŞ, foundǱ Řŗś.ŖŝŖř.  
 
 
MethǇluŵďellifeƌoŶe BeŶzǇl Etheƌ ;ϮĐͿ 
The puriied product was isolated as a colorless solid ǻŜŘŞ mg, Ŝř%Ǽ.  
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ ŝ.ŚŘ ǻd, řJ = Ş.Ş Hz, ŗH, Cś-HǼ, ŝ.řş – ŝ.Řř ǻm, śH, Carom-
HǼ, Ŝ.ŞŜ ǻdd, řJ = Ş.Ş Hz, ŚJ = Ř.ś Hz, ŗH, CŜ-HǼ, Ŝ.ŞŖ ǻd, ŚJ = Ř.ś Hz, ŗH, CŞ-HǼ, 
Ŝ.Ŗś ǻd, ŚJ = ŗ.Ř Hz, ŗH, CŘ-HǼ, ś.Ŗś ǻs, ŘH, Cŗŗ-HǼ, Ř.řŗ ǻd, ŚJ = ŗ.Ř Hz, řH, 
CŗŖ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗŜŗ.ŝ, ŗŜŗ.Ř, ŗśś.Ř, ŗśŘ.ś, ŗřś.ş, ŗŘŞ.Ş, ŗŘŞ.Ś, ŗŘŝ.ś, ŗŘś.Ŝ, 
ŗŗř.Ş, ŗŗŘ.ş, ŗŗŘ.ŗ, ŗŖŘ.Ŗ, ŝŖ.ś ǻCŗŗǼ, ŗŞ.Ŝ ǻCŗŖǼ ppm.  
HRMS ǻESIǼ  m/zǱ calcd. for CŗŝHŗŚOř [M+H]+Ǳ ŘŜŝ.ŗŖŘŗ, foundǱ ŘŜŝ.ŗŖŗŜ.  
 
 
MethǇluŵďellifeƌoŶe ButǇŶǇl Etheƌ ;ϮdͿ 
The puriied product was isolated as a colorless solid ǻśřş mg, Şř%Ǽ.  
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ Έ ŝ.ŚŚ ǻd, řJ = Ş.Ŝ Hz, ŗH, Cś-HǼ, Ŝ.şŖ – Ŝ.ŝş ǻm, ŘH, Cś/Ŝ-
HǼ, Ŝ.ŖŞ ǻd, ŚJ = ŗ.Ř Hz, ŗH, CŘ-HǼ, Ś.ŜŚ ǻq,śJ = Ř.ř Hz, ŘH, Cŗŗ-HǼ, Ř.řř ǻd, 
ŚJ = ŗ.Ř Hz, řH, CŗŖ-HǼ, ŗ.ŞŖ ǻt, śJ = Ř.ř Hz, řH, CŗŚ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ Έ ŗŜŗ.ŘŖ, ŗŜŖ.ŝŝ, ŗśś.ŗŗ, ŗśŘ.ŚŜ, ŗŘś.ŚŞ ǻCśǼ, ŗŗř.şŝ, ŗŗŘ.Şŝ, 
ŗŗŘ.Řŗ, ŗŖŘ.Ŗŝ, ŞŚ.Şś, ŝŘ.şŞ ǻCŗŗǼ, śŜ.Şş, ŗŞ.ŜŚ ǻCŗŖǼ ppm.  
HRMS ǻESIǼ  m/zǱ calcd. for CŗŚHŗŘOř [M+H]+Ǳ ŘŘş.ŖŞŜś, foundǱ ŘŘş.ŖŞŜŖ.  
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ϱ.ϯ.ϰ CaƌďoǆǇĐouŵaƌiŶ Deƌiǀaiǀes  
The synthesis protocol was adapted from RUFF et. al.[ŘŚŘ] 
 
 
ϯ-CaƌďoǆǇĐuŵaƌiŶ-ethǇlesteƌ ;ϯͿ 
This synthesis was carried out by N“TH“LIE NETT.[ŘśŖ] 
Ř,Ś-Dihydroxybenzaldehyde ǻŘ.şş g, Řŗ.Ŝ mmol, ŗ.ŗ eqǼ was dissolved in dry methanol 
ǻŗŜ mLǼ, and diethylmalonate ǻř.ŗś g, ŗş.ŝ mmol, ŗ.Ŗ eqǼ was added and heated to boiling. “s 
catalyst mixture morpholine (163 µl, ŗ.Şŝ mmol, Ŗ.Ŗş eqǼ and acetic acid (52 µl, Ŗ.şŖ mmol, 
Ŗ.Ŗś eqǼ in ŗ ml dry methanol was added to the reaction. “fter ř h, the reaction mixture was 
cooled to room temperature and the yellow solid was iltered and washed with methanol. 
Puriication by crystallization from methanol ǻca. śŖ mLǼ yielded the product ř as a colorless 
solid ǻŗ.Ŗř g, Ś.ŝś mmol, ŘŘ%Ǽ. 
ŗH-NMR  ǻřŖŖ MHz, DMSO-dŜǼǱ δ Ş.Ŝŝ ǻs, ŗH, Cř-HǼ, ŝ.ŝś ǻd, řJ = Ş.Ŝ Hz, ŗH, Cś-HǼ, Ŝ.ŞŚ 
ǻdd, řJ = Ş.Ŝ Hz, ŚJ = Ř.ř Hz, ŗH, CŜ-HǼ, Ŝ.ŝŘ ǻd, ŚJ = Ř.Ř Hz, ŗH, CŞ-HǼ, Ś.ŘŜ ǻq, 
řJ = ŝ.ŗ Hz, ŘH, Cŗŗ-HǼ, ŗ.Řş ǻt, řJ = ŝ.ŗ Hz, řH, CŗŘ-HǼ ppm.  
13C-NMR  (75 MHz, DMSO-d6Ǽ Έ ŗŜř.ś, ŗśŝ.ŝ, ŗśŜ.ş, ŗŚş.Ş, ŗřŘ.ś, ŗŗŚ.Ş, ŗŗŖ.ŝ, ŗŖŘ.ř, Ŝŗ.Ř, 
40.6, 40.6, 14.6 ppm. 
HRMS ǻAPCIǼ  m/zǱ calcd. for CŗŘHŗŖOś [M+H]+Ǳ Řśŝ.ŖŚŘŖ, foundǱ Řśŝ.ŖŚŘŖ.  
 
 
GeŶeƌal Method I foƌ Etheƌ-PƌoteĐted ϯ-CCE Deƌiǀaiǀes 
ř-CCE ǻř, ŗ.Ŗ eqǼ, potassium carbonate ǻŗ.Ř eqǼ and the corresponding bromide ǻŗ.Ř eqǼ were 
dispersed in a small amount of DMF in a ŗŖ mL round-botom lask. The mixture was heated 
for Ř h at ŞŖ°C and then stirred without heating for an additional ŗŞ h. The solvent was 
evaporated in vacuo, and the raw product puriied by column chromatography. 
GeŶeƌal Method II foƌ Etheƌ-PƌoteĐted ϯ-CCE Deƌiǀaiǀes 
Following a protocol described by RUFF et al.[ŘŚŘ]  
ř-CCE ǻř, ŗ.Ŗ eqǼ was suspended in Śś ml toluene and concentrated at ŗŘŖ°C to ś ml. “fter 
cooling the yellow suspension to room temperature, NaH ǻŜŖ% dispersion in mineral oil, 
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ŗ.Ŝ eqǼ was added and the solvent was evaporated. The obtained orange salt was dried 
overnight and directly implemented with the ether protection groupǱ The sodium salt 
ǻŗ.Ŗ eqǼ was dissolved in dry DMF and heated to ŗŘŖ°C. During heating the corresponding 
bromide ǻŖ.Ŗş eqǼ was added. “fter stirring Ř h at ŗŘŖ°C a second batch of bromide ǻŗ.Ś eqǼ 
and after ř h a third batch of bromide ǻŖ.ř eqǼ were supplemented. The mixture was stirred 
for further Ś h at ŗŘŖ°C. “fter cooling to room temperature, the solution was poured into ice 
water to precipitate the product. The solid was iltered, washed with water and extracted 
with dichloromethane. The organic layer was dried over NaŘSOŚ and the solvent evaporated 
in vacuo. Puriication by column chromatography yielded the product as colorless solid. 
 
 
ϳ-PƌopaƌgǇloǆǇ-ϯ-ĐaƌďoǆǇĐouŵaƌiŶ-ethǇlesteƌ ;ϯaͿ 
This synthesis was carried out by N“TH“LIE NETT following Method II.[ŘśŖ] 
Starting from Ř.ŞŚ mmol ř, the product was puriied by column chromatography ǻsilica, 
DCM/EtO“c ŘŖǱŗǼ and isolated as colorless solid ǻŘřŘ mg, Ŗ.Şś mmol, řŖ%Ǽ. 
TLC Rf = Ŗ.ś ǻDCMǱEtO“c ŘŖǱŗǼ 
ŗH-NMR  ǻřŖŖ MHz, CDClřǼǱ δ Ş.śŗ ǻs, ŗH, Cř-HǼ, ŝ.śŝ – ŝ.śŖ ǻm, ŗH, CŞ-HǼ, Ŝ.şş – Ŝ.şŘ 
ǻm, ŘH, Cś/Ŝ-HǼ, Ś.ŝş ǻd, ŚJ = Ř.Ś Hz, ŘH, Cŗř-HǼ, Ś.ŚŖ ǻq, řJ = ŝ.ŗ Hz, ŘH, Cŗŗ-
HǼ, Ř.ŜŖ ǻt, ŚJ = Ř.Ś Hz, ŗH, Cŗś-HǼ, ŗ.ŚŖ ǻt, řJ = ŝ.ŗ Hz, řH, CŗŘ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHz, CDClřǼǱ δ ŗŜř.ś, ŗŜŘ.ş, ŗśŝ.Ś, ŗŚŞ.ş, ŗřŖ.ş, ŗŗś.Ŗ, ŗŗŚ.Ř, ŗŗŘ.Ś, ŗŖŗ.Ş, 
ŝŜ.ŝ, Ŝŗ.ş ǻCŗŗǼ, śŜ.Ŝ ǻCŗřǼ, ŗŚ.Ś ǻCŗŘǼ ppm.  
HRMS ǻAPCIǼ  m/zǱ calcd. for CŗśHŗŘOś [M+Na]+Ǳ Řşś.ŖśŞŖ, foundǱ Řşś.Ŗśŝŝ. 
 
 
ϳ-AllǇloǆǇ-ϯ-ĐaƌďoǆǇĐouŵaƌiŶ-ethǇlesteƌ ;ϯaͿ 
This synthesis was carried out by KERSTIN M“RK during a lab rotation, following Method I.  
Starting from Ŗ.Śŗ mmol ř, the product was puriied by column chromatography ǻsilica, 
DCM/EtO“c ŗśǱŗǼ and isolated as light yellow solid ǻşř mg, Ŗ.řŚ mmol, ŞŚ%Ǽ. 
TLC Rf = Ŗ.ŘŞ ǻDCMǱEtO“c ŗśǱŗǼ 
ŗH-NMR  ǻřŖŖ MHz, DMSO-dŜǼǱ δ Ş.ŝŗ ǻs, ŗH, Cř-HǼ, ŝ.ŞŚ ǻd, řJ = Ş.Ř Hz, ŗH, CŞ-HǼ, ŝ.Ŗŝ 
– Ŝ.şŞ ǻm, ŘH, Cś/Ŝ-HǼ, Ŝ.ŖŜ ǻddt, ř,transJ = ŗŝ.Ř  Hz, ř,cisJ = ŗŖ.Ŝ Hz, řJ = ś.ř Hz, 
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ŗH, CŗŚ-HǼ, ś.ŚŚ ǻdd, ř,transJ = ŗŝ.ř Hz, ŘJ = ŗ.Ŝ Hz, ŗH, Cŗś-HǼ, ś.řŗ ǻdd, 
ř,cisJ = ŗŖ.ś, ŘJ = ŗ.ś Hz, ŗH, Cŗś-HǼ, Ś.ŝř ǻd, J = Ŝ.Ŝ Hz, ŘH, Cŗř-HǼ, Ś.Řŝ ǻq, 
řJ = ŝ.ŗ Hz, řH, Cŗŗ-HǼ, ŗ.řŖ ǻt, řJ = ŝ.ŗ Hz, řH, CŗŘ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHz, DMSO-dŜǼǱ δ ŗŜř.Ŝ, ŗŜŘ.Ş, ŗśŜ.Ş, ŗśŜ.Ř, ŗŚş.Ŗ, ŗřŘ.Ŝ, ŗřŗ.Ŝ, ŗŗŞ.ř, 
ŗŗř.Ŝ, ŗŗř.Ś, ŗŗŗ.ś, ŗŖŗ.Ŗ, Ŝş.ŗ, ŜŖ.ş, ŗŚ.ŗ ǻCŗŘǼ ppm. 
HRMS ǻESIǼ  m/zǱ calcd. for CŗśHŗŚOś [M+H]+Ǳ Řŝś.ŖşŗŚ, foundǱ Řŝś.ŖşŘř. 
 
 
ϳ-BeŶzoǆǇ-ϯ-ĐaƌďoǆǇĐouŵaƌiŶ-ethǇlesteƌ ;ϯĐͿ 
This synthesis was carried out by N“TH“LIE NETT following Method II.[ŘśŖ] 
Starting from Ś.ŖŞ mmol ř, the product was puriied by column chromatography ǻsilica, 
DCM/EtO“c ŘŖǱŗǼ and isolated as colorless solid ǻŗ.Ŗř g, ř.ŗŝ mmol, ŜŞ%Ǽ. 
TLC Rf = Ŗ.ś ǻDCMǱEtO“c ŘŖǱŗǼ 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ δ Ş.śŖ ǻs, ŗH, Cř-HǼ, ŝ.śŖ ǻd, řJ = Ş.ŝ Hz, ŗH, Cś-HǼ, ŝ.Śś – 
ŝ.řś ǻm, śH, Carom-HǼ, Ŝ.şŜ ǻdd, řJ = Ş.ŝ Hz, ŚJ = Ř.Ś Hz, ŗH, CŜ-HǼ, Ŝ.ŞŞ ǻd, 
ŚJ = Ř.Ř Hz, ŗH, CŞ-HǼ, ś.ŗś ǻs, ŘH, Cŗř-HǼ, Ś.ŚŖ ǻd, řJ = ŝ.ŗ Hz, ŘH, Cŗŗ-HǼ, 
ŗ.ŚŖ ǻt, řJ = ŝ.ŗ Hz, řH, CŗŘ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ δ ŗŜŚ.ř, ŗŜř.Ŝ, ŗśŝ.Ŝ, ŗŚş.Ŗ, ŗřś.ś, ŗřŖ.ş, ŗŘş.Ŗ, ŗŘŞ.ŝ, ŗŘŝ.ŝ, 
ŗŗŚ.Ś, ŗŗŘ.Ŗ, ŗŖŗ.Ŝ, ŝŖ.ş ǻCŗřǼ, Ŝŗ.ş ǻCŗŗǼ, ŗŚ.Ś ǻCŗŘǼ ppm.  
HRMS ǻAPCIǼ  m/zǱ calcd. for CŗşHŗŜOś [M+H]+Ǳ řŘś.ŗŖŝŗ, foundǱ řŘś.ŗŖŝŗ. 
 
 
ϳ-ButǇŶǇloǆǇ-ϯ-ĐaƌďoǆǇĐouŵaƌiŶ-ethǇlesteƌ ;ϯdͿ 
This synthesis was carried out by N“TH“LIE NETT following Method II.[ŘśŖ] 
Starting from Ř.ŗŝ mmol ř, the product was puriied by column chromatography ǻsilica, 
DCMǱEtO“c ŘŖǱŗǼ and isolated as colorless solid ǻŚŘş mg, ŗ.Ś mmol, ŜŚ%Ǽ. 
TLC Rf = Ŗ.ś ǻDCMǱEtO“c ŘŖǱŗǼ 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ δ Ş.śŗ ǻs, ŗH, Cř-HǼ, ŝ.śŗ ǻd, řJ = Ş.ś Hz, ŗH, Cś-HǼ, Ŝ.şŞ – 
Ŝ.şŗ ǻm, ŘH, CŜ/Ş-HǼ, Ś.ŝŚ ǻq, śJ = Ř.ř Hz, ŘH, Cŗř-HǼ, Ś.ŚŖ ǻq, řJ = ŝ.ŗ Hz, ŘH, 
Cŗŗ-HǼ, ŗ.Şŝ ǻt, śJ = Ř.ř Hz, řH, CŗŜ-HǼ, ŗ.ŚŖ ǻt, řJ = ŝ.ŗ Hz, řH, CŗŘ-HǼ ppm.  
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ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ δ ŗŜř.Ŝ, ŗŜř.Ś, ŗśŝ.ś, ŗśŝ.Ř, ŗŚş.Ŗ, ŗřŖ.Ş, ŗŗŚ.ŝ, ŗŗŚ.Ś, ŗŗŘ.ŗ, 
ŗŖŗ.ŝ, Şś.ś, ŝŘ.ŝ, Ŝŗ.ş ǻCŗŗǼ, śŝ.ř ǻCŗřǼ, ŗŚ.Ś ǻCŗŘǼ ppm.  
HRMS ǻAPCIǼ  m/zǱ calcd. for CŗŜHŗŚOś [M+H]+Ǳ řŖş.ŖŝřŚ, foundǱ řŖş.Ŗŝřř. 
 
 
ϳ-;ϭ-PheŶǇlethǇloǆǇͿ-ϯ-ĐaƌďoǆǇĐouŵaƌiŶ-ethǇlesteƌ ;ϯgͿ 
This synthesis was carried out by CHRISTI“N SPRINGER following Method I.[ŘŜŖ]  
Starting form Ŗ.řř mmol ř, the product was puriied by column chromatography ǻsilica, 
DCMǱEtO“c ŘŖǱŗǼ to yield racemic řg as crystalline, of-white solid ǻŝ.ŗ mg, Ŗ.Řŗ mmol, ŜŚ%Ǽ. 
Enantiomeric separation of the amount necessary for mutant screening was achieved via 
HPLC ǻsee Chapter Enantiomeric Separation, page ŝŘǼ, and yielded R-řg ǻŚ.ř mg, 
Ŗ.Ŗŗř mmol, Ś%Ǽ and S-řg ǻř.Ŗ mg, Ŗ.ŖŖş mmol, ř%Ǽ as slightly yellow oils. 
TLC Rf = Ŗ.řś ǻDCMǱEtO“c ŘŖǱŗǼ 
ŗH-NMR ǻřŖŖ MHz, CDClřǼǱ δ Ş.ŚŚ ǻs, ŗH, Cř-HǼ, ŝ.ŚŘ ǻd, řJ = Ş.ŝ Hz, ŗH, Cś-HǼ, ŝ.řŘ 
ǻm, śH, Carom-HǼ, Ŝ.Şş ǻdd, řJ = Ş.ŝ Hz, ŚJ = Ř.Ś Hz, ŗH, CŜ-HǼ, Ŝ.ŝŘ ǻd, 
ŚJ = Ř.Ś Hz, ŗH,CŞ-HǼ, ś.řŝ ǻq, řJ = Ŝ.Ś Hz, ŗH, Cŗř-HǼ, Ś.řŞ ǻq, řJ = ŝ.ŗ Hz, ŘH, 
Cŗŗ-HǼ, ŗ.Ŝş ǻd, řJ = Ŝ.Ś Hz, řH, CŗŚ-HǼ, ŗ.řŞ ǻt, řJ = ŝ.ŗ Hz, řH, CŗŘ-HǼ ppm. 
ŗřC-NMR ǻŝś MHz, CDClřǼǱ δ ŗŜř.ŝ, ŗŜř.Ŝ, ŗśŝ.ś, ŗśŝ.ř, ŗŚş.Ŗ, ŗŚŗ.ŝ, ŗřŖ.ŝ, ŗŘş.ŗ, ŗŘŞ.ř, 
ŗŘś.Ŝ, ŗŗś.Ŗ, ŗŗŚ.ř, ŗŗŗ.ŝ, ŗŖŘ.Ŝ, ŝŝ.ś ǻCŗřǼ, Ŝŗ.Ş ǻCŗŗǼ, ŘŚ.ś ǻCŗŚǼ, ŗŚ.Ś ǻCŗŘǼ 
ppm. 
HRMS ǻESIǼ m/zǱ calcd. for CŘŖHŗŞOś [M+Na]+Ǳ řŜŗ.ŗŖŚŜ, foundǱ řŜŗ.ŗŖŚş. 
 
 
ϳ-;ϰ-ChloƌoďeŶzǇlͿ-ϯ-ĐaƌďoǆǇĐuŵaƌiŶ-ethǇlesteƌ ;ϯhͿ 
This synthesis was carried out by ELIS“”ETH ENGELS”ERGER during an internship, following 
a modiied version of Method I.  
ř-CCE ǻř, řŖŖ mg, ŗ.ŘŞ mmol, ŗ.ŖŖ eqǼ was dissolved in Ś mL DMF. Potassium carbonate ǻřśŝ 
mg, Ř.śŞ mmol, Ř.ŖŘ eqǼ was added, and the mixture heated to ŞŖ°C, upon which the 
suspension turned yellow. ŗ mL DMF was added to provide proper stirring. 
ŗ-ǻ”romomethylǼ-Ś-chlorobenzene ǻŚŖř mg, ŗ.şŜ mmol, ŗ.śř eqǼ was added and stirred at 
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ŞŖ°C for Ś.ś h, then another ŜŖ h at room temperature. The solvent was removed in vacuo, 
and the raw product puriied by column chromatography ǻhexanesǱEtO“c ŗǱŗǼ. “fterwards 
the product remained slightly yellow and was puriied further two times by column 
chromatography over silica ǻDCM/MeOH řŖǱŗ and DCM/MeOH śŖǱŗǼ. The product ǻŗŝŜ.Ŝ 
mg, Ŗ.Śş mmol, řş%Ǽ was obtained as a colorless solid. 
TLC Rf = Ŗ.śŖ ǻhexǱEtO“c ŗǱŗǼ 
 Rf = Ŗ.řŗ ǻDCM/MeOH řŖǱŗǼ 
 Rf = Ŗ.Řř ǻDCM/MeOH śŖǱŗǼ 
ŗH-NMR  ǻřŖŖ MHz, DMSO-dŜǼǱ Έ Ş.ŝŘ ǻs, ŗH, Cř-HǼ, ŝ.ŞŜ ǻd, řJ = Ş.ŝ Hz, ŗH, Cś-HǼ, ŝ.ŜŖ 
– ŝ.Śŗ ǻm, ŚH, Carom-HǼ, ŝ.Řŗ – Ŝ.şŜ ǻm, ŘH, CŜ/Ş-HǼ, ś.ŘŜ ǻs, ŘH, Cŗř-HǼ, Ś.Řŝ 
ǻq, řJ = ŝ.ŗ Hz, ŘH, Cŗŗ-HǼ, ŗ.řŖ ǻt, řJ = ŝ.ŗ Hz, řH, CŗŘ-HǼ ppm. 
ŗřC-NMR  ǻŝś MHz, DMSO-dŜǼ Έ ŗŜŚ.Ŗŗ, ŗŜř.ŘŜ, ŗśŝ.řŗ, ŗśŜ.Ŝŝ, ŗŚş.śŗ, ŗřś.śŗ, ŗřř.řŖ, 
ŗřŘ.ŗŝ, ŗřŖ.ŘŞ, ŗŘş.ŖŚ, ŗŗŚ.ŘŜ, ŗŗŚ.ŖŞ, ŗŗŘ.ŗŝ, ŗŖŗ.Ŝş, Ŝş.ŝş, Ŝŗ.ŚŘ ǻCŗŗǼ, ŗŚ.śş 
ǻCŗŘǼ ppm. 
HRMS ǻESIǼ  m/zǱ calcd. for CŗşHŗśClOśNa [M+Na]+Ǳ řŞŗ.ŖśŖŖ foundǱ řŞŗ.ŖśŖŖ. 
 
 
ϳ-;Ϯ-PǇƌidiŶǇlͿ-ϯ-ĐaƌďoǆǇĐuŵaƌiŶ-ethǇlesteƌ ;ϯiͿ 
This synthesis was carried out by JULIUS WINKLER and J“NOSCH KETTLER during a lab 
rotation, following Method I.  
Starting from Ŗ.Şś mmol ř, the product was puriied by column chromatography ǻsilica, 
DCMǱEtO“c řǱŘǼ and isolated as of-white solid ǻŗşŚ gǲ Ŗ.ŜŖ mmolǲ ŝŖ%Ǽ. 
TLC Rf = Ŗ.ŗŜ ǻDCMǱEtO“c řǱŘǼ 
ŗH-NMR ǻřŖŖ MHz, DMSO-dŜǼǱ δ Ş.ŝŚ ǻs, ŗH, Cř-HǼ, Ş.ŜŘ ǻddd, řJ = Ś.ş Hz, ŚJ = ŗ.Ş Hz, 
ŚJ = ŗ.Ŗ Hz, ŗH, CŗŞ-HǼ, ŝ.şŚ – ŝ.ŞŘ ǻm, ŘH, Cś/ŗŜ-HǼ, ŝ.śŞ ǻdt, řJ = ŝ.Ş Hz, 
ŚJ = ŗ.ŗ Hz, ŗH, Cŗś-HǼ, ŝ.řş ǻddd, řJ = ŝ.Ŝ Hz, řJ = Ś.Ş Hz, ŚJ = ŗ.Ř Hz, ŗH, 
Cŗŝ-HǼ, ŝ.ŗŜ ǻd, ŚJ = Ř.Ś Hz, ŗH, CŞ-HǼ, ŝ.ŗř ǻdd, řJ = Ş.Ŝ Hz, ŚJ = Ř.Ś Hz, ŗH, 
CŜ-HǼ, ś.řś ǻs, ŘH, Cŗř-HǼ, Ś.Řş ǻq, řJ = ŝ.ŗ Hz, ŘH, Cŗŗ-HǼ, ŗ.řŘ ǻt, řJ = ŝ.ŗ Hz, 
řH, CŗŘ-HǼ ppm. 
ŗřC-NMR ǻŝś MHz, DMSO-dŜǼǱ δ ŗŜř.ś, ŗŜŘ.ŝ, ŗśŜ.Ş, ŗśŜ.ŗ, ŗśś.ś, ŗŚş.Ř, ŗŚş.Ŗ, ŗřŝ.ŗ, 
ŗřŗ.ŝ, ŗŘř.Ř, ŗŘŘ.ŗ, ŗŗř.ŝ, ŗŗŗ.ŝ, ŗŖŗ.Ř, ŝŗ.ŗ, ŜŖ.ş ǻCŗŗǼ, ŗŚ.ŗǻCŗŘǼ ppm. 
HRMS ǻESIǼ m/zǱ calcd. for CŗŞHŗśNOś [M+H]+Ǳ řŘŜ.ŗŖŘř, foundǱ řŘŜ.ŗŖŘŘ. 
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ϱ.ϯ.ϱ Bƌoŵides 
GeŶeƌal Method foƌ the SǇŶthesis of Bƌoŵides fƌoŵ AlĐohols 
Following a protocol described by H“ZR“ et al.[Řşř] 
Triphenylphosphine ǻŗ.ŗ eqǼ was dissolved in dry dichloromethane and cooled to Ŗ°C. 
”romine ǻŗ.ŗ eqǼ was added dropwise until a yellow suspension was formed. The correspon-
ding alcohol ǻŗ.Ŗ eqǼ was dissolved in dry dichloromethane and added slowly to the 
suspension. The transparent solution was stirred for ŗ h at Ŗ°C. The still slightly yellow 
solution was then allowed to warm to room temperature, before ŗśŖ ml hexanes were added. 
“fter řŖ min, the colorless solid was iltered through a short silica column and washed with 
hexane, which yielded the colorless product. 
 
 
ϭ-Bƌoŵo-ďut-Ϯ-ǇŶe ;d-BƌͿ 
This synthesis was carried out by N“TH“LIE NETT.[ŘśŖ] 
Starting from ŚŖ.ŝ mmol of but-Ř-yn-ŗ-ol, and after puriication by iltering over a short silica 
column ǻhexanesǼ, the product was isolated as a colorless oil ǻŜ.Ŗŗ g, řś.Ş mmol, Şş%, in 
hexaneǼ. 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ δ ř.şŖ ǻq, śJ = Ř.ś Hz, ŘH, Cŗ-HǼ, ŗ.ŞŞ ǻt, śJ = Ř.ś Hz, řH, 
CŚ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ δ Şř.ş, ŝŚ.ś, ŗś.Ş, Ś.Ŗ ppm. 
 
 
ϭ-Bƌoŵo-ŶoŶ-Ϯ-ǇŶe ;e-BƌͿ 
This synthesis was carried out by N“TH“LIE NETT.[ŘśŖ] 
Starting from ŗŖ.ŝ mmol of non-Ř-yn-ŗ-ol, and after puriication by iltering over a short silica 
column ǻhexanesǼ, the product was isolated as a colorless oil ǻŘ.Řŝ g, ŗŖ.ŝ mmol, quant. yieldǼ. 
ŗH-NMR ǻřŖŖ MHzǲ CDClřǼǱ δ ř.şř ǻt, śJ = Ř.ř Hz, ŘH, Cŗ-HǼ, Ř.Řř ǻddt, ŘJ = ş.Ś, řJ = Ś.Ŝ, 
śJ = Ř.ř Hz, ŘH, CŚ-HǼ, ŗ.śŞ – ŗ.řř ǻm, ŘH, Cś-HǼ, ŗ.řř ǻt, J = Ř.Ř Hz, ŜH, 
CŜ,ŝ,Ş-HǼ, Ŗ.Şş ǻt, řJ = Ŝ.ŝ Hz, řH, Cş-HǼ ppm.  
ŗřC-NMR ǻŝś MHzǲ CDClřǼǱ δ ŞŞ.ś, ŝś.Ś, řŗ.Ś, ŘŞ.ŝ, ŘŞ.ś, ŘŘ.ŝ, ŗş.ŗ, ŗś.ş, ŗŚ.Ř ppm.  
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ϯ-Bƌoŵo-ϭ-pheŶǇlpƌop-ϭ-ǇŶe ;f-BƌͿ 
This synthesis was carried out by N“TH“LIE NETT.[ŘśŖ] 
Starting from ŘŘ.ŝ mmol of ř-phenylprop-Ř-yn-ŗ-ol, and after puriication by column 
chromatography ǻhexanesǱEtO“c ŘşǱŗǼ yielded the product as a colorless oil ǻŚ.Řř g, şś%Ǽ. 
TLC Rf = Ŗ.Ŝś ǻhex Ǳ EtO“c ŘşǱŗǼ. 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ δ ŝ.řŝ ǻdd, řJ = Ś.ş Hz, řJ = Ř.Ŝ Hz, ŘH, Cś/ş-HǼ, ŝ.Řś ǻm, 
řH, CŜ-CŞ-HǼ, Ś.Ŗş ǻs, ŘH, Cŗ-HǼ ppm.  
ŗřC-NMR  ǻŝś MHzǲ CDClřǼǱ δ ŗřŘ.Ŗ, ŗŘş.Ŗ, ŗŘŞ.ś, ŗŘŘ.ř, ŞŜ.ş, ŞŚ.Ś, ŗś.Ś ppm.  
HRMS ǻEIǼ  m/zǱ calcd. for CşHŝ”r [M+H]+Ǳ ŗşř.şŝřŗ, foundǱ ŗşř.şŝřř. 
 
 
ϭ-Bƌoŵo-ethǇlďeŶzeŶe ;g-BƌͿ 
This synthesis was carried out by CHRISTI“N SPRINGER.[ŘŜŖ]  
Starting from Ŗ.Şř mmol of enantiopure ǻRǼ- or ǻSǼ-ŗ-phenyl-ethanol, and after puriication 
by iltering over a short silica column ǻhexanesǼ, the presumably racemic product was 
isolated as a colorless oil ǻŝŚ mg, Ŗ.ŚŖ mmol, ŚŞ%Ǽ. 
TLC Rf = Ŗ.ŞŞ ǻDCMǱEtO“c ŘŖǱŗǼ. 
ŗH-NMR  ǻřŖŖ MHzǲ CDClřǼǱ δ ŝ.řŝ ǻm, śH, Carom-HǼ, ś.ŘŘ ǻq, řJ = Ŝ.ş Hz, ŗH, Cŗ-HǼ, Ř.ŖŜ 
ǻd, řJ = Ŝ.ş Hz, řH, CŘ-HǼ ppm. 
ŗřC-NMR ǻŝś MHzǲ CDClřǼǱ δ ŗŚř.Ś, ŗŘŞ.Ş, ŗŘŞ.ś, ŗŘŝ.Ŗ, Śş.ŝ ǻCŗǼ, Řŝ.Ŗ ǻCŘǼ ppm. 
 
 
ϭ-;BƌoŵoŵethǇlͿ-ϰ-ĐhloƌoďeŶzeŶe ;h-BƌͿ 
This synthesis was carried out by ELIS“”ETH ENGELS”ERGER during an internship.  
Starting from ś.Ŝŗ mmol Ś-chlorobenzylalcohol, and after puriication by iltering over a 
short silica column ǻhexanesǼ, the product was isolated as a colorless solid ǻŖ.şŞś g, 
Ś.ŝş mmol, ŞŜ%Ǽ. 
ŗH-NMR  ǻřŖŖ MHz, DMSO-dŜǼǱ Έ ŝ.śŜ – ŝ.řŞ ǻm, ŚH, Carom-HǼ, Ś.ŝŗ ǻs, ŘH, Cŗ-HǼ. 
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ϱ.ϰ SĐƌeeŶiŶg  
ϱ.ϰ.ϭ GeŶeƌal Methods 
For liquid handling of single samples and şŜ-well plates, either standard single- and multi-
channel micropipetes ǻEPPENDORF or THERMOSCIENTIFICǼ or dispensers ǻmultidrop, 
multipeteǼ were used, or an automated approach with a TEC“N robotic system equipped 
with a liquid handling arm ǻLiH“Ǽ and multi-pipete option ǻTe-MOǼ, which was controlled 
using GEMINI software Vř.śŖ.  
 
ϱ.ϰ.Ϯ LiďƌaƌǇ IŶfoƌŵaioŶ 
Taƌgeted Sites aŶd Used Methods 
Existing libraries were stored as glycerol stocks ǻřŖ%Ǽ of E. coli ”LŘŗ-GoldǻDEřǼ ǻMERCK-
MILLIPOREǼ at -ŞŖ°C in the REETZ lab. 
The irst library, termed Mega-Site, was constructed by C“RLOS G. “CEVEDO-ROCH“ in 
connection to another project ǻunpublishedǼ. ”riely, the PŚśŖ”Mř gene ǻř,ŗśŖ bpsǼ was cloned 
under the Tŝ-promoter of plasmid pRSF-Duet-ŗ ǻNovagenǼ without His-tag, as described 
earlier.[ŗśŞ] Saturation mutagenesis was applied in two rounds. In the irst step, the 
QuikChange protocol was used to introduce three mutations at position LŚřŝS/N/“. “fter its 
extraction, the plasmid was used as template to introduce three mutations at four more sitesǱ 
RŚŝL/W/T, SŝŘV/I/F, “ŞŘW/F/M, and FŞŝV/I/M, using overlap extension PCR. Since the wt 
residue was included as building block in each case, there were ś residues randomized to Ś 
diferent amino acids, which represents a complexity of ŗ,ŖŘŚ variants. It was transformed 
into the model E. coli ”LŘŗ-GoldǻDEřǼ, before the cells were seeded onto L” agar plates ǻŗś 
cmǼ with the right antibiotics. The plates were incubated at řŝ°C and the next day, şśŖ 
colonies were picked into ŞŖŖ µL of L” media with the proper antibiotic in ten şŜ-well MTPs. 
“ wt-control was included per plate in well ŗ“ ǻşś colonies from the libraryǼ. 
The second library, termed ȃS“”RIN“Ȃs collectionȄ, was prepared by S“”RIN“ HOE”ENREICH 
as described before.[ŗŜŗ,ŗŜŘ,ŘŚŞ] ”riely, the PŚśŖ”Mř gene was cloned into the plasmid pETM-ŗŗ 
ǻEM”L, HeidelbergǼ, which contains an N-terminal His-tag and kanamycin marker. The 
PŚśŖ”Mř FŞŝ“ variant was used as a template to prepare six librariesǱ Řx “, Řx ”, and Řx C. 
Library “ included residues RŚŝ, TŚş and Yśŗǲ all randomized using the same alphabet 
consisting of ŗŘ amino acids ǻR, D, N, C, G, H, I, L, S, V, F, and YǼ. Library C, which included 
residues MŗŞś and LŗŞŞ, was randomized using the same amino acid alphabet. Finally, 
library ” included residues VŝŞ and “ŞŘǲ full randomization was either achieved with a 
nonredundant set of ŘŖ codons or by using the NNK degeneracy ǻřŘ codonsǼ. The sizes of 
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libraries “ were śŖŝŜ and řŞŜŚ, that of libraries ” řŖŖŞ and ŗŘŘŘǲ and that of libraries C ŝśŘ 
and ŜŝŘ transformants. However, only those mutants identiied as ȃhitsȄ in the original 
study were combined in triplicates to a smaller collection, composed of ~ŗśŖ unique mutants, 
which were used for the screening ǻfull list see “ppendix ŗŗǼ.  
Finally, a number of MŖŗ-derived PŚśŖ”Mř mutants[ŘşŚ] were also available at the REETZ lab, 
and constructed by site-directed mutagenesis as indicated elsewhere.[Řşś] 
Hit mutants from diferent projects were assembled to a new collection, termed şŜer plate 
ǻfull list see “ppendix ŗŘǼ. 
 
SeƋueŶĐiŶg 
Genetic sequencing was performed by G“TC and results were analyzed using ”IOEDIT 
Sequence “lignment Editor Vŝ.Ř.Ŗ.[ŘşŜ] 
 
Taďle ϱ-ϱ.  Pƌiŵeƌs used foƌ seƋueŶĐiŶg. 
Naŵe SeƋueŶĐe 
Tϳ ACGCTTGATACAATTGG 
ϮŶd CGAGAACATTCGCTATC 
ϯƌd TTAATTGTAACGGCGTC 
ϰth ATACCCGGCGTGTGAAATG 
 
ϱ.ϰ.ϯ GlǇĐeƌol StoĐks 
Overnight culture (700 µLǼ was mixed with 200 µL of ŗŖŖ% glycerol and shock-frozen in 
liquid nitrogen before being stored at -ŞŖ°C. 
 
ϱ.ϰ.ϰ Cultuƌe CoŶdiioŶs 
Protocol according to KILLE.[ŘŚŞ] For pre-cultures, ŞŖŖ µL L” media containing śŖ µg/mL 
kanamycin ǻL”KanǼ per well were inoculated in a deep-well MTP using a şŜ-tip comb from 
library glycerol stocks, covered with gas-permeable seals ǻSIGM“Ǽ  and grown overnight at 
řŝ°C, shaking at ŞŖŖ rpm in an HT INFORS MULTITRON Standard shaker equipped with 
horizontal plate holders. For expression cultures, ŗŖŖ µL of overnight culture were 
transferred into ŝŖŖ µL T” media containing kanamycin, IPTG, Power Mix and TTM-Mix. 
Expression was performed by shaking for ŝ h at řŖ°C and ŘřŖ rpm. They were centrifuged at 
ŗŗŖŖ g and Ś°C for ŗŖ min. The supernatant was discarded, the pellets resuspended by 
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vortexing with ŜŖŖ µL PŚśŖ washing bufer and centrifuged again for ŗŖ min. The 
supernatant was removed and the pellets stored at -ŞŖ°C until use. 
ϱ.ϰ.ϱ LǇsate PƌepaƌaioŶ 
Pellets from the MTPs were thawed in a water bath ǻřŖ-ŚŖ°CǼ and resuspended in 430 µL 
lysis bufer by vortexing. The plates were incubated at řŖ-řŝ°C for Ř h, shaking at ŞŖŖ rpm in 
an HT INFORS MULTITRON Standard shaker equipped with a table containing horizontal plate 
holders. “fter closing the plates with a lid, they were centrifuged at ŗŗŖŖ g and Ś°C for 
ŗŖ min and the supernatant was used for screening reactions. 
 
ϱ.ϰ.ϲ Suďstƌate ReaĐioŶ 
The current protocol was adapted for luorescent read-out from KILLE et al.[ŗŜŗ] 
Lysate supernatant ǻśŖ µLǼ were transferred into a fresh deep-well MTP containing ŚŚś µL 
reaction bufer I using the TEC“N system. The reaction was started by addition of ś µL 
substrate solution. Plates were covered with gas-permeable seals ǻSIGM“Ǽ and incubated for 
şŖ min at řŖ°C, shaking at ŞŖŖ rpm. Plates were then centrifuged at ŗŗŖŖ g and Ś°C for 
ŗŖ min, ŘŖŖ µL of the supernatant transferred to black lat botom MTPs and analyzed by 
luorescent read-out at the appropriate wavelengths for the substrate, which are shown in 
Table ś-ŗ, page ŝŖ. 
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ϱ.ϱ EŶzǇŵe PuƌiiĐaioŶ aŶd ChaƌaĐteƌizaioŶ 
ϱ.ϱ.ϭ GeŶeƌal Methods 
Culture vessels were incubated in an HT INFORS MULTITRON Standard shaker. Cell lysis for 
protein puriication was done using a ”“NDELIN SONOPULS HDŘŘŖŖ sonicator equipped with 
a ŗř mm sonotrode. Protein puriication was performed at Ś°C on an “MERSH“M 
”IOSCIENCES Äkta FPLC system equipped with pump P-şŘŖ, mixer M-şŘś, sample injection 
valve INV-şŖŝ, fraction collector Frac-şśŖ, monitor UPC-şŖŖ and remote connector CU-şśŖ, 
controlled via UNICORN Vś.Ŗ software. The following column materials were usedǱ  
“nion Exchange loose DEśŘ WH“TM“NN DE“E cellulose resin  
TOSOH TSK-Gel DE“E-śPWǻřŖǼ column 
Desalting  HiTrap columns by GE HE“LTHC“RE 
Gel Filtration   HiLoad ŘŜ/ŜŖ Superdex ŘŖŖ column by GE HE“LTHC“RE 
 
ϱ.ϱ.Ϯ EǆpƌessioŶ Cultuƌes 
Carried out by K“TJ“ KRÄLING.  
L”K“N,tet ǻś µg/mlǼ medium was inoculated from randomly picked colonies or glycerol stocks 
and grown overnight at řŝ°C and ŘřŖ rpm ǻŗŜ hǼ. Expression cultures were inoculated by 
diluting overnight culture ŗŖŖŖ-fold in T”řŖ µg/mL K“N media containing power mix, TTM mix 
and MgClŘ to a total volume of ŗ L. Induction was performed at ODŜŖŖ of Ŗ.Ŝ-Ŗ.Ş by addition 
of IPTG to a inal concentration of ŗŖŖ µM. “fter ŝ h of expression at řŖ°C, ŘřŖ rpm, cultures 
were centrifuged at ŚŖŖŖ rpm, Ś°C for ŜŖ min. The supernatant was discarded and the cell 
pellets were resuspended using a pipete with ŜŖŖ mL PŚśŖ washing bufer ǻŗŖŖ mM KPi, pH 
ŝ.Ś, ś% v/v glycerinǼ and centrifuged again for ŗŖ min at ŚŖŖŖ rpm, Ś°C. The supernatant was 
discarded and pellets stored at -ŞŖ°C until further use. 
 
ϱ.ϱ.ϯ LǇsate PƌepaƌaioŶ 
The resuspended pellet was thawed and subjected to sonication. During the process, the 
vessel was kept on ice. Three sonication steps at ŞŖ% power for ŗ min were performed, 
allowing for cooling breaks of ś min in between. The slurry was centrifuged for ŜŖ min at Ś°C 
and ŗŝŖŖŖ rpm and the supernatant was used for puriication after sterile iltration via a 
syringe ilter ǻŖ.Śś µmǼ.  
Of this and all following steps, samples were taken for SDS P“GE analysis.  
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ϱ.ϱ.ϰ SDS PAGE 
Protein expression and purity was checked by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis ǻSDS-P“GEǼ.  
Gels were prepared by ixing a gel caster with glass and spacer sheets for ŗŘ gels, and 
checking for leaks with water, before illing in freshly prepared resolving gel mix. The mix 
was layered with isopropanol to create an even surface, and left to polymerize. The 
isopropanol was removed, and freshly prepared loading gel mix was added to the caster. 
Combs for sample pockets were inserted, and the gels left to polymerize completely. 
For sample preparation, ŗś µL of protein sample were mixed with ś µL SDS sample bufer in 
an EPPENDORF tube, and heated to şŖ°C for ŗŖ min in a Thermocycler. 
To run a gel, it was ited into the running chamber, the comb removed, and the chamber 
illed with SDS running bufer. “ commercially available protein ladder was loaded into the 
irst lane, and an appropriate amount of centrifuged sample solution was added into each 
following pocket ǻdepending on protein concentration and sample pocket size between ř-
ŗŖ µLǼ. The gel was then developed at ŗŘŖ V until the run marker reached the botom. It was 
taken out of the chamber, and the glass sheets carefully removed. “fter rinsing the gel with 
water, it was covered with SDS gel stain solution, and microwaved for ŗ min at maximum 
power. Repeated rinsing and microwaving in fresh water removed the stain from the gel 
matrix. “fter washing, an image was taken of each gel using an electronic camera. 
 
ϱ.ϱ.ϱ PƌoteiŶ PuƌiiĐaioŶ ǁithout His-tag 
Weak AŶioŶ EǆĐhaŶge ColuŵŶ 
“ glass column with a diameter of Ř.ś cm was packed with ŘŖ g of DEśŘ WH“TM“N cellulose 
resin ǻsuspended in KPi buferǼ. The sample was loaded onto the column, and fractions were 
immediately collected in case of unbound protein elution. The column was washed with 
řŖ mL of KPi bufer, before eluting the protein with elution bufer. The volume collected in 
the last step was concentrated to ŗŖ mL using ŗŖŖ kDa centrifugation concentrators ǻMERCK-
MILLIPOREǼ. 
DesaliŶg ColuŵŶ 
Five consecutive HiTrap Desalting columns ǻś mL, ŝŗ-ŝŗśŚ-ŖŖ “K by GE HE“LTHC“REǼ were 
connected to the Äkta system and equilibrated with HEPES bufer, prior to sample loading. 
Protein elution was monitored via UV detection at Śŗŝ nm. Separation was achieved at a 
low rate of ŗ mL/min and fractions of the eluent were collected in ŗś mL Falcon tubes until 
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UV absorption decreased. Protein-containing fractions were collected and iltered via a 
syringe ilter ǻŖ.Śś µmǼ. 
DEAE ColuŵŶ 
“ TOSOH TSK-Gel DE“E-śPWǻřŖǼ column was connected to the Äkta system and 
equilibrated with ”ufer “, before loading the sample. Elution was performed at a low rate 
of ŗ mL/min with a gradient from Ŗ-ŗŖŖ% ”ufer ” under fractionated collection. Main 
fractions were combined, concentrated to Ř mL using ŗŖŖ kDa centrifugation concentrators 
ǻMERCK-MILLIPOREǼ and iltered via a syringe ilter ǻŖ.Śś µmǼ. 
Gel FiltƌaioŶ ColuŵŶ 
“ gel iltration column ǻHiLoad ŘŜ/ŜŖ Superdex ŘŖŖ by GE HE“LTHC“REǼ was connected to 
the Äkta system and equilibrated with HEPES bufer. The sample was loaded onto the 
column and puriied at a low rate of ŗ mL/min.  
Upon elution, main fractions were combined and concentrated using ŗŖŖ kDa centrifugation 
concentrators ǻMERCK-MILLIPOREǼ, changing the bufer to KPi by diluting multiple times. 
Samples were aliquoted and shock-frozen with liquid nitrogen before storing the protein 
at -ŞŖ°C until further use. 
 
ϱ.ϱ.ϲ PƌoteiŶ PuƌiiĐaioŶ ǁith His-tag 
Raw extract was puriied by ainity chromatography over  Ni-NT“ His-trap columns by GE 
HE“LTHC“RE. Columns were equilibrated with KPi bufer ǻŗŖŖ mMǼ, before the extract was 
loaded with protein and rinsed with ”ufer “ until the baseline is stable ǻ~ŚŖ mLǼ. The 
enzyme was eluted by gradually increasing the Histidine concentration in the eluent by 
running a gradient to ŗŖŖ% ”ufer ” over ŘŖ min at a low rate of Ř mL/min. Upon elution, 
main fractions were combined. “fter washing and concentrating the sample by 
ultracentrifugation ǻŗŖŖ kD“ concentrator, MERCK-MILLIPOREǼ, the sample was divided into 
aliquots, shock-frozen with liquid nitrogen and stored at -ŞŖ°C until further use. 
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ϱ.ϲ DeteƌŵiŶaioŶ of BioĐheŵiĐal ChaƌaĐteƌisiĐs 
ϱ.ϲ.ϭ CoŶĐeŶtƌaioŶ 
Cytochrome PŚśŖ concentrations were determined using an adapted protocol, running 
reactions in triplicates.[ŘŜŘ]  
Puriied protein samples were thawed slowly on ice. Per mutant, six stirrable quarz cuvetes 
were prepared and illed with şŞŖ µL KPi bufer and ŘŖ µL protein, leading to a dilution 
factor of śŖ. “fter activating the auto-zero function of the spectraphotometer, sample 
temperature was brought to Řś°C and blanks were measured at the following wavelengths, 
corresponding to diferent speciesǱ 
ŚşŖ nm  ≙ baseline referene for all PŚśŖs 
ŚŚş nm  ≙ active protein 
ŚŘř nm  ≙ inactive protein with Cys detached from heme 
Three of the six cuvetes were then treated with CO-gas for ŜŖ s, bubbling through a canule 
at approximately one bubble per second. One analytical spoon full ǻ~ŗ mgǼ of NaŘSŘOŚ was 
added to all six cuvetes, they were covered with parailm and mixed by inverting them ŗŖ 
times, until the salt had dissolved completely. “bsorption at the above mentioned 
wavelengths was then measured immediately, and concentrations of active and inactive 
enzyme calculated following the method described in the literature. 
 
ϱ.ϲ.Ϯ SeleĐiǀitǇ aŶd OƌthogoŶalitǇ 
Reactions for determining steady-state activity were carried out in analogy to screening 
reactions ǻsee Chapter ś.Ś.Ŝ, page şřǼ in śŖŖ µL reaction bufer I or II at inal enzyme and 
substrate concentrations of Ŗ.ŗ µM and śŖ-ŗŖŖ µM, respectively, unless otherwise speciied. 
Fluorescence read-out was determined after şŖ min reaction time at řŖ°C, centrifugation of 
the reaction mixture and transfer of ŘŖŖ µL into black lat botom MTPs. For HPLC analysis, 
reaction mixtures were extracted with ř x śŖŖ µL ethyl acetate, dried and resuspended in 
śŖŖ µL acetonitrile, unless otherwise speciied. 
Real-time monitoring of reactions was conducted under standard reaction conditions in 
bufer II, using the N“DPH recycling system and ŗa at a concentration of ŗŖŖ µM, running 
the reaction directly in black lat botom MTPs at a total reaction volume of ŘŖŖ µL. 
Coumarine substrates are not suitable for this type of monitoring due to the interference of 
N“DPH at the necessary wavelengths. To study orthogonality, two enzymes were added to 
the reaction from the start or successively after the irst half of the reaction time. 
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”y choosing highly selective mutations, it is possible to have two independent reactions in 
the same system without interference from one another ǻcf. ś.Ŝ.ŘǼ. This can be an advantage 
when going towards living cells, and could pave the way for applications in organic 
synthesis, where the reliable orthogonal removal of protection groups is a valuable asset. 
 
ϱ.ϲ.ϯ KiŶeiĐ Paƌaŵeteƌs 
“ll measurements were conducted in duplicates or triplicates and carried out in stirrable 
high precision quarz glass cuvetes ǻd = ŗ cmǼ, stirring with a magnetic stirrer bar at 
şŖŖ rpm. ”efore and after each step, cuvetes were cleaned with Virkon and dest. HŘO and 
dried at śŖ°C. 
N“DPH consumption, leak rate and product formation rate were calculated following 
literature known protocols ǻresults see Table ř-ŘǼǱ[ŗřŜ,ŗŜŗ,Řşŝ] 
KPi bufer (965 µLǼ was brought to řŖ°C in the cuvetes, and 10 µL DMF or substrate stock in 
DMF ǻŖ.ŗ-ŗŖ mMǼ were added. The auto-zero function of the spectraphotometer was 
activated, 20 µL of ŘŖ mg/mL N“DPH-solution ǻin KPiǼ were added and the recording 
started immediately. “t a timepoint of ŘŖ s exactly, the enzyme was added to a speciied inal 
concentration (0.1 µM unless otherwise statedǼ, and the decline in absorbance was detected.  
For analysis of the initial cofactor concentration, absorption was determined at ŗś s ǻbefore 
the addition of PŚśŖ”MřǼ. For analysis of the initial reaction rates, slopes of the initial reaction 
ǻmeasured over a ŗŖ s time starting ś s after additionǼ were calculated using the J“SCO 
Spectra Manager VŘ, kinetics function. In case of substrates, the reaction was followed until 
the curve latened completely, before 400 µL of the reaction mix were extracted three times 
with ethyl acetate. Phase separation can be improved by centrifugation at Ś°C. Organic 
phases were combined and the solvent removed in vacuo. Samples were then stored at -ŞŖ°C 
until HPLC analysis of conversion and product formation. 
Reactions were run at maximum substrate concentration, determining initial rates by time-
dependent absorption measurements of N“DPH ǻεϯϰϬ = Ŝ.ŘŘ mM-ŗ ∙ cm-ŗ, εϯϮϬ = Ś.řŝ mM-ŗ ∙ cm-ŗ, 
εϯϲϬ = Ś.Řś mM-ŗ ∙ cm-ŗǼ, starting at a N“DPH concentration of ca. Ŗ.ś mM. Wavelengths were 
adjusted for minimal interference with the substrate.  
Since coumarin derivatives interfere with measurements at řŚŖ nm, those values were 
obtained at slightly shifted wavelengths to minimize the efect. Figure ś-ŗ shows absorption 
spectra of N“DPH and substrates Ř and ř, indicating the used wavelengths. Extinction 
coeicients were determined from the spectrum based on the known ΉřŚŖ of Ŝ.ŘŘ mM-ŗ ∙ cm-ŗ. 
For MICH“LIS-MENTEN measurements of luorescein substrate ŗa, it was possible to follow 
product formation directly by measuring luorescence development over time ǻat a reaction 
volume of ŘŖŖ µL in black lat botom şŜ-well platesǼ. Coumarin substrate řd, on the other 
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hand, had to be measured by N“DPH consumption multiplied with the CE, due to the 
strong background luorescence at the observed wavelengths. 
 
Figure ϱ-ϭ.  AďsoƌpioŶ speĐtƌa of ĐofaĐtoƌ NADPH aŶd ĐouŵaƌiŶ ĐoŵpouŶds Ϯ aŶd ϯ. Both 
ĐoŵpouŶds iŶteƌfeƌe ǁith ŵeasuƌeŵeŶts at the aďsoƌpioŶ ŵaǆiŵuŵ of NADPH ;ϯϰϬ ŶŵͿ, 
ďut suitaďle ǁaǀeleŶgths aƌe easilǇ fouŶd at ϯϮϬ Ŷŵ ;ϯͿ oƌ ϯϲϬ Ŷŵ ;ϮͿ. The aďsoƌpioŶ 
ĐoeiĐieŶt used iŶ ĐalĐulaioŶs ǁas adjusted aĐĐoƌdiŶglǇ. 
 
ϱ.ϲ.ϰ StaďilitǇ  
“ll stability reactions were carried out on the mutant TFFIS in analogy to screening reactions 
ǻsee Chapter ś.Ś.Ŝ, page şřǼ in śŖŖ µL reaction bufer II at inal enzyme and substrate 
concentrations of Ŗ.ŗ µM and ŗŖŖ µM, respectively, unless otherwise speciied. Fluorescence 
read-out was determined after şŖ min reaction time at řŖ°C, centrifugation of the reaction 
mixture and transfer of ŘŖŖ µL into black lat botom MTPs. 
pH 
This work was partly carried out by RO”ERT GIESSM“NN. 
Reactions were carried out in deep-well MTPs, using ”riton-Robinson ǻ”&RǼ bufers of 
diferent pH values or KPi bufer.  Three series of experiments were conductedǱ 
 Reactions at the speciied pH 
Standard reactions were carried out in ”&R bufers at pH values of Ř-ŗŖ and substrate 
concentration was determined by luorescence measurements. “s a control, luorescence 
of ŗ was measured at the same pH values. 
 Reactions at pH ŝ after pre-incubation  
The enzyme ǻř.Ř µLǼ was diluted in ”&R bufers ǻŘŘ µLǼ at pH values of Ř-ŗŖ to a 
concentration of Ř µM, before incubation for ŜŖ min at room temperature. Samples were 
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then diluted with ”&R bufer ǻpH ŝ, ŚŜś µLǼ. The reaction was started by the addition of 
N“DPH and substrate stock ǻś µL eachǼ. “s a control, reactions were run in the same 
bufer mixes with preincubation of the enzyme at pH ŝ. 
 Time-dependent analysis after pre-incubation 
The enzyme ǻŗŗ µLǼ was diluted in ”&R bufers ǻŝŚ.ś µLǼ at pH values of Ś-ś to a 
concentration of Ř µM, before incubation for diferent periods of time at room 
temperature. “fter the speciied time had passed, an aliquot of each solution was 
transferred to a black lat-botom MTP containing ”&R ǻpH ŝ, ŗŞŜ µLǼ. “fter the last 
aliquot was transferred, the reaction was started by the addition of N“DPH and 
substrate stock ǻŘ µL eachǼ. 
CofaĐtoƌ DepeŶdeŶĐe 
This work was carried out by RO”ERT GIESSM“NN. 
Reactions were carried out at diferent starting concentrations of N“DPH ranging from ś-
řŖŖ µM in the reaction mix.  
Addiiǀes 
The performance of the enzyme in diferent media or presence of diferent additives was 
tested. Final ”Mř-concentration was kept at Ŗ.ŗ µM, and the reactions were carried out using 
N“DPH ǻřŖŖ µMǼ instead of the GDH recycling system, to prevent interactions of the 
additives with GDH from inluencing the results. Table ś-Ŝ gives an overview over the 
experiments.  
 
Taďle ϱ-ϲ.  Bufeƌs aŶd addiiǀes used foƌ staďilitǇ tests of TFFIS. 
EŶtƌǇ Bufeƌ/Addiiǀe CoŶĐeŶtƌaioŶ Dissolǀed iŶ AddiioŶal ĐoŵŵeŶts
 
ϭ HeLa lǇsate I  -  
Ϯ HeLa lǇsate II  -  
ϯ PBS  -  
ϰ Deǆ-Sulfate  ϭϮ ŵg/ŵL Ϭ.ϱ M NaCl adjust pH to ϲ.ϱ ǁith Ϭ.ϭ M HCl 
ϱ PolǇ-AƌgiŶiŶe  ϭϮ ŵg/ŵL Ϭ.ϱ M NaCl ŵilkǇ pƌeĐipitate oďseƌǀed 
ϲ EDTA  Ϭ.Ϯ M HϮO adjust pH to ϲ.ϱ ǁith Ϭ.ϭ M HCl 
ϳ TƌitoŶ X ϭϬϬ ϭ% total KPi Ŷo iŶĐuďaioŶ iŵe 
ϴ TuƌďoFeĐt ϭϮ aŶd Ϯϰ µL - ≙ Ϭ.ϴ oƌ ϭ.ϲ µL/µg pƌoteiŶ 
ϵ Deǆ-TRITC  ϭϬ ŵg/ŵL HϮO ǁas ŵiǆed ϭ:ϭ ǁith ϭϮ.ϱ ʅL TFFIS 
 
To evaluate the activity of the enzyme in cell-like environment, HeLa lysate was also used 
instead of reaction bufer for one reaction, and directly compared to P”S bufer used during 
lysis ǻentries ŗ-řǼ. 
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Of entries Ś-Ŝ, ŘŖ µL were incubated with the protein ǻTFFIS, ř.Ř µLǼ for ŗś min at Ŗ°C, then 
diluted with KPi bufer to ŚşŖ µL before starting the reaction by adding substrate and 
N“DPH. To study the time dependent activity for entry Ş, samples were diluted with KPi 
bufer to a total volume of śŖŖ µL after řŖ min, Ś h and ŘŚ h incubation at RT, and reactions 
started immediately. One batch each was mixed with bufer instead of TUR”OFECT for 
comparison of prolonged incubation at RT. 
IoŶiĐ StƌeŶgth 
KPi and NaPi bufer ǻpH ŝ.Ś, ŗŖŖ mMǼ was diluted to diferent values ionic strength and the 
performance of the enzyme was tested under standard conditions ǻcf. CRŖŚŘ, řŖŖµM 
N“DPH instead of recycling systemǼ.  
MeĐhaŶiĐal DistuƌďaŶĐe 
Protein in bufer solution was vortexed at highest speed or suspended in an ultrasound bath 
for the given time ǻřŖ s - ŗś minǼ at ambient temperatures, then stored on ice until the 
reaction was started by addition of substrate and N“DPH. 
”uild-up of foam was observed in the vortexed samples, increasing with longer mixing 
times. 
 
ϱ.ϳ DoĐkiŶg aŶd MD siŵulaioŶs 
MD simulations were performed by RICH“RD LONSD“LE and details are published.[ŗ] ”riely, 
the mutant models of PŚśŖ”Mř were constructed using the wt crystal structure as a template 
ǻPD”-ID ŗ”Uŝ[ŘŜś]Ǽ, inserting point mutations according to the found variants. Substrates 
were modelled and then docked into the active site, with the prosthetic heme group in 
compound I state. Molecular dynamics simulations on the docking poses were used to assess 
the stability of the observed binding conformations. 
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ϱ.ϴ EǆpeƌiŵeŶts iŶ LiǀiŶg Cells 
ϱ.ϴ.ϭ MiĐƌosĐopiĐ IŵagiŶg 
Confocal luorescent microscopy imaging of E. coli was performed by FELIX DEMPWOLFF 
ǻGR“UM“NN labǼ on a LEIC“ SPŞ laser scanning microscope equipped with a ŗŖŖX HCX PL 
“PO STED Objective ǻN“ ŗ.ŚǼ, a white light laser source and LEIC“ HyD detectors. Images 
were analyzed using the L“S “F ǻLEIC“Ǽ software. E. coli were immobilized on coverslips by 
SŝśŖ medium containing agarose pads ǻŗ% w/vǼ.  
Microscopic imaging of HeLa cells was performed by MIKH“IL ZYUZIN ǻP“R“K labǼ on a 
ZEISS 510 Meta confocal laser scanning microscope equipped with an oil-immersed Plan-
Apochromat 63x/1.40 DIC M27 objective, 505-550 nm ilter, an argon laser (488 nm, at 60%) as 
light source and photo-multiplier tube detector. Images were analyzed using ZEN 2009 black 
edition software. 
 
ϱ.ϴ.Ϯ EsĐheƌiĐhia Đoli  
This work was carried out in collaboration with N“TH“LIE NETT.[ŘśŖ] 
E. coli ”LŘŗ-GoldǻDEřǼ containing the pRSF-Duetŗ-”Mř plasmid encoding wt or mutant 
PŚśŖ”Mř were expressed in deep-well MTPs as triplicates for every substrate. Cells expressing 
the wt were used as negative controls. ŞŖŖ µL T”K“NśŖ, IPTGŗŖŖµM media per well were 
inoculated with ŗŖŖ µL of a pre-culture in L”K“NśŖ at řŖ°C, ŘŘŖ rpm in an HT Infors Multitron 
Standard shaker. The cells were expressed for ŝ h. To initiate the reaction, 8 µL substrate 
ǻŗŖŖ mM stock solution in DMFǼ were added to every well and incubated for ŗŜ h at řŖ°C and 
ŘŘŖ rpm in an HT Infors Multitron Standard shaker. “fter centrifugation of the reaction 
mixture ǻŚŖŖŖ rpm, ŗŖ min, Ś°CǼ, ŘŖŖ µL of the supernatant were transferred to black lat 
botom MTPs and analyzed by luorescent read-out at the appropriate wavelength for the 
substrates ǻFehler! Verweisquelle konnte nicht gefunden werden.Ǽ. The pellets were 
washed with ŚŖŖ µL KPi bufer ǻŚ.ŖŖŖ rpm, ŗŖ min, Ś°CǼ and resuspended again in ŘŖŖ µL 
KPi bufer. “ sample of the prepared cells was analyzed by confocal luorescent microscopy 
ǻFELIX DEMPWOLFF, “K Graumann, MarburgǼ. “nother sample was washed once with KPi 
bufer, treated with lysis bufer for Ř h at řŝ°C and ŘŘŖ rpm, followed by centrifugation and 
transfer of the lysate to black lat botom MTPs and analysis by luorescent read-out ǻdata see 
Figure ř-řŗǼ. 
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ϱ.ϴ.ϯ HeLa Cells 
Gƌoǁth ĐoŶdiioŶs 
The human cervical carcinoma cells ǻHeLaǼ were obtained from the “MERIC“N TYPE 
CULTURE COLLECTION ǻ“TCCǼ. 
DUL”ECCOȂs Modiied E“GLEȂs Medium ǻDMEMǼ supplemented with ŗŖ% fetal bovine 
serum ǻF”SǼ, Ř mM L-glutamine, ŗŖŖ U/mL penicillin and ŗŖŖ µg/mL streptomycin was used 
as growth medium at řŝ°C in ś% COŘ. Growth vessels were ŝś cmŘ cultivation lasks. 
In order to keep the cells in their exponential growth rate, it is necessary to periodically 
decrease the density of the cells every Ř-ř days. For this, old cell medium was removed from 
the cultivation lask using a pipete. “dherent cells were then washed with Ŝ mL P”S to 
remove serum from the growth medium. To detach the cells from the botom of the lask by 
degrading surface proteins, they were treated with Trypsin-EDT“ ǻŖ.Ŗś%, ř mLǼ for Ř 
minutes at řŝ°C in ś% COŘ. The enzyme-reaction was stopped by adding ş mL DMEM, and 
the detached cells were centrifuged at ŗŖŖŖ rpm for ś min at room temperature. “fter 
decantation of the supernatant, the cells were re-suspended in fresh medium. Cells were 
counted using a NEU”“UER chamber under a microscope at ŗŖŖx magniication and 
Ř∙ŗŖŜ cells were seeded into a new ŝś cmŘ cultivation lask with an end volume ŗś mL DMEM 
and grown to a surface coverage of ŞŖ-şŖ%. 
LǇsis 
Cells from a Řś mL culture were irst cleared of the medium, washed with Ŝ mL P”S bufer, 
and then treated with ř.ś mL Trypsin ǻŖ.Řś%Ǽ at řŝ°C for ś min. The suspension was 
transferred to a falcon tube and centrifuged at ŗŖŖŖ rpm for ś min, before being resuspended 
in ś mL DMEM. ~Ŗ.Ş mL were used for inoculation of a new culture. The rest was 
centrifuged again, the supernatant discarded, and the cells washed with ř mL P”S. 
Lysis Method I 
Harvested HeLa cells were lysed by a method adapted from the dissertation of “NNE 
“D“MS.[ŘşŞ] Lysis was achieved by incubating the cells for Śś min on ice in Ś mL P”S bufer 
with Triton X ǻŗ%Ǽ. The lysate was shock-frozen in liquid nitrogen and stored at -ŞŖ°C until 
further use. 
Lysis Method II 
Lysation was achieved by freezing the cells at -ŝŞ°C and subsequently thawing them in a 
thermocycler ǻřŖ°C, ŞŖŖ rpm, ś minǼ. The cycle was repeated ř times, before storing the 
lysate at -ŘŖ°C until further use. 
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ToǆiĐitǇ 
Carried out in collaboration by MIKH“IL ZYUZIN. 
HeLa cells were seeded into a şŜ-well plate at ŗśŖŖŖ cells per well, and incubated for ŘŚ h. 
Cells were washed, and new medium containing substrate ǻdissolved in DMF, stock conc. 
ŗŖ mMǼ at diferent concentrations ǻŖ-ŗŖŖ µMǼ was added. To another set of experiments, only 
DMF was added at diferent concentrations ǻŖ-ŗŚŖ µMǼ. Cells were incubated for ŝ h, before 
the medium with substrate/DMF was removed and fresh medium containing resazurin 
ǻŗŖ%Ǽ was added. “fter ř hours of incubation, emission spectra were measured to determine 
cell viability. 
For tests in DMSO ǻstock conc. ŗŖ mMǼ, the total concentration of DMSO was kept constant 
over all measurements, and exposure time was extended to ŘŚ h to cover a full cell cycle. 
These experiments were carried out in duplicates. 
TƌaŶsfeĐioŶ of Puƌiied PƌoteiŶ 
Carried out by MIKH“IL ZYUZIN. 
“ day before the experiment, HeLa cells were seeded in an Ş-well-plate at an amount of 
ŘŖ,ŖŖŖ cells/cmŘ in řŖŖ µL DMEM, and grown for ŘŚ h at řŝ°C with ś% COŘ. 
On the day of the experiment, ř.Ř µl of TFFIS ǻŗś.ś µMǼ were mixed with either ŗŘ µl or ŘŚ µl 
ǻcorresponding to Ŗ.Ş or ŗ.Ŝ µL/µg total protein of TUR”OFECT Transfection Reagent[ŘŝŜ] ǻfrom 
THERMO SCIENTIFICǼ and incubated at room temperature for ŘŖ min, before the volume of the 
mixture was illed up to ŗŖŖ µl with serum free cell medium. 
Cells were washed with P”S, ŘśŖ µL of serum free cell medium were added, before adding 
śŖ µL of the TUR”OFECT mix to the cells dropwise. Cell were incubated at řŝ°C with ś% COŘ 
for Ś h and ŘŖ h, respectively. “fter incubation, they were washed with P”S, before řŖŖ µl 
cell medium with serum containing ŗ% of substrate ŗa ǻdissolved in DMF, inal 
concentration of ŗŖŖ µMǼ was added. 
In the case of ŘŖ h of incubation, řŖŖ µM N“DPH co-factor ǻdissolved in P”SǼ was also 
added to the cells. Cells were monitored using an confocal scanning laser microscope, ixing 
ś positions per well and taking snapshots of visible light and luorescence ǻexcitation ŚŞŞ nm, 
ilter <śŖś nm, emission >śŗś nmǼ every ŗŖ min for multiple hours. 
TƌaŶsfeĐioŶ of ŵRNA 
Carried out by JO“NN“ REJM“N, Munich. 
The isolated plasmid DN“ was linearized using one of the following restrictions enzymes or 
combinations. Resulting DN“ concentrations are given in bracketsǱ ”lpI ǻno pelletǼ, XbaI 
ǻř.Řř µg/µLǼ, DraII ǻř.śŞ µg/µLǼ, DraII and XbaI ǻŘ.ś µg/µLǼ.  
For in vitro transcription, a commercially available “M”ION LIFE TECHNOLOGIES mMESS“GE 
mM“CHINE kit was used following the standard protocol.[Řşş] mRN“ was then modiied 
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with a Polyǻ“Ǽ Tailing kit from “PPLIED ”IOSYSTEMS, again following standard protocols.[řŖŖ] 
Transfection tests of all samples with and without poly“ tail were performed using 
LIPOFECT“MINE[Řŝŝ] and OPTIMEM reduced serum medium ǻfrom GI”COǼǱ Ř.Ś µL 
LIPOFECT“MINE were mixed with Śŝ.Ŝ µl OPTIMEMǲ mRN“ was diluted to Ŗ.ŗ µg/µL, before 
Ś µL of this new stock were mixed with ŚŜ µL of the OPTIMEM solution and incubated at 
ambient temperature for ŗŖ min, after which another şŖŖ µL OPTIMEM were added. HeLa 
cells were treated with the solution and incubated at řŝ°C with ś% COŘ prior to microscopy. 
MiĐƌoĐapsules 
Original Capsule Synthesis  
ŗŖŖ µL TFFIS were added to a Ŝŗś µL of a solution of NaŘCOř ǻŖ.řř MǼ and NaCl ǻŖ.ś MǼ in 
P”S bufer ǻpH ŝ.ŘǼ, and stirred for řŖ s at ŗŖŖŖ rpm with a magnetic stirrer at room 
temperature. “ solution of CaClŘ ǻŖ.řř MǼ and NaCl ǻŖ.ś MǼ in P”S ǻŜŗś µLǼ was added, 
mixed for řŖ s and incubated for ŗ-Ř min, upon which a cloudy precipitate formed. The 
mixture was transferred to an Eppendorf tube, centrifuged and the precipitate washed twice 
with water. For coating, śŖŖ-ŗŖŖŖ µL dextran sulfate solution ǻŗ mg/mL, Ŗ.ś M NaCl, at 
pH Ŝ.śǼ were added, vortexed for ŗŖ-ŗś min, before centrifuging and washing twice with 
water. This process was repeated with a poly-L-arginine solution ǻŗ mg/mL, Ŗ.ś M NaCl, at 
pH Ŝ.śǼ.  
For multi-layered capsules, the alternating coating steps were repeated another Ř-Ś times. For 
trigger-release capsules, Ř mL of ŗś nm gold-nanoparticle solution were mixed with 200 µL 
NaCl ǻŖ.ś MǼ, added to the capsule mix and sonicated for ŗ min, upon which the precipitate 
turned blue-black. “nother Ř.Ř mL of gold/NaCl solution was added, the mix centrifuged, 
and part of the supernatant discarded before the coating process was continued with dextran 
sulfate and poly-arginine ǻŗ layer eachǼ. 
“fter washing of the particles, they were resuspended in EDT“ solution ǻŖ.Ř M, pH ŜǼ and 
subjected to soniication for ŗŖ min to dissolve the cores. “fter centrifugation and 
resuspension in KPi bufer, they were stored at Ś°C until use. 
Capsule Synthesis Modiications  
”ased on this protocol and insights from the stability tests ǻChapters ś.Ŝ.Ś, page şş, and 
Chapter ř.Ŝ.Ř, page śşǼ, some modiications were tried to render the synthesis more enzyme-
friendlyǱ 
- Exchanging each step of vortexing for řŖs of sonication 
- Reducing stirring speed to ŞŖŖ rpm instead of ŗŖŖŖ rpm to reduce foam formation 
- Washing with KPi instead of water 
- Controlling temperatures ǻŚ°C instead of room temperatureǼ 
For controls, empty capsules or capsules containing a luorescent marker ǻDextrane-
Rhodamine, Ř mg/mL in waterǼ instead of the PŚśŖ protein were synthesized. 
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AppeŶdiǆ ϭ. List of AďďƌeǀiaioŶs 
ŗH-NMR proton nuclear magnetic resonance spectroscopy 
ŗřC-NMR carbon nuclear magnetic resonance spectroscopy 
CCE carboxycoumarin-ethylester 
CDClř chloroform deuterated 
cf. confer ǻlat.Ǳ compareǼ 
conc. concentrated 
CYP cytochrome PŚśŖ 
d doublet 
Έ chemical shift 
DCM dichloromethane 
Dex  dextrane 
DexS dextrane sulfate 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DN“ deoxyribonucleic acid 
E.coli Escherichia coli 
EDT“ ethylenediaminetetraacetate 
e.g. exempli gratia ǻlat.Ǳ for exampleǼ 
EPR enhanced permeability and retention efect 
ESI electrospray ionization 
et al. et alii ǻlat.Ǳ and othersǼ 
EtO“c ethyl acetate 
F“D lavin adenine dinucleotide 
FMN lavin mononucleotide 
FPLC fast protein liquid chromatography 
AppeŶdiǆ ϭ  -   List of AďďƌeǀiaioŶs 
_________________________________________________ 
 
 
 
ϭϮϮ | 
GFP green luorescence protein 
HeLa human cell-line, derived from a tumor taken from Henrieta Lacks 
HEPES Ř-[Ś-ǻŘ-hydroxyethylǼpiperazin-ŗ-yl]ethanesulfonic acid 
HPLC high performance liquid chromatography 
HR high resolution 
Hz Herz 
IPTG isopropyl Ά-D-ŗ-thiogalactopyranoside 
IR infrared spectroscopy 
ISM iterative saturation mutagenesis 
J coupling constant 
KPi potassium phosphate bufer 
N“DǻPǼH nicotinamide adenine dinucleotide ǻphosphateǼ 
n nano ǻŗŖ-şǼ 
n.o. not observed 
λ wavelength 
m unitǱ meterǲ  preixǱ milli ǻŗŖ-řǼǲ  NMRǱ multiplet  
M molarity 
µ micro ǻŗŖ-ŜǼ 
MD molecular dynamics 
MeOH methanol 
min minute 
MS mass spectroscopy 
P“H  polyǻallylamineǼ hydrochloride 
P”S phosphate bufered saline 
PG protection group 
PolyR  poly-arginine 
ppm parts per million 
PSS  sodium polystyrene sulfonate 
q quartet 
RN“ ribonucleic acid 
Rf retention factor 
rpm revolutions per minute 
RT room temperature 
s singlet 
SDS sodium dodecyl sulfate 
t triplet 
TLC thin layer chromatography 
UV ultraviolet ǻlightǼ 
wt wild type  
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AppeŶdiǆ Ϯ. List of Figuƌes 
Figure ŗ-ŗ.  Chemical biology provides the tools needed to inluence and study cellular 
processes, connecting biochemistry with many other branches of the life sciences. . Ř 
Figure ŗ-Ř.  Schematic representation of a chemical reporter strategy used in chemical biologyǱ 
after the target ǻdark greenǼ is tagged using a reporter ǻblueǼ, detection occurs by 
fusing the reporter to a signaling probe ǻorangeǼ. Reproduced from PRESCHER et al. 
with permission from M“CMILL“N PU”LISHERS LTD.[Ŝ] ................................................ ř 
Figure ŗ-ř.  Typical uncaging approaches. Cleavage of the protection group can either be light-
triggered ǻ“Ǽ, chemically induced ǻ”Ǽ, or facilitated by a catalyst ǻCǼ. The gray 
spheres represent the site of atachment for the caged molecule, while R residues 
show variable positions for derivatization. Examples for each approach are shown 
belowǱ “Ǽ Commonly used scafolds for photo-uncaging reactions, as reviewed by 
C“SEY et al.[řŜ] ”Ǽ Chemically induced activation by a click-to-release approach[ŗř,Śŗ] 
ǻtopǼ and N-oxide/boron release system ǻbotomǼ.[Śř] CǼ Metal-mediated uncaging 
reactions reported in biological environments.[Śś] ........................................................ ś 
Figure ŗ-Ś.  Catalysis in vivo – examples for diferent approaches. “Ǽ Nucleic acid templated 
reactions use naturally occurring oligomers to facilitate reactions, either for 
detection or prodrug releaseǲ ”Ǽ artiicial proteases and nucleases are equipped 
with a speciic ligand, directing them to their target, which can then be deactivated 
by hydrolysisǲ CǼ tagging of biomolecules for their detection can be achieved either 
by using a speciic ligand with a click-handle ǻleftǼ or by directly introducing the 
handle via non-natural amino acids ǻrightǼǲ DǼ a variety of methods are used for 
the activation of diferent compounds, and applications range from sensing to 
prodrug activationǲ EǼ interfering with the redox state of cells can be beneicial in 
anti-cancer treatments, with the generation of reactive oxygen species ǻROSǼ as 
main approach................................................................................................................ ŝ 
Figure ŗ-ś.  Iterative cycle of directed evolution. Starting from a parent gene usually found in 
nature, diversity is generated by mutagenesis. The resulting gene library is then 
transfected into a host species for expression, in order to select or screen for the 
desired trait. The identiied improved variants can then be used as starting point 
for another iteration, until the desired performance is reached by the evolved 
protein........................................................................................................................... ŗŖ 
Figure ŗ-Ŝ.  Model of PŚśŖ”Mř, a class VIII oxidoreductase. “Ǽ Dimerization is necessary for 
oxygenase activity ǻPD”-ID ŗ”VY[ŗśŝ]Ǽǲ ”Ǽ Potential model of the three subdomains. 
The PŚśŖ and FMN subunit of ”Mř ǻgreen and purple, respectivelyǲ PD”-ID ŗ”VYǼ 
were aligned with the F“D subdomain of a yeast–human N“DPH cytochrome 
PŚśŖ reductase ǻblue, PD”-ID řFJO[ŗśŞ]Ǽ along their FMN domain. Reproduced in 
analogy to “IGR“IN et al.[ŗśŜ] ......................................................................................... ŗř 
Figure ŗ-ŝ.  Catalytic cycle of mono-oxidation by CYPs. The substrate replaces water upon 
binding to the active site with its heme group. Under reduction by N“DPH, a 
dioxygen molecule is cleaved and one atom liberated as water, while the other is 
transferred to the substrate in a radical rebound mechanism. .................................. ŗŚ 
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Figure ŗ-Ş.  Possible electron transfer pathways in PŚśŖ”Mř between monomers and 
subdomains. “Ǽ crossing monomers between FMN and PŚśŖ domainsǲ ”Ǽ crossing 
monomers between F“D and FMN domainsǲ CǼ experimental approach for the 
investigation of the pathway using two mutants with either an inactivated FMN or 
PŚśŖ domain. ................................................................................................................ ŗś 
Figure ŗ-ş.  “spects of drug delivery. “round the central aspect of administration, the target 
tissue ǻleftǼ, the nature of the compound ǻtopǼ and the molecular delivery system 
ǻbotomǼ are equally important for successful treatment. ......................................... ŗŜ 
Figure ŗ-ŗŖ.  Classiication of nanoparticles based on their structure and materials. ................... ŘŖ 
Figure ŗ-ŗŗ.  Subcellular targets in a eukaryotic cell. ...................................................................... Řŗ 
Figure Ř-ŗ.  Concept of the bioorthogonal enzymatic activation of caged compounds. The 
substrate “Ǽ is activated by uncaging, a reaction which is catalyzed by an 
engineered enzyme ”Ǽ. Delivery system CǼ brings the catalyst inside the cell to its 
intended site of action. ................................................................................................. Řś 
Figure Ř-Ř.  Mechanism of the ether-deprotection reaction catalyzed by PŚśŖ mutants. The 
insertion of a single oxygen atom at the methylene group creates an unstable hemi-
acetal, which in turn undergoes spontaneous hydrolysis in aqueous media........... ŘŜ 
Figure ř-ŗ.  Cofactor recycling system for the in situ generation of N“DPH, for PŚśŖ”Mř-
catalyzed deprotection reactions. N“DP+ is converted to N“DPH by GDH, under 
oxidation of D-glucose. The cofactor can then be used by PŚśŖ”Mř for the 
hydroxylation of substrates. ........................................................................................ řŗ 
Figure ř-Ř.  Results of the pre-screen of luorescein derivatives ŗa-c using ŗŗ puriied enzymes 
at ŗŖŖ nM ǻleft, ŗŖ µM substrateǼ and a small test collection of řŘ variants ǻright, 
lysate reaction of ŗŖŖ µM substrateǼ. Top panels show overall intensity, botom 
panels illustrate relative substrate selectivity. Reactions were carried out in ”ufer I 
following standard conditions. ................................................................................... řŘ 
Figure ř-ř.  Schematic representation of the optimized screening process, from glycerol stock 
to substrate reaction. No further workup is necessary before luorometric analysis.
 ....................................................................................................................................... řŘ 
Figure ř-Ś. PYMOL[ŘŚŞ] renderings of PŚśŖ”Mř wt in a co-crystallized structure with N-
palmitoylglycine ǻPD”-ID ŗJPZ[ŘŚş]Ǽ, as full view ǻleftǼ and zoom into the active site 
ǻrightǼ. Highlighted are the prosthetic heme group ǻredǼ and amino acid residues 
targeted in S“”RIN“Ȃs Collection ǻblueǼ, the MegaSite library ǻorangeǼ, or both 
ǻgreenǼ. The substrate is shown in black. .................................................................... řř 
Figure ř-ś.  Vector map of pRSFDuet-ŗ as used for creation of the MegaSite library, including 
all primer sites. Optional His-tag for puriication and TEV restriction site are 
included in the representation..................................................................................... řŚ 
Figure ř-Ŝ.  Example of screening results for MegaSite plate No. ŝ, indicating activity ǻtop 
panelǼ and relative selectivity ǻbotom panelǼ. Horizontal lines indicate background 
intensity ǻredǼ and the minimum activity threshold that was chosed for genetic 
sequencing ǻgreen, results cf. “ppendix ŜǼ. Reactions were carried out in ”ufer I 
with lysate at a inal substrate concentration of ŗŖŖ µM. ........................................... řś 
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Figure ř-ŝ.  Results for the deprotection reaction of ŗa as determined by luorescence assay on 
the mixed şŜer collection plate ǻmutant details cf. “ppendix ŗŘǼ. Hit variants from 
this project are highlighted. Reproducibility is shown over time and diferent 
experimenters ǻthe data row denoted N.N. was generated by N“TH“LIE NETTǼ. 
Reactions were carried out in ”ufer I with lysate at a inal substrate concentration 
of ŗŖŖ µM using the N“DPH recycling system described in Figure ř-ŗ................... řŜ 
Figure ř-Ş.  HPLC traces of chiral resolution of enantiomers řg, before ǻblackǼ and after semi-
preparative puriication via HPLC ǻorangeǱ ǻRǼ-řgǲ greenǱ ǻSǼ-řgǼ. Separation was 
conducted on a CHIR“LP“K I” column using MeCN Ǳ Ŗ.ŗ% TF“/HŘO as solvents, 
following gradient IV as described in Table ś-Ś, page ŝŘ. ......................................... ŚŖ 
Figure ř-ş.  “ctivity of PŚśŖ”Mř mutants towards diferent caged compounds arranged in an 
MTP format ǻşŜ samplesǼ. Fluorescein- ŗa-f ǻgreenǼ and coumarin-based substrates 
ǻŘa, c, d, red and řa, c, d, blueǼ were used for library screening. Fluorescence 
intensities are normalized to the lowest/highest values included in the plates, 
brighter colors showing higher activity ǻfor original values see “ppendix ŞǼ. ........ Śŗ 
Figure ř-ŗŖ.  Results of the lysate reaction of diferent mutants towards enantiomers řg. “ll but 
one tested mutant ǻLFFF“Ǽ favor the S-enantiomer. Top panels show overall 
intensity, botom panels illustrate relative selectivity. Reactions were carried out in 
”ufer I with lysate at a inal substrate concentration of ŗŖŖ µM.............................. ŚŘ 
Figure ř-ŗŗ.  Concentration determination of PŚśŖ”Mř. Shown are absorption spectra of the 
reduced enzyme, averaged over three measurements with ǻgreenǼ and without 
addition of CO ǻorangeǼ, as well as the calculated diference spectrum ǻpurpleǼ. .. Śř 
Figure ř-ŗŘ. HPLC traces of luorescein ǻleftǼ and umbelliferone derivatives ǻrightǼ. Separation 
was conducted on a reversed-phase CŗŞ column using MeCN Ǳ Ŗ.ŗ% TF“/HŘO as 
solvents, following gradient I ǻleft panelǼ as described in Table ś-Ś, page ŝŘ or at 
isocratic conditions ǻśŖǱśŖ, right panelǼ. ..................................................................... Śś 
Figure ř-ŗř. Evaluation of extraction solvents on luorescein und umbelliferone derivatives. 
Separation was conducted on a reversed-phase CŗŞ column using MeCN Ǳ Ŗ.ŗ% 
TF“/HŘO as solvents at isocratic conditions  of ŝŖ% ǻleft panelǼ or śŖ% acetonitrile 
ǻright panelǼ. The peak denoted with an asterisk is due to unidentiied water-
soluble components. .................................................................................................... ŚŜ 
Figure ř-ŗŚ. Evaluation of extraction methods, normalized to the observed concentrations in 
corresponding ixed dilution measurements. The left panel emphasizes varying 
degrees of extraction completeness across the derivatives, while the right panel 
accentuates the diference between methods. Separation was conducted on a 
reversed-phase CŗŞ column using MeCN Ǳ Ŗ.ŗ% TF“/HŘO as solvents, following 
gradient I ǻleft panelǼ as described in Table ś-Ś, page ŝŘ. Corresponding peak areas 
were then normalized to the value measured for analysis of a solution with known 
concentration ǻgrayǼ. .................................................................................................... Śŝ 
Figure ř-ŗś.  In vitro characterization. Enzymatic activity of PŚśŖ”Mř hit mutants towards caged 
compounds, normalized to the largest observed luorescence response for each 
substrate ǻoriginal dataǱ cf. “ppendix şǼ. Reactions were carried out in ”ufer I, 
generally following standard conditions at inal concentrations of Ŗ.ŗ µM and 
ŗŖŖ µM for enzyme and substrate, respectively. ........................................................ ŚŞ 
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Figure ř-ŗŜ. Real-time luorescence monitoring of the reactions TFFIS/ŗa. The reaction was 
carried out in ”ufer I, following standard conditions at inal concentrations of 
Ŗ.ŗ µM and ŗŖŖ µM for enzyme and substrate, respectively. Completion of the 
reaction is observed after ca. ŚŖ min ǻstage ŗ, greenǼ. Functionality of the enzyme 
was checked by a second addition of substrate ǻstage Ř, redǼ, and N“DPH ǻstage ř, 
orangeǼ. “ second addition of enzyme ǻstage Ś, blueǼ showed some conversion, but 
signiicantly lower than before, pointing towards an inactivation of PŚśŖ”Mř. ........ ŚŞ 
Figure ř-ŗŝ.  Orthogonality test with diferent mutants in the case of substrate ŗa.  ”oth enzymes 
were either added at the same time ǻblack linesǼ or successively ǻcolored lines, 
addition time marked by arrowsǼ. LeftǱ TFFIS and MŖŗǲ RightǱ TFFIS and WMV. 
The TIFFIS/MŖŗ pair shows expected orthogonality, whereas the data of the 
TFFIS/WMV pair provides evidence for the formation of mixed dimers with 
changed catalytic properties. Reactions were carried out in ”ufer I, generally 
following standard conditions at a inal substrate concentrations ŗŖŖ µM. The inal 
enzyme concentration was Ŗ.ŗ µM for TFFIS and MŖŗ, and Ŗ.Ŗŗ µM for WMV, to 
account for the diference in performance. ................................................................. Śş 
Figure ř-ŗŞ.  HPLC traces of reactions as used for quantiication. Hit mutants are shown in 
green, clearly showing product formation – in case of substrate ŗd, mono-
deprotected luorescein ŗdȂ is formed by mutant TFFIS ǻleftǼ. WMV ǻrightǼ shows 
total conversion of substrate řd. No conversion occurs in wt reactions ǻorangeǼ. 
Grey lanes show a control of chemically synthetized derivatives. The substance 
marked * is an unidentiied compound present in all enzyme reactions, 
independent of the substrate. Separation was conducted on a reversed-phase CŗŞ 
column using MeCN Ǳ Ŗ.ŗ% TF“/HŘO as solvents, following gradient I as described 
in Table ś-Ś, page ŝŘ. .................................................................................................... śŗ 
Figure ř-ŗş.  MICH“ELIS-MENTEN plots for TFFIS with ŗa ǻleftǼ and WMV with řd ǻrightǼ. “t 
lower concentrations ǻgrey data pointsǼ, the high leak rate of WMV without 
substrate interferes with the measurement. ............................................................... śŘ 
Figure ř-ŘŖ. In silico results. Docking poses for ǻaǼ substrate ŗa in TFFIS, ǻbǼ substrate řd in 
WMV and ǻcǼ substrate Řa in MŖŗ. Highlighted are the oxidized prosthetic heme 
groups ǻredǼ, substrate ǻgreenǼ and mutated residues ǻorangeǱ RŚŝx, blueǱ FŞŝxǼ... śŚ 
Figure ř-Řŗ.  Cytotoxicity of substrate ŗa against HeLa cells, with DMF and DMSO as co-
solvents, as determined via a resazurin luorescence assay. “dherent cells were 
incubated with varying concentrations of the substrate ǻŖ.ŗ-ŗŖŖ µMǼ for ŝ h before 
treatment with resazurin, and the signal was normalized to a control of cells 
treated with the same co-solvent but no substrate. .................................................... śŜ 
Figure ř-ŘŘ.  Transfection of HeLa cells with puriied TFFIS using TUR”OFECT at Ŗ.Ş ǻleftǼ and 
ŗ.Ŝ µL/µg protein ǻrightǼ. Toxicity of the treatment is easily visible by the round 
shape of the cells, indicating detachment from the plate, and the formation of 
vesicles. ......................................................................................................................... śŝ 
Figure ř-Řř.  “poptosis of HeLa cells upon addition of substrate ŗa after TUR”OFECT transfection 
of TFFIS. ........................................................................................................................ śŞ 
Figure ř-ŘŚ.  Transfection of HeLa cells with mRN“ encoding for TFFIS, using LIPOFECT“MINE 
ǻleftǱ luorescence channel, rightǱ bright ieldǼ. The treatment is toxic for the cells 
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ǻround shape, formation of vesiclesǼ. This has to be atributed to this particular 
mRN“, since a control with GFP did not show any toxicity ǻdata not shownǼ. ...... śŞ 
Figure ř-Řś.  Stability of TFFIS in presence of diferent additives, normalized to the signal in KPi 
bufer. Reactions were carried out in ”ufer II following standard conditions at 
inal concentrations of Ŗ.ŗ µM and ŗŖŖ µM for enzyme and substrate, respectively.
 ....................................................................................................................................... śş 
Figure ř-ŘŜ.  Stability of TFFIS at diferent pH values across a wide range of Ř-ŗŖ ǻleftǼ, and in a 
time dependent analysis of a narrow range of Ś-ś ǻrightǼ. Reactions were carried 
out at pH ŝ after incubation of the enzyme at the speciied pH for ŜŖ min or the 
speciied amount of time. Reactions were carried out in ”ufer I following standard 
conditions at inal concentrations of Ŗ.ŗ µM and ŗŖŖ µM for enzyme and substrate, 
respectively. .................................................................................................................. ŜŖ 
Figure ř-Řŝ.  “ctivity test of TFFIS. Left panelǱ “ctivity after subjecting the enzyme to diferent 
mechanical disturbances for varying amounts of time. Reactions were carried out 
in ”ufer I. Right panelǱ activity in presence of diferent cations at varying ionic 
strength. Reactions were carried out in analogy to ”ufer II. “ll reactions followed 
standard conditions at inal concentrations of Ŗ.ŗ µM and ŗŖŖ µM for enzyme and 
substrate, respectively. ................................................................................................ Ŝŗ 
Figure ř-ŘŞ.  Stability of TFFIS during diferent steps of capsule synthesis. Reactions were 
carried out in ”ufer II following standard conditions at inal concentrations of 
Ŗ.ŗ µM and ŗŖŖ µM for enzyme and substrate, respectively. ..................................... ŜŘ 
Figure ř-Řş.  Schematic description of capsule synthesis. Solutions of sodium carbonate and 
calcium chloride are combined and mixed, forming a inely distributed precipitate. 
These particles are used as templates for a layer-by-layer approach. Treatment of 
the cores is alternated between anionic and cationic polymers, until the desired 
thickness is reached. The core can then be dissolved using EDT“ as a calcium 
chelate agent. ................................................................................................................ ŜŘ 
Figure ř-řŖ.  Live cell experiments. E. coli expressing TFFIS ǻtopǼ show a high luorescence 
signal after treatment with substrate ŗa, indicating successful deprotection. No 
signiicant signal level is observed in the wt ǻbotomǼ. Shown are luorescence 
channel ǻleftǼ, optical channel ǻmiddleǼ and overlay of both channels ǻrightǼ. Scale 
bars indicate Ř µm. ....................................................................................................... Ŝř 
Figure ř-řŗ.  Results of luorescence read-out of supernatants and lysates of whole cell reactions. 
Signals are normalized to the maximum activity observed for the corresponding 
luorophore in this assay, negative signals are due to unrelated substances present 
in medium or lysate ǻoriginal data see “ppendix ŗŖǼ................................................ Ŝř 
Figure ś-ŗ.  “bsorption spectra of cofactor N“DPH and coumarin compounds Ř and ř. ”oth 
compounds interfere with measurements at the absorption maximum of N“DPH 
ǻřŚŖ nmǼ, but suitable wavelengths are easily found at řŘŖ nm ǻřǼ or řŜŖ nm ǻŘǼ. 
The absorption coeicient used in calculations was adjusted accordingly. ............. şş 
Figure ŝ-ŗ. Fluorescence calibration – shown are linear ranges of luorophores ŗ ǻoutlier shown 
in gray, but excluded from itǼ, ŗaȂ, Ř and ř. ............................................................. ŗřŘ 
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Figure ŝ-Ř.  HPLC calibration curve for luorescein derivatives ŗ, ŗa, ŗaȂ and ŗd at set 
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Figure ŝ-ř.  HPLC calibration curve for luorescein derivatives derivatives ŗ, ŗa, ŗaȂ and ŗd 
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Figure ϳ-ϭ. FluoƌesĐeŶĐe ĐaliďƌaioŶ – shoǁŶ aƌe liŶeaƌ ƌaŶges of luoƌophoƌes ϭ ;outlieƌ shoǁŶ iŶ 
gƌaǇ, ďut eǆĐluded fƌoŵ itͿ, ϭa’, Ϯ aŶd ϯ.  
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Figure ϳ-Ϯ.  HPLC ĐaliďƌaioŶ Đuƌǀe foƌ luoƌesĐeiŶ deƌiǀaiǀes ϭ, ϭa, ϭa’ aŶd ϭd at set ĐoŶĐeŶtƌaioŶs. 
 
 
Figure ϳ-ϯ.  HPLC ĐaliďƌaioŶ Đuƌǀe foƌ luoƌesĐeiŶ deƌiǀaiǀes deƌiǀaiǀes ϭ, ϭa, ϭa’ aŶd ϭd ateƌ 
eǆtƌaĐioŶ. 
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AppeŶdiǆ ϲ. ϭst GeŶeƌaioŶ SĐƌeeŶ SeƋueŶĐiŶg Data  
Taďle ϳ-ϭ. MutaioŶs of the hits fouŶd foƌ iƌst geŶeƌaioŶ suďstƌates, as deteƌŵiŶed fƌoŵ the 
seƋueŶĐiŶg ƌesults. EŶtƌies aƌe ƌaŶked ďǇ aĐiǀitǇ toǁaƌds suďstƌate ϭa. GƌaǇ eŶtƌies aƌe 
dupliĐate ǀaƌiaŶts ǁith loǁeƌ eǆpƌessioŶ leǀels.  
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F 
 
F V 
  
S 
řŖ TVFVS Ϯϳϵϰ ϭϰϱϴ Ϭ.ϱϮ T 
 
V 
 
F V 
  
S 
řŗ TFWIN Ϯϲϲϵ ϵϮϲ Ϭ.ϯϱ T 
 
F 
 
W I 
  
N 
řŘ ďad seƋ. ϮϲϭϮ ϲϱϵ Ϭ.Ϯϱ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ 
řř TFFIL Ϯϱϴϳ ϱϭϵ Ϭ.ϮϬ T 
 
F 
 
F I 
   řŚ LSWIN Ϯϰϵϴ ϭϬϲϲ Ϭ.ϰϯ L 
   
W I 
  
N 
řś WFFFS Ϯϰϳϳ Ϯϵϴ Ϭ.ϭϮ W 
 
F 
 
F 
   
S 
řŜ TSFFN ϮϰϮϯ Ϯϵϲ Ϭ.ϭϮ T 
   
F 
   
N 
  
_________________________________________________ 
 
 
 
| ϭϯϱ 
 
Shoƌt  
Naŵe 
AĐiǀitǇ SeleĐiǀitǇ MutaioŶs 
EŶtƌǇ ϭa ϭď ϭď/ϭa Rϰ
ϳ 
AS
Ϯ 
Sϳ
Ϯ 
Vϳ
ϴ 
Aϴ
Ϯ 
Fϴϳ
 
Vϭ
ϳϴ
 
Vϯ
ϭϰ
 
Lϰϯ
ϳ 
řŝ TFFIL ϮϰϬϮ ϱϴϲ Ϭ.Ϯϰ T 
 
F 
 
F I 
   řŞ TFVFL ϮϮϵϬ ϲϱϰ Ϭ.Ϯϵ T 
 
F 
 
V 
    řş TSWIA ϮϮϰϲ ϴϮϰ Ϭ.ϯϳ T 
   
W I 
  
A 
ŚŖ LFFAL ϮϮϰϬ ϵϱϳ Ϭ.ϰϯ L 
 
F 
 
F A 
   Śŗ WSWIA ϮϬϰϳ ϭϬϳϴ Ϭ.ϱϯ W 
   
W I 
  
A 
ŚŘ LIFIL ϮϬϭϴ ϱϱϭ Ϭ.Ϯϳ L 
 
I 
 
F I 
   Śř RSFAǆ+AIVV ϭϬϳϱ ϲϰϴ Ϭ.ϲϬ 
   
I F A 
  
~~ 
ŚŚ RSFAL+AMVVe ϳϮϬ ϰϲϱ Ϭ.ϲϱ 
   
M F A 
   Śś YSFAL+FWVI Ϯϯϵ ϲϬ Ϭ.Ϯϱ Y F 
 
W F A 
 
I 
 ŚŜ RSFAL+ALEV ϭϲϭ ϴϮ Ϭ.ϱϭ 
   
L F A E 
  Śŝ YSFAL+FAVI ϭϰϰ ϳϵ Ϭ.ϱϱ Y F 
 
A F A 
 
I 
 ŚŞ RSVAL+AWVVf ϭϭϰ ϱϯ Ϭ.ϰϳ 
   
W V A 
   AddiioŶal ŵutaioŶs: aͿ EϮϵϯ sileŶt: GAA→GGA; ďͿ TϮϰϱ?: ACG→.CG; ĐͿ EϮϵϯG: GAA→GGA;  
dͿ DϮϮϮY: GAT→TAT; eͿ Lϱϳ sileŶt ;CTA→TTAͿ, EϮϵϯ sileŶt: GAA→GGA; fͿ Lϱϳ sileŶt ;CTA→TTAͿ.   
 
 
 
 
AppeŶdiǆ ϳ. ColleĐted SĐƌeeŶiŶg Results of all Puƌiied MutaŶts 
Taďle ϳ-Ϯ.  Oǀeƌǀieǁ oǀeƌ sĐƌeeŶiŶg ƌesults of puƌiied ŵutaŶts as deteƌŵiŶed fƌoŵ oƌigiŶal lǇsate 
ƌeaĐioŶs. Hit paiƌs aƌe highlighted. Suďstƌate deƌiǀaiǀes ǁhiĐh aƌe Ŷot listed ǁeƌe 
disĐoŶiŶued. 
 Suďstƌate → ϭa ϭd Ϯa ϮĐ Ϯd ϯĐ ϯd 
SĐƌeeŶ 
MutaŶt 
Naŵe ↓ [au] [au] [au] [au] [au] [au] [au] 
 ǁt ϭϭϯ ϭϭϵϮ ϰϮϲϳ ϰϯϳϰ ϰϮϮϱ ϭϲϯϵϲ ϭϮϳϮϮ 
 ǁt+His ϭϰϴ ϭϭϲϬ ϰϮϲϵ ϰϮϱϴ ϰϮϴϮ ϭϲϰϯϱ ϭϮϱϯϯ 
GeŶ I TFFIS ϱϬϵϬ ϭϭϵϬ ϰϱϱϵ ϰϮϭϳ ϰϴϰϴ ϭϭϯϵϭ ϭϮϬϱϳ 
GeŶ II YFM-WEI-A ϳϬ ϮϬϲϲ ϰϯϲϬ ϰϮϴϱ ϯϳϲϱ Ϯϭϯϱϵ ϮϬϮϯϭ PC-A ϰϲ ϮϰϯϬ ϰϬϬϬ ϯϵϬϲ ϯϴϵϵ ϱϬϱϱϲ ϭϮϵϴϰ 
GeŶ III 
MϬϭ ϰϮϵ ϭϬϮϲ ϵϭϱϱ ϲϳϲϯ ϰϵϯϭ ϯϮϭϴϯ ϰϭϮϴϵ 
Mϭϭ ϯϴϰ ϭϭϴϵ ϭϬϬϲϭ ϳϰϱϴ ϱϯϱϭ ϯϬϭϮϬ ϮϵϬϯϴ 
WMV ϭϳϭ ϭϭϰϭ ϱϲϰϯ ϭϯϲϴϵ ϰϳϲϴ ϭϯϰϯϲϭ ϱϲϴϱϯ 
LV ϭϱϬ ϭϭϱϮ ϰϵϳϰ ϳϮϭϵ ϰϯϲϱ ϵϭϵϰϮ ϮϮϳϵϮ 
WWV-MQ’ ϮϬϭ ϭϯϳϲ ϰϲϭϴ ϰϲϴϬ ϰϵϭϯ ϯϴϴϲϵ ϵϳϰϬϱ 
 
  
  
_________________________________________________ 
 
 
 
ϭϯϲ | 
AppeŶdiǆ ϴ. SĐƌeeŶiŶg Data as ploted iŶ Figuƌe ϯ-ϵ 
Taďle ϳ-ϯ.  EǆeŵplaƌǇ sĐƌeeŶiŶg ƌesults foƌ luoƌesĐeiŶ-ďased deƌiǀaiǀes ϭa-f ;plate Ŷuŵďeƌ ϯ of the 
MegaSite liďƌaƌǇͿ. The hit ŵutaŶt TFFIS shoǁiŶg the highest aĐiǀitǇ is highlighted. 
 
Suďstƌate → ϭa ϭď ϭĐ ϭd ϭe ϭf 
EŶtƌǇ Well 
      ϭ ϭA ϳϬ ϲϮ ϲϮ ϯϱϴ ϳϬ ϳϭ 
Ϯ ϮA ϲϬ ϰϮ ϯϭ ϭϭϱ ϱϳ ϯϵ 
ϯ ϯA ϱϴ ϰϮ ϯϯ ϲϲϴ ϯϰ ϰϱ 
ϰ ϰA ϱϭ ϰϱ ϯϮ ϰϱϳ ϲϭ ϯϯ 
ϱ ϱA ϱϳ ϰϳ ϯϰ ϯϵϲ ϲϬ ϰϮ 
ϲ ϲA ϳϳ ϲϬ ϰϯ ϰϯϱ ϰϵ ϲϱ 
ϳ ϳA ϲϳ ϲϬ ϯϵ ϰϴϱ ϰϳ ϰϳ 
ϴ ϴA ϲϲ ϰϴ ϯϬ ϯϳϭ ϱϱ ϰϮ 
ϵ ϵA ϭϰϵ ϭϲϴ ϯϴ ϭϯϰ ϭϬϳ ϳϭ 
ϭϬ ϭϬA ϳϬ ϱϮ ϰϬ ϵϬϵ ϲϭ ϱϭ 
ϭϭ ϭϭA ϭϭϲ ϭϭϱ ϰϳ ϮϬϴ ϳϱ ϲϰ 
ϭϮ ϭϮA ϳϬ ϲϲ ϰϯ ϳϬϯ ϳϱ ϳϴ 
ϭϯ ϭB ϯϲϱϲ ϮϬϴϰ ϲϭ ϴϴϳ ϳϲ ϳϮ 
ϭϰ ϮB ϳϯ ϲϰ ϰϱ ϵϲ ϳϵ ϳϰ 
ϭϱ ϯB ϴϲϬ Ϯϵϳ ϯϵ ϭϭϬϰ ϲϯ ϰϱ 
ϭϲ ϰB ϲϰ ϲϮ ϰϯ ϵϲ ϰϵ ϱϱ 
ϭϳ ϱB ϴϳ ϳϲ ϲϬ ϳϴϱ ϰϱ ϱϭ 
ϭϴ ϲB ϴϭϱ ϮϮϵ ϱϵ ϰϱ ϭϬϮ ϱϰ 
ϭϵ ϳB ϵϭ ϴϯ ϱϯ ϵϬϬ ϱϯ ϲϯ 
ϮϬ ϴB ϲϳ ϳϴ ϱϲ ϯϲϲ ϭϭϲ ϰϴ 
Ϯϭ ϵB ϭϳϬϲ ϲϬϯ ϲϯ ϱϮϵ ϭϮϴ ϴϲ 
ϮϮ ϭϬB ϳϲ ϲϬ ϱϮ ϲϵϴ ϭϭϱ ϱϮ 
Ϯϯ ϭϭB ϲϳ ϲϬ ϰϮ ϭϭϱ ϱϯ ϲϵ 
Ϯϰ ϭϮB ϳϱ ϱϭ Ϯϴ ϳϰϱ ϲϵ ϰϴ 
Ϯϱ ϭC ϲϱ ϱϱ ϰϭ ϰϮ ϱϴ ϰϱ 
Ϯϲ ϮC ϵϲ ϳϮ ϲϰ ϵϭϬ ϱϮ ϲϱ 
Ϯϳ ϯC ϴϰ ϲϰ ϱϲ ϭϲϱ ϱϲ ϰϭ 
Ϯϴ ϰC ϲϰ ϲϭ ϰϭ ϭϯϰ ϯϴ ϯϮ 
Ϯϵ ϱC ϳϭ ϱϴ ϯϴ ϴϳϬ ϲϰ ϰϴ 
ϯϬ ϲC ϵϴ ϵϭ ϱϯ ϭϳϲ ϱϳ ϰϵ 
ϯϭ ϳC ϴϰϰϯ ϯϭϴϬ ϱϮ ϭϴϬϱ ϱϰ ϲϴ 
ϯϮ ϴC Ϯϴϴ ϴϮ ϰϯ ϵϳϮ ϴϯ ϰϰ 
ϯϯ ϵC ϲϲ ϱϬ ϯϮ ϭϭϴ ϰϱ ϯϱ 
ϯϰ ϭϬC ϱϳ ϱϯ ϯϱ ϳϵ ϰϲ ϰϱ 
ϯϱ ϭϭC ϭϰϴϮ ϰϳϱ ϲϱ ϭϭϲϮ ϭϬϲ ϳϮ 
ϯϲ ϭϮC ϲϭ ϴϬ ϯϴ ϭϱϭ ϳϰ ϱϱ 
ϯϳ ϭD ϲϮ ϱϵ ϰϬ ϴϵ ϱϲ ϰϱ 
ϯϴ ϮD ϭϭϮ ϵϮ ϲϭ ϭϱϱ ϲϱ ϱϮ 
ϯϵ ϯD ϭϴϭϮ ϴϰϮ ϰϱ ϵϬϰ ϳϱ ϱϲ 
AppeŶdiǆ ϴ  -   SĐƌeeŶiŶg Data as ploted iŶ Figuƌe ϯ-ϵ 
_________________________________________________ 
 
 
 
| ϭϯϳ 
 Suďstƌate → ϭa ϭď ϭĐ ϭd ϭe ϭf 
EŶtƌǇ Well       
ϰϬ ϰD ϯϭϰ ϭϭϭ ϰϳ ϮϴϬ ϲϲ ϰϱ 
ϰϭ ϱD ϵϳ ϳϮ ϰϳ ϭϭϳ ϳϬ ϲϮ 
ϰϮ ϲD ϳϯ ϲϲ ϱϮ ϴϯϳ ϲϴ ϰϴ 
ϰϯ ϳD ϲϴ ϲϱ ϰϰ ϰϬϮ ϱϰ ϯϯ 
ϰϰ ϴD ϲϴ ϲϯ ϰϲ ϭϲϯ ϱϯ ϱϰ 
ϰϱ ϵD ϳϭ ϱϳ ϰϬ ϭϱϰ ϱϲ ϰϱ 
ϰϲ ϭϬD ϱϲ ϰϳ ϯϭ ϵϱϳ ϰϮ ϯϬ 
ϰϳ ϭϭD ϲϯ ϱϱ ϯϵ ϭϰϲ ϲϰ ϱϲ 
ϰϴ ϭϮD ϱϲ ϰϳ Ϯϵ ϳϮϳ ϯϰ ϯϲ 
ϰϵ ϭE ϳϴ ϲϰ ϱϱ ϭϰϵ ϭϮϵ ϱϭ 
ϱϬ ϮE ϳϮ ϱϵ ϰϱ ϳϰϳ ϯϳ ϰϱ 
ϱϭ ϯE ϲϴ ϲϲ ϯϲ ϯϬϰ ϲϬ ϰϭ 
ϱϮ ϰE ϭϮϵ ϲϲ ϰϱ ϭϰϭ ϰϴ ϱϲ 
ϱϯ ϱE ϴϭ ϲϴ ϱϳ ϳϭϳ ϰϵ ϱϮ 
ϱϰ ϲE ϲϯ ϱϰ ϰϭ ϯϮ ϲϰ ϯϲ 
ϱϱ ϳE ϳϴ ϳϯ ϰϴ ϵϬϯ ϰϲ ϯϴ 
ϱϲ ϴE ϲϮ ϱϱ ϰϬ ϭϯϰ ϲϬ Ϯϵ 
ϱϳ ϵE ϭϳϳ ϭϮϯ ϰϳ ϭϴϵ ϲϮ ϲϱ 
ϱϴ ϭϬE ϱϮ ϰϳ Ϯϳ ϵϲϮ ϰϯ ϯϮ 
ϱϵ ϭϭE ϲϭ ϰϵ ϯϯ ϯϮϲ ϰϲ ϰϳ 
ϲϬ ϭϮE ϭϰϭϱ ϰϳϲ ϲϬ ϱϮ ϳϴ ϲϵ 
ϲϭ ϭF ϳϬ ϱϲ ϰϲ ϴϯϬ ϳϳ ϱϱ 
ϲϮ ϮF ϳϭ ϲϭ ϰϱ ϭϭϴ ϰϭ ϰϴ 
ϲϯ ϯF ϳϬ ϱϳ ϰϯ ϳϰϬ ϯϲ ϯϲ 
ϲϰ ϰF ϴϱ ϲϰ ϰϭ ϭϮϰ ϲϮ ϰϴ 
ϲϱ ϱF ϳϰ ϳϭ ϱϯ ϳϯϬ ϲϮ ϰϴ 
ϲϲ ϲF ϲϴ ϲϮ ϰϬ ϭϭϮ ϱϬ ϱϯ 
ϲϳ ϳF ϱϵ ϯϵ Ϯϵ ϲϯ ϯϯ ϯϯ 
ϲϴ ϴF ϱϱϴ ϭϳϳ ϱϴ ϭϬϲϳ ϱϳ ϱϴ 
ϲϵ ϵF ϲϮ ϰϲ ϯϭ ϭϰϲ ϱϱ Ϯϵ 
ϳϬ ϭϬF ϭϴϳϯ ϭϲϲ ϱϬ ϲϰϲ ϲϯ ϲϱ 
ϳϭ ϭϭF ϰϵ ϰϯ Ϯϴ ϭϭϬϱ ϰϰ ϯϱ 
ϳϮ ϭϮF ϲϵ ϳϰ ϰϰ ϭϱϲ ϭϮϭ ϭϭϮ 
ϳϯ ϭG ϰϳ ϰϳ Ϯϱ Ϯϴϲ Ϯϲ Ϯϭ 
ϳϰ ϮG ϲϮ ϰϴ ϯϯ ϭϬϭ ϰϰ Ϯϱ 
ϳϱ ϯG ϲϱ ϱϳ ϰϬ ϳϭϱ ϰϲ ϯϱ 
ϳϲ ϰG ϲϵ ϲϭ ϰϰ ϭϱϮ ϰϲ ϲϯ 
ϳϳ ϱG ϴϳ ϲϲ ϱϱ ϭϭϮ ϲϲ ϰϴ 
ϳϴ ϲG ϲϵ ϲϮ ϰϵ ϭϭϬϯ ϱϯ ϯϵ 
ϳϵ ϳG ϭϱϮ ϭϬϱ ϱϵ ϭϴϬ ϭϮϲ ϯϳ 
ϴϬ ϴG ϮϳϮ ϭϬϯ ϰϲ ϲϵϳ ϲϬ ϱϵ 
ϴϭ ϵG ϳϳ ϱϵ ϰϵ ϭϬϰ ϱϲ ϰϰ 
ϴϮ ϭϬG ϵϬ ϲϱ ϯϭ ϳϭϯ ϰϲ ϰϭ 
ϴϯ ϭϭG ϭϮϳ ϭϮϳ ϰϯ ϰϬ ϵϰ ϰϲ 
ϴϰ ϭϮG ϲϯ ϱϴ ϯϴ ϴϮϲ ϱϴ ϲϳ 
AppeŶdiǆ ϴ  -   SĐƌeeŶiŶg Data as ploted iŶ Figuƌe ϯ-ϵ 
_________________________________________________ 
 
 
 
ϭϯϴ | 
 Suďstƌate → ϭa ϭď ϭĐ ϭd ϭe ϭf 
EŶtƌǇ Well       
ϴϱ ϭH ϱϵ ϱϭ ϯϯ ϭϱϵ ϲϱ ϰϰ 
ϴϲ ϮH ϴϭ ϱϴ ϰϳ ϳϭϭ ϴϬ ϳϮ 
ϴϳ ϯH ϳϯϭ Ϯϱϲ ϱϵ Ϯϳϵ ϳϬ ϲϴ 
ϴϴ ϰH ϲϵ ϲϲ ϰϲ ϳϭϮ ϴϭ ϰϴ 
ϴϵ ϱH ϲϬ ϱϰ ϯϰ ϭϰϳ ϰϭ ϰϬ 
ϵϬ ϲH ϲϭ ϱϱ ϰϰ ϳϲϴ ϲϵ ϱϱ 
ϵϭ ϳH ϳϱ ϲϭ ϰϲ ϭϯϳ ϰϵ ϰϮ 
ϵϮ ϴH ϳϬ ϲϭ ϱϯ ϳϮϳ ϱϮ ϱϭ 
ϵϯ ϵH ϴϳ ϳϬ ϰϵ ϭϭϴ ϴϴ ϲϭ 
ϵϰ ϭϬH ϭϮϮϲ ϲϴϮ ϳϲ ϵϯϮ ϱϰ ϰϴ 
ϵϱ ϭϭH ϰϮϮ Ϯϯϲ ϲϲ Ϯϱϵ ϭϬϱ ϰϴ 
ϵϲ ϭϮH ϭϬϴϬ ϯϳϱ ϰϳ ϴϵϭ ϴϵ ϴϯ 
 
Taďle ϳ-ϰ. SĐƌeeŶiŶg ƌesults foƌ ĐouŵaƌiŶ-ďased deƌiǀaiǀes Ϯa, Đ, d aŶd ϯa, Đ, d ;ŵutaŶt ĐolleĐioŶ 
ďased oŶ this aŶd otheƌ pƌojeĐtsͿ. Hit ŵutaŶts MϬϭ ;ϴAͿ aŶd WMV ;ϱBͿ aƌe highlighted.  
 
Suďstƌate → Ϯa ϮĐ Ϯd ϯa ϯĐ ϯd 
EŶtƌǇ Well 
      ϭ ϭA ϰϰϴϲ ϰϭϳϭ ϰϯϳϱ ϭϬϭϭϱ ϵϴϮϳ ϴϬϵϮ 
Ϯ ϮA ϰϮϲϳ ϰϯϳϰ ϰϮϮϱ ϳϴϳϴ ϭϲϯϵϲ ϭϮϳϮϮ 
ϯ ϯA ϰϲϵϰ ϱϭϴϲ ϰϴϱϲ ϯϬϯϮϳ ϳϬϴϮϰ ϯϲϲϲϯ 
ϰ ϰA ϰϬϬϮ ϰϰϯϲ ϯϳϲϬ ϭϲϮϮϵ ϭϵϳϲϵ ϭϳϴϮϰ 
ϱ ϱA ϰϵϳϰ ϳϮϭϵ ϰϯϲϱ ϭϲϲϬϵ ϵϭϵϰϮ ϮϮϳϵϮ 
ϲ ϲA ϱϬϮϯ ϲϬϲϮ ϰϰϱϴ ϱϬϲϮϳ ϲϳϯϳϱ ϯϵϴϱϴ 
ϳ ϳA ϰϵϮϬ ϲϮϵϮ ϰϯϬϮ ϯϮϱϲϮ ϴϭϲϴϰ ϮϳϳϮϱ 
ϴ ϴA ϵϭϱϱ ϲϳϲϯ ϰϵϯϭ Ϯϯϯϴϱ ϯϮϭϴϯ ϰϭϮϴϵ 
ϵ ϵA ϰϳϱϵ ϱϯϬϬ ϰϱϬϲ ϭϴϯϬϰ ϰϴϬϬϲ ϮϳϬϵϵ 
ϭϬ ϭϬA ϰϵϰϬ ϱϲϬϰ ϰϯϯϮ ϭϲϲϰϳ ϮϳϳϲϮ ϯϬϭϭϮ 
ϭϭ ϭϭA ϰϭϭϲ ϰϭϲϱ ϰϭϮϬ ϭϯϴϲϭ ϭϰϵϯϵ ϭϱϯϰϭ 
ϭϮ ϭϮA ϭϬϬϲϭ ϳϰϱϴ ϱϯϱϭ ϰϬϲϯϰ ϯϬϭϮϬ ϮϵϬϯϴ 
ϭϯ ϭB ϱϭϭϮ ϱϮϱϮ ϰϮϳϰ ϭϮϰϴϬ ϭϲϯϭϰ ϭϲϱϭϲ 
ϭϰ ϮB ϱϯϮϭ ϰϭϱϭ ϱϬϱϳ ϭϭϲϮϰ ϭϳϮϬϰ ϭϵϬϮϲ 
ϭϱ ϯB ϱϴϲϵ ϰϰϯϵ ϰϳϵϮ ϭϳϮϴϯ ϭϵϰϮϯ Ϯϲϯϴϯ 
ϭϲ ϰB ϰϴϱϵ ϲϰϴϱ ϰϲϱϮ ϲϵϵϭϵ ϴϬϰϱϬ ϰϬϳϴϯ 
ϭϳ ϱB ϱϲϰϯ ϭϯϲϴϵ ϰϳϲϴ ϭϲϲϳϮ ϭϯϰϯϲϭ ϱϲϴϱϯ 
ϭϴ ϲB ϰϳϬϭ ϰϯϰϴ ϰϯϮϰ ϭϬϰϮϲ ϭϯϬϵϵ ϭϰϬϬϭ 
ϭϵ ϳB ϱϬϴϴ ϰϭϱϱ ϰϵϯϴ ϱϵϭϱ ϭϲϯϬϳ ϭϯϴϮϱ 
ϮϬ ϴB ϰϳϭϯ ϰϱϵϱ ϰϱϵϳ ϭϯϲϱϳ ϮϬϮϰϱ ϭϴϱϬϭ 
Ϯϭ ϵB ϰϱϴϬ ϰϰϲϲ ϰϰϰϰ ϭϭϰϲϯ ϭϰϲϴϭ ϭϳϭϮϱ 
ϮϮ ϭϬB ϰϳϴϬ ϰϳϬϰ ϰϰϵϮ ϭϯϬϵϭ ϭϴϲϭϰ ϭϲϴϴϰ 
Ϯϯ ϭϭB ϰϳϵϮ ϰϯϱϭ ϰϰϵϲ ϭϮϲϱϱ ϭϯϳϮϳ ϭϰϬϲϬ 
Ϯϰ ϭϮB ϱϬϭϵ ϱϰϱϭ ϰϮϭϵ ϭϮϰϰϬ ϭϵϮϯϱ ϯϮϯϲϲ 
Ϯϱ ϭC ϱϵϳϳ ϱϬϭϯ ϰϵϱϵ ϭϬϮϮϵ ϭϮϯϰϯ ϴϵϬϬ 
Ϯϲ ϮC ϰϳϴϮ ϱϬϲϮ ϰϮϮϴ ϭϯϳϴϲ ϭϱϱϴϮ ϭϱϵϵϮ 
Ϯϳ ϯC ϱϱϰϭ ϰϳϮϬ ϱϯϮϵ ϭϱϴϵϬ ϭϲϮϲϯ ϭϱϬϱϵ 
AppeŶdiǆ ϴ  -   SĐƌeeŶiŶg Data as ploted iŶ Figuƌe ϯ-ϵ 
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| ϭϯϵ 
 Suďstƌate → Ϯa ϮĐ Ϯd ϯa ϯĐ ϯd 
EŶtƌǇ Well       
Ϯϴ ϰC ϱϯϬϳ ϲϬϰϱ ϰϲϯϯ ϵϴϰϱ ϭϲϬϯϭ ϭϬϵϳϲ 
Ϯϵ ϱC ϰϱϳϬ ϰϲϰϲ ϰϴϱϵ ϭϮϴϯϴ ϭϲϬϯϲ ϭϯϱϲϵ 
ϯϬ ϲC ϰϳϬϭ ϰϴϵϴ ϰϱϵϲ ϭϮϴϳϬ ϭϵϰϳϵ ϮϬϯϰϯ 
ϯϭ ϳC ϰϰϱϭ ϰϮϲϰ ϰϮϲϳ ϭϰϵϮϲ ϭϱϲϱϰ ϭϰϱϴϱ 
ϯϮ ϴC ϰϴϯϲ ϰϱϯϲ ϰϱϲϬ ϴϱϵϮ ϮϮϲϬϰ ϭϳϵϯϭ 
ϯϯ ϵC ϰϵϴϳ ϱϰϮϬ ϰϵϲϴ ϮϮϴϬϬ ϮϬϮϴϳ Ϯϲϯϭϯ 
ϯϰ ϭϬC ϰϵϱϳ ϰϮϴϮ ϰϱϵϳ Ϯϯϭϯϱ ϯϱϳϭϮ ϱϰϵϰϳ 
ϯϱ ϭϭC ϰϴϱϯ ϲϬϮϰ ϰϲϮϬ ϭϮϭϲϵ ϲϯϰϵϬ ϮϮϳϭϯ 
ϯϲ ϭϮC ϰϮϲϵ ϰϮϱϴ ϰϮϴϮ ϭϮϲϳϵ ϭϲϰϯϱ ϭϮϱϯϯ 
ϯϳ ϭD ϰϯϰϯ ϰϯϳϳ ϰϰϮϱ ϭϭϴϳϵ ϭϮϬϲϲ ϵϳϴϴ 
ϯϴ ϮD ϰϲϯϰ ϰϯϭϱ ϰϯϴϲ ϭϵϳϴϭ ϮϴϯϭϬ Ϯϵϳϯϭ 
ϯϵ ϯD ϰϲϵϵ ϰϮϲϯ ϰϱϵϮ ϭϰϵϯϰ ϭϱϵϵϰ ϭϱϭϵϵ 
ϰϬ ϰD ϰϯϭϱ ϰϰϰϰ ϰϰϯϯ ϭϰϰϵϬ ϭϱϯϲϲ ϭϲϭϯϱ 
ϰϭ ϱD ϰϱϲϬ ϰϲϬϬ ϰϱϮϵ ϭϯϰϮϲ ϭϲϭϳϴ ϭϰϲϮϳ 
ϰϮ ϲD ϱϯϰϮ ϰϲϳϬ ϰϱϬϳ ϭϯϱϵϳ ϮϬϰϴϯ ϭϵϮϯϱ 
ϰϯ ϳD ϰϯϱϭ ϰϯϳϱ ϰϭϳϮ ϭϯϬϴϰ ϭϰϵϯϴ ϭϯϮϯϱ 
ϰϰ ϴD ϰϲϴϮ ϰϰϲϳ ϰϱϯϮ ϭϬϵϲϲ ϭϲϰϱϯ ϭϱϳϴϭ 
ϰϱ ϵD ϰϰϴϱ ϰϱϵϬ ϰϰϲϱ ϭϰϮϲϯ ϭϲϲϰϳ ϭϯϴϯϵ 
ϰϲ ϭϬD ϱϬϵϵ ϰϭϵϰ ϰϲϯϰ ϭϮϬϯϴ ϭϳϮϱϮ Ϯϲϳϵϳ 
ϰϳ ϭϭD ϰϱϭϲ ϰϮϵϳ ϰϯϲϳ ϭϭϵϳϬ ϭϰϯϱϳ ϭϮϱϲϰ 
ϰϴ ϭϮD ϰϳϵϬ ϰϯϱϯ ϰϰϵϭ ϭϬϲϬϲ ϭϯϬϳϬ ϭϰϲϬϵ 
ϰϵ ϭE ϰϱϰϳ ϰϵϲϵ ϰϰϮϮ ϭϬϰϲϲ ϭϴϲϬϮ ϭϮϴϵϲ 
ϱϬ ϮE ϰϱϳϵ ϰϮϱϬ ϰϰϵϯ ϭϭϭϱϰ ϭϬϮϰϴ ϭϱϰϭϬ 
ϱϭ ϯE ϰϱϰϱ ϰϭϳϲ ϰϯϬϴ ϭϯϳϳϲ ϭϯϲϭϬ ϭϯϬϯϳ 
ϱϮ ϰE ϰϲϵϱ ϰϰϯϴ ϰϲϬϭ ϭϴϮϳϵ ϭϳϯϰϭ ϯϰϭϱϲ 
ϱϯ ϱE ϰϱϲϱ ϰϯϲϯ ϰϱϴϱ ϭϵϯϰϴ ϯϲϬϲϰ ϰϳϱϱϮ 
ϱϰ ϲE ϰϵϲϵ ϰϭϱϮ ϰϯϯϲ ϮϱϬϬϳ ϮϮϵϰϮ Ϯϰϴϴϵ 
ϱϱ ϳE ϰϲϭϴ ϰϲϴϬ ϰϵϭϯ Ϯϴϳϴϲ ϯϴϴϲϵ ϵϳϰϬϱ 
ϱϲ ϴE ϰϵϴϰ ϰϱϰϭ ϰϱϵϯ ϭϴϴϭϲ ϰϳϳϱϰ ϰϯϯϱϳ 
ϱϳ ϵE ϰϲϯϮ ϰϮϵϮ ϰϱϯϲ ϭϲϰϭϵ ϭϲϬϬϴ ϮϰϮϵϯ 
ϱϴ ϭϬE ϰϳϭϴ ϰϮϴϮ ϰϱϴϲ ϭϬϯϴϵ ϮϮϯϱϵ ϱϭϴϮϬ 
ϱϵ ϭϭE ϰϳϭϳ ϰϰϰϵ ϰϯϲϮ ϭϱϭϳϵ Ϯϯϲϱϭ Ϯϯϴϵϴ 
ϲϬ ϭϮE ϰϴϮϳ ϰϮϴϲ ϰϵϵϳ Ϯϳϴϳϯ ϱϵϯϰϮ ϮϱϬϭϱ 
ϲϭ ϭF ϰϳϱϴ ϰϬϱϰ ϰϯϵϭ ϭϬϬϳϭ ϵϱϲϳ ϲϱϬϭ 
ϲϮ ϮF ϰϯϮϴ ϰϯϴϰ ϰϰϮϯ ϭϱϬϰϵ Ϯϳϱϴϭ ϮϮϭϴϴ 
ϲϯ ϯF ϱϱϬϯ ϰϮϬϳ ϱϳϮϴ ϭϱϬϵϲ ϮϮϴϬϰ ϭϵϱϭϴ 
ϲϰ ϰF ϰϯϴϵ ϰϯϰϵ ϰϮϱϵ ϭϰϬϭϰ ϭϮϳϰϴ ϭϮϱϳϲ 
ϲϱ ϱF ϰϱϴϬ ϰϯϮϭ ϰϰϳϯ ϭϭϵϳϱ ϭϱϯϵϳ ϭϮϭϵϭ 
ϲϲ ϲF ϰϯϵϲ ϰϯϲϯ ϰϰϮϳ ϭϯϱϮϯ ϭϴϱϲϲ ϭϳϰϰϱ 
ϲϳ ϳF ϰϱϰϱ ϰϭϱϭ ϰϭϳϯ ϭϬϲϴϳ ϯϬϭϭϲ ϭϮϵϯϯ 
ϲϴ ϴF ϱϬϵϭ ϰϯϱϯ ϰϳϬϳ ϵϳϱϱ ϭϳϯϲϲ Ϯϭϰϳϴ 
ϲϵ ϵF ϰϲϮϲ ϱϭϱϵ ϰϯϳϬ ϭϬϲϳϳ ϲϯϮϮϯ ϭϯϵϮϰ 
ϳϬ ϭϬF ϰϲϰϯ ϰϮϲϮ ϰϯϳϬ ϭϲϵϱϳ ϱϬϴϱϳ ϮϵϬϬϳ 
ϳϭ ϭϭF ϰϱϱϵ ϰϮϭϳ ϰϴϰϴ ϴϲϱϴ ϭϭϯϵϭ ϭϮϬϱϳ 
ϳϮ ϭϮF ϰϰϵϯ ϰϰϯϮ ϰϮϴϱ ϭϮϭϴϯ ϭϱϵϲϵ ϭϯϰϭϳ 
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ϳϯ ϭG ϰϴϮϳ ϰϭϴϯ ϰϮϳϰ ϲϮϮϮ ϴϳϴϴ ϲϱϭϭ 
ϳϰ ϮG ϰϳϲϮ ϱϭϭϭ ϰϳϰϴ ϴϱϵϰ ϯϭϱϰϲ ϭϯϲϮϮ 
ϳϱ ϯG ϰϲϱϰ ϰϬϮϬ ϰϮϴϳ ϭϮϮϱϵ ϭϭϮϴϮ ϭϮϬϵϵ 
ϳϲ ϰG ϰϴϰϬ ϰϭϲϰ ϰϳϵϲ ϳϵϲϮ ϳϵϱϯ ϴϯϴϱ 
ϳϳ ϱG ϰϴϭϭ ϰϬϰϱ ϰϯϮϯ ϭϯϰϲϳ ϭϴϲϱϯ ϭϮϳϮϵ 
ϳϴ ϲG ϱϮϵϬ ϰϯϰϱ ϰϱϬϮ ϭϰϲϲϰ ϰϰϯϱϭ ϮϯϴϴϮ 
ϳϵ ϳG ϰϲϰϮ ϰϬϵϯ ϰϲϯϲ ϭϬϴϯϮ ϭϮϰϱϵ ϭϭϯϮϮ 
ϴϬ ϴG ϰϲϮϲ ϰϭϮϲ ϰϰϬϱ ϭϬϭϬϲ ϭϯϱϭϵ ϭϰϯϭϳ 
ϴϭ ϵG ϰϮϭϱ ϰϬϴϵ ϰϯϱϰ ϭϭϴϴϲ ϭϲϰϰϮ ϭϭϴϵϯ 
ϴϮ ϭϬG ϰϰϲϰ ϰϰϯϴ ϰϬϴϲ ϭϬϭϰϮ ϭϮϳϱϮ ϭϰϲϴϱ 
ϴϯ ϭϭG ϰϲϵϲ ϰϭϲϳ ϰϯϭϮ ϭϮϮϱϵ ϭϯϰϴϳ ϭϰϵϭϲ 
ϴϰ ϭϮG ϰϰϭϴ ϰϭϱϰ ϰϭϳϮ ϭϯϳϰϭ ϮϳϬϵϰ ϭϱϰϰϭ 
ϴϱ ϭH ϰϰϯϲ ϰϭϭϴ ϰϭϳϮ ϴϭϱϬ ϳϱϱϮ ϳϳϴϳ 
ϴϲ ϮH ϰϭϭϯ ϰϮϭϵ ϰϯϬϯ ϳϭϬϳ ϭϴϲϭϮ ϯϬϵϳϯ 
ϴϳ ϯH ϰϰϴϰ ϯϵϴϬ ϰϮϳϮ ϭϭϱϭϮ ϴϯϵϴ ϳϳϰϳ 
ϴϴ ϰH ϰϰϭϮ ϰϯϳϵ ϰϯϳϭ ϯϭϳϰϬ ϲϭϴϵϳ ϯϬϰϳϰ 
ϴϵ ϱH ϰϰϱϭ ϰϱϮϵ ϰϮϲϭ ϭϱϲϱϳ ϱϬϳϯϴ ϱϵϮϱϭ 
ϵϬ ϲH ϰϯϴϬ ϰϭϰϱ ϰϭϳϬ ϭϲϮϳϬ ϭϳϴϬϰ ϭϰϮϱϭ 
ϵϭ ϳH ϰϬϴϮ ϰϳϳϱ ϰϯϰϲ ϭϲϱϰϱ ϳϭϰϳϭ ϭϱϲϳϲ 
ϵϮ ϴH ϰϱϲϴ ϰϮϭϵ ϰϮϰϬ ϵϳϰϳ Ϯϯϱϴϰ ϰϱϱϵϵ 
ϵϯ ϵH ϰϰϲϭ ϰϮϯϰ ϰϮϰϴ ϯϬϲϮϱ ϱϯϵϬϳ ϯϰϯϭϬ 
ϵϰ ϭϬH ϰϰϭϵ ϰϮϮϬ ϰϮϭϳ ϭϬϳϬϴ ϰϴϮϰϮ ϭϲϰϯϮ 
ϵϱ ϭϭH ϰϮϬϯ ϯϵϰϬ ϰϬϭϭ ϭϭϮϵϭ ϯϱϬϱϰ ϭϲϳϱϯ 
ϵϲ ϭϮH ϰϰϭϳ ϰϯϵϵ ϰϮϬϱ ϭϬϵϮϰ ϲϰϵϵϳ ϭϱϵϬϬ 
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| ϭϰϭ 
AppeŶdiǆ ϵ. EŶzǇŵaiĐ AĐiǀitǇ Data as ploted iŶ Figuƌe ϯ-ϭϱ 
Taďle ϳ-ϱ.  EŶzǇŵaiĐ aĐiǀitǇ as oďtaiŶed fƌoŵ puƌiied eŶzǇŵes at a ĐoŶĐeŶtƌaioŶ of Ϭ.ϭ µM. 
Suďstƌate →  TFFIS  WMV  MϬϭ  ǁt 
MutaŶt ↓   oƌg. 
Data Ŷoƌŵ. 
 oƌg. 
Data Ŷoƌŵ. 
 oƌg. 
Data Ŷoƌŵ. 
 oƌg. 
Data Ŷoƌŵ. 
ϭa   ϲϵϵϭ ϭϬϬ%  ϯϳϯ ϱ%  ϭϱϯ Ϯ%  ϭϯϱ Ϯ% 
ϭd   ϭϰϳϴ Ϯϭ%  ϲϮϮ ϵ%  ϱϲϬ ϴ%  ϰϳϰ ϳ% 
Ϯa   Ϯϰϵϲ ϮϬ%  ϭϮϮϴϭ ϭϬϬ%  ϰϱϴϭ ϯϳ%  ϭϭϯϮ ϵ% 
ϮĐ   ϳϬϵ ϲ%  ϴϮϭϬ ϲϳ%  ϯϮϲϰ Ϯϳ%  ϲϳϱ ϱ% 
ϯĐ   ϮϰϮϲ ϭ%  ϭϰϮϲϲϱ ϱϱ%  ϭϯϮϯϬ ϱ%  ϴϰϲϯ ϯ% 
ϯd   ϱϰϮϯ Ϯ%  ϮϲϬϵϬϰ ϭϬϬ%  ϭϲϰϰϳ ϲ%  ϰϯϱϱ Ϯ% 
 FluoƌesĐeŶĐe aĐiǀitǇ ǁas ŵeasuƌed, ďufeƌ sigŶal suďtƌaĐted ;soŵeiŵes leadiŶg to Ŷegaiǀe sigŶalsͿ aŶd 
theŶ Ŷoƌŵalized to the highest oďseƌǀed sigŶal ŵeasuƌed iŶ this eǆpeƌiŵeŶt foƌ the ĐoƌƌespoŶdiŶg paƌeŶt 
ĐoŵpouŶd ;highlightedͿ. 
 
AppeŶdiǆ ϭϬ. Liǀe Cell AĐiǀitǇ Data as ploted iŶ Figuƌe ϯ-ϯϭ 
Taďle ϳ-ϲ.  FluoƌesĐeŶĐe sigŶals ŵeasuƌed iŶ supeƌŶataŶt aŶd lǇsates oďtaiŶed ateƌ ƌeaĐioŶs iŶ liǀiŶg 
E. Đoli. 
Suďstƌate →  ϭa  Ϯa  ϯd  ϯĐ 
MutaŶt ↓   oƌg. 
Data Ŷoƌŵ. 
 oƌg. 
Data Ŷoƌŵ. 
 oƌg. 
Data Ŷoƌŵ. 
 oƌg. 
Data Ŷoƌŵ. 
WT Sup  ϭϴ ϳ%  ϭϯϰ ϴ%  ϲϱϬϮ ϴ%  ϭϵϯϲ Ϯ% LǇs  -ϲ -Ϯ%  -ϭϯ -ϭ%  -ϴϲϰ -ϭ%  -ϯϵϱϭ -ϱ% 
TFFIS Sup  ϱϭ ϭϵ%  ϱϳ ϰ%  ϳϴϳϳ ϭϬ%  ϭϭϴϲ ϭ% LǇs  ϮϲϮ ϭϬϬ%  Ϭ Ϭ%  -ϭϭϲϰ -ϭ%  -ϰϵϭϯ -ϲ% 
WMV Sup  ϰϴ ϭϴ%  ϳϲϮ ϰϳ%  ϴϭϵϰϯ ϭϬϬ%  ϲϯϮϳ ϴ% LǇs  -ϭϮ -ϱ%  Ϯϯϱ ϭϰ%  ϮϳϮϰϰ ϯϯ%  -Ϯϰϰϱ -ϯ% 
MϬϭ Sup  ϯϰ ϭϯ%  ϭϲϮϳ ϭϬϬ%  ϭϮϮϭϰ ϭϱ%  Ϯϲϱϭ ϯ% LǇs  -ϲ -Ϯ%  ϯϰϳ Ϯϭ%  ϲϲϵϲ ϴ%  -ϮϳϬ Ϭ% 
LV Sup  ϭϳ ϳ%  -ϭϭϱ -ϳ%  Ϯϯϳϱϯ Ϯϵ%  ϱϯϱϭ ϳ% LǇs  -ϲ -Ϯ%  ϱϯ ϯ%  ϯϰϳϭϲ ϰϮ%  ϭϬϭϮϭ ϭϮ% 
FluoƌesĐeŶĐe aĐiǀitǇ ǁas ŵeasuƌed, ďufeƌ sigŶal suďtƌaĐted ;soŵeiŵes leadiŶg to Ŷegaiǀe sigŶalsͿ aŶd theŶ 
Ŷoƌŵalized to the highest oďseƌǀed sigŶal ŵeasuƌed iŶ this eǆpeƌiŵeŶt foƌ the ĐoƌƌespoŶdiŶg paƌeŶt 
ĐoŵpouŶd ;highlightedͿ. 
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ϭϰϮ | 
AppeŶdiǆ ϭϭ. Details foƌ SABRINA’s ColleĐioŶ 
Taďle ϳ-ϳ.  List of PϰϱϬBMϯ ŵutaŶts iŶ SABRINA’s ĐolleĐioŶ.[ϭϲϭ,ϭϲϮ,Ϯϰϴ] All PϰϱϬ ǀaƌiaŶts fƌoŵ the 
sǇŶtheized geŶe liďƌaƌies ;)FE aŶd KSA-ϮϵϳͿ ĐoŶtaiŶ sileŶt ŵutaioŶs at Lϱϳ ;CTA → TTAͿ 
aŶd AϮϮϱ ;GCA → GCTͿ. 
Plate/posiioŶ ID Ŷuŵďeƌ  of ŵutaŶt ŵutaioŶs 
KSA-Ϭϭ-Ϭϭ BMϯ ǁt BMϯ 
KSA-Ϭϭ-Ϭϰ FϴϳA FϴϳA 
KSA-Ϭϭ-Ϭϳ KSA-KB-ϭϬϮ-ϬϮ-ϴϮ FϴϳV 
KSA-Ϭϭ-ϭϬ KSA-KB-ϭϬϮ-ϬϮ-ϭϭ FϴϳT 
KSA-Ϭϭ-ϭϯ KSA-KD-ϯϰϳ-Ϭϭ-ϰϱ FϴϳA-SϳϮA 
KSA-Ϭϭ-ϭϲ KSA-KD-ϯϯϳ-Ϭϭ-ϴϱ FϴϳA-AϯϯϬL 
KSA-Ϭϭ-ϭϵ KSA-KD-ϯϯϳ-Ϭϭ-Ϯϴ FϴϳA-AϯϯϬV 
KSA-Ϭϭ-ϮϮ KSA-KD-ϯϯϳ-Ϭϭ-ϳϯ FϴϳA-AϯϯϬW 
KSA-Ϭϭ-Ϯϱ KSA-KB-ϭϯϭ-ϭϭ-ϬϮ RϰϳV-TϰϵY-YϱϭF-FϴϳA 
KSA-Ϭϭ-Ϯϴ KSA-KB-ϭϯϭ-ϭϮ-ϱϴ RϰϳF-TϰϵV-FϴϳA 
KSA-Ϭϭ-ϯϭ KSA-KB-ϭϯϭ-ϮϬ-ϵϲ RϰϳC-TϰϵF-YϱϭC-FϴϳA 
KSA-Ϭϭ-ϯϰ KSA-KB-ϭϯϭ-Ϯϭ-ϳϵ RϰϳY-TϰϵY-FϴϳA 
KSA-Ϭϭ-ϯϳ KSA-KB-ϭϯϭ-Ϯϱ-Ϭϱ RϰϳY-TϰϵN-FϴϳA 
KSA-Ϭϭ-ϰϬ KSA-KB-ϭϯϭ-Ϯϵ-ϯϮ RϰϳF-TϰϵF-FϴϳA 
KSA-Ϭϭ-ϰϯ KSA-KB-ϭϯϭ-ϯϮ-Ϯϲ RϰϳY-TϰϵF-FϴϳA-KϮϮϰE-IϯϭϰV 
KSA-Ϭϭ-ϰϲ KSA-KB-ϭϯϭ-ϯϴ-ϰϮ RϰϳF-TϰϵI-FϴϳA 
KSA-Ϭϭ-ϰϵ KSA-KB-ϭϯϭ-ϬϮ-ϵϲ RϰϳI-TϰϵI-YϱϭI-FϴϳA 
KSA-Ϭϭ-ϱϮ KSA-KB-ϭϯϭ-ϰϯ-ϲϬ RϰϳN-TϰϵI-FϴϳA 
KSA-Ϭϭ-ϱϱ KSA-KB-ϭϯϭ-ϰϰ-ϰϳ RϰϳN-TϰϵC-YϱϭF-FϴϳA 
KSA-Ϭϭ-ϱϴ KSA-KB-ϭϯϭ-ϰϰ-ϱϭ RϰϳF-TϰϵF-YϱϭF-FϴϳA 
KSA-Ϭϭ-ϲϭ Miǆ of ŵutaŶts 
KSA-Ϭϭ-ϲϰ KSA-KB-ϭϯϭ-ϰϵ-ϲϳ RϰϳC-TϰϵC-FϴϳA 
KSA-Ϭϭ-ϲϳ Miǆ of ŵutaŶts 
 KSA-Ϭϭ-ϳϬ KSA-KB-ϭϯϭ-ϱϬ-ϯϱ RϰϳY-TϰϵI-YϱϭN-FϴϳA 
KSA-Ϭϭ-ϳϯ KSA-KB-ϭϯϭ-ϱϮ-ϯϰ RϰϳF-TϰϵS-FϴϳA 
KSA-Ϭϭ-ϳϲ KSA-KB-ϭϯϭ-ϱϯ-ϰϬ RϰϳF-TϰϵN-YϱϭF-FϴϳA 
KSA-Ϭϭ-ϳϵ KSA-KB-ϭϯϭ-ϱϯ-ϳϳ RϰϳC-TϰϵF-FϴϳA 
KSA-Ϭϭ-ϴϮ KSA-KB-ϭϯϭ-ϱϰ-Ϭϳ RϰϳF-TϰϵY-FϴϳA 
KSA-Ϭϭ-ϴϱ KSA-KB-ϭϯϭ-ϱϰ-ϭϱ RϰϳY-TϰϵF-YϱϭF-FϴϳA 
KSA-Ϭϭ-ϴϴ KSA-KB-ϭϯϭ-ϱϰ-ϳϯ RϰϳI-TϰϵF-FϴϳA 
KSA-Ϭϭ-ϵϭ )FE-)C-ϬϮϬ-Ϭϯ-ϳϮ RϰϳI-TϰϵT-FϴϳA 
KSA-Ϭϭ-ϵϰ )FE-)C-ϬϮϬ-Ϭϱ-ϱϱ RϰϳN-TϰϵY-FϴϳA 
   
 
 
 
 
 
 
AppeŶdiǆ ϭϭ  -   Details foƌ SaďƌiŶa’s ColleĐioŶ 
_________________________________________________ 
 
 
 
| ϭϰϯ 
   
Plate/posiioŶ ID Ŷuŵďeƌ  of ŵutaŶt ŵutaioŶs 
KSA-ϬϮ-Ϭϭ FϴϳA FϴϳA 
KSA-ϬϮ-Ϭϰ )FE-)C-ϬϮϬ-Ϭϲ-ϰϬ RϰϳC-TϰϵD-FϴϳA 
KSA-ϬϮ-Ϭϳ )FE-)C-ϬϮϬ-ϭϬ-ϵϱ RϰϳC-TϰϵY-FϴϳA 
KSA-ϬϮ-ϭϬ )FE-)C-ϬϮϬ-ϭϰ-ϵϲ TϰϵV-FϴϳA 
KSA-ϬϮ-ϭϯ )FE-)C-ϬϮϬ-ϭϳ-ϱϭ RϰϳY-TϰϵI-FϴϳA 
KSA-ϬϮ-ϭϲ )FE-)C-ϬϮϬ-Ϯϵ-ϴϯ RϰϳF-TϰϵH-FϴϳA 
KSA-ϬϮ-ϭϵ )FE-)C-ϬϮϬ-ϰϭ-ϵϬ RϰϳY-TϰϵL-FϴϳA 
KSA-ϬϮ-ϮϮ KSA-KB-ϭϯϭ-ϰϮ-ϭϮ RϰϳC-TϰϵL-FϴϳA 
KSA-ϬϮ-Ϯϱ KSA-KB-ϭϯϭ-Ϭϳ-Ϯϴ RϰϳV-TϰϵF-YϱϭN-FϴϳA 
KSA-ϬϮ-Ϯϴ KSA-KB-ϭϯϭ-ϭϲ-ϱϯ RϰϳV-TϰϵI-YϱϭN-FϴϳA 
KSA-ϬϮ-ϯϭ KSA-KB-ϭϯϭ-ϰϯ-ϴϳ RϰϳC-TϰϵC-YϱϭG-FϴϳA 
KSA-ϬϮ-ϯϰ KSA-KB-ϭϯϭ-ϰϯ-ϵϰ RϰϳC-TϰϵI-YϱϭV-FϴϳA 
KSA-ϬϮ-ϯϳ KSA-KB-ϭϯϭ-ϰϱ-ϵϭ RϰϳI-TϰϵV-YϱϭI-FϴϳA 
KSA-ϬϮ-ϰϬ KSA-KB-ϭϯϭ-ϰϲ-ϲϱ RϰϳI-TϰϵL-YϱϭN-FϴϳA 
KSA-ϬϮ-ϰϯ KSA-KB-ϭϯϭ-ϰϴ-ϳϲ RϰϳI-TϰϵI-YϱϭN-FϴϳA 
KSA-ϬϮ-ϰϲ KSA-KB-ϭϯϭ-ϰϵ-ϴϳ RϰϳI-TϰϵI-YϱϭV-FϴϳA 
KSA-ϬϮ-ϰϵ KSA-KB-ϭϯϭ-ϱϬ-ϰϵ RϰϳI-TϰϵC-YϱϭV-FϴϳA 
KSA-ϬϮ-ϱϮ )FE-)C-ϬϮϬ-ϬϮ-ϱϱ RϰϳN-TϰϵI-YϱϭV-FϴϳA 
KSA-ϬϮ-ϱϱ )FE-)C-ϬϮϬ-ϬϮ-ϳϮ RϰϳV-TϰϵL-YϱϭN-FϴϳA 
KSA-ϬϮ-ϱϴ )FE-)C-ϬϮϬ-Ϭϰ-ϳϯ TϰϵV-YϱϭI-FϴϳA 
KSA-ϬϮ-ϲϭ )FE-)C-ϬϮϬ-Ϭϱ-ϰϯ TϰϵI-YϱϭI-FϴϳA 
KSA-ϬϮ-ϲϰ )FE-)C-ϬϮϬ-Ϭϲ-ϰϴ RϰϳN-TϰϵL-YϱϭL-FϴϳA 
KSA-ϬϮ-ϲϳ )FE-)C-ϬϮϬ-Ϭϲ-ϱϵ RϰϳC-TϰϵL-YϱϭI-FϴϳA 
KSA-ϬϮ-ϳϬ )FE-)C-ϬϮϬ-Ϭϲ-ϵϲ RϰϳV-TϰϵC-YϱϭI-FϴϳA 
KSA-ϬϮ-ϳϯ )FE-)C-ϬϮϬ-ϭϬ-Ϯϲ RϰϳS-TϰϵI-YϱϭI-FϴϳA 
KSA-ϬϮ-ϳϲ )FE-)C-ϬϮϬ-ϭϳ-ϲϬ RϰϳV-TϰϵI-YϱϭI-FϴϳA 
KSA-ϬϮ-ϳϵ )FE-)C-ϬϮϬ-Ϯϯ-ϳϯ TϰϵL-YϱϭI-FϴϳA 
KSA-ϬϮ-ϴϮ )FE-)C-ϬϮϬ-Ϯϱ-Ϭϲ RϰϳN-TϰϵL-YϱϭI-FϴϳA 
KSA-ϬϮ-ϴϱ )FE-)C-ϬϮϬ-Ϯϵ-ϳϮ RϰϳN-TϰϵI-YϱϭI-FϴϳA 
KSA-ϬϮ-ϴϴ KSA-KC-Ϯϵϳ-ϭϬ-ϳϯ VϳϴY-AϴϮE-FϴϳA 
KSA-ϬϮ-ϵϭ KSA-KC-Ϯϳϳ-Ϭϵ-ϯϴ VϳϴI-AϴϮD-FϴϳA 
KSA-ϬϮ-ϵϰ KSA-KC-Ϯϵϳ-Ϭϭ-ϰϬ VϳϴL-AϴϮD-FϴϳA 
   
   
   
 
 
 
  
   
   
   
   
   
   
   
AppeŶdiǆ ϭϭ  -   Details foƌ SaďƌiŶa’s ColleĐioŶ 
_________________________________________________ 
 
 
 
ϭϰϰ | 
   
Plate/posiioŶ ID Ŷuŵďeƌ  of ŵutaŶt ŵutaioŶs 
KSA-Ϭϯ-Ϭϭ FϴϳA FϴϳA 
KSA-Ϭϯ-Ϭϰ KSA-KC-Ϯϵϳ-ϬϮ-ϰϴ VϳϴV-AϴϮD-FϴϳA 
KSA-Ϭϯ-Ϭϳ KSA-KC-Ϯϳϳ-ϭϬ-Ϯϱ VϳϴM-AϴϮD-FϴϳA 
KSA-Ϭϯ-ϭϬ Miǆ of ŵutaŶts 
 KSA-Ϭϯ-ϭϯ KSA-KC-Ϯϵϳ-Ϭϵ-ϳϴ VϳϴM-AϴϮE-FϴϳA 
KSA-Ϭϯ-ϭϲ KSA-KC-Ϯϵϳ-Ϭϳ-ϴϭ VϳϴV-AϴϮQ-FϴϳA 
KSA-Ϭϯ-ϭϵ KSA-KC-Ϯϳϳ-Ϭϯ-ϵϰ VϳϴI-AϴϮE-FϴϳA 
KSA-Ϭϯ-ϮϮ KSA-KC-Ϯϳϳ-Ϭϳ-ϴϮ VϳϴV-AϴϮN-FϴϳA 
KSA-Ϭϯ-Ϯϱ KSA-KC-Ϯϵϳ-ϭϬ-ϱϯ VϳϴI-AϴϮQ-FϴϳA 
KSA-Ϭϯ-Ϯϴ KSA-KC-Ϯϵϳ-Ϭϱ-ϴϭ VϳϴC-AϴϮN-FϴϳA 
KSA-Ϭϯ-ϯϭ KSA-KC-Ϯϵϳ-ϭϬ-ϱϮ VϳϴV-AϴϮS-FϴϳA 
KSA-Ϭϯ-ϯϰ KSA-KC-Ϯϳϳ-Ϯϯ-ϯϮ VϳϴL-AϴϮE-FϴϳA 
KSA-Ϭϯ-ϯϳ KSA-KC-Ϯϵϳ-Ϭϯ-ϭϳ VϳϴI-AϴϮS-FϴϳA 
KSA-Ϭϯ-ϰϬ KSA-KC-Ϯϳϳ-Ϯϯ-ϵϰ VϳϴM-AϴϮN-FϴϳA 
KSA-Ϭϯ-ϰϯ KSA-KC-Ϯϳϳ-ϮϬ-ϵϬ VϳϴC-AϴϮG-FϴϳA 
KSA-Ϭϯ-ϰϲ KSA-KC-Ϯϳϳ-Ϭϱ-ϯϴ VϳϴA-AϴϮA-FϴϳA 
KSA-Ϭϯ-ϰϵ KSA-KC-Ϯϵϳ-ϭϭ-ϯϰ VϳϴL-AϴϮC-FϴϳA 
KSA-Ϭϯ-ϱϮ KSA-KC-Ϯϵϳ-Ϭϱ-ϴϳ VϳϴC-AϴϮL-FϴϳA 
KSA-Ϭϯ-ϱϱ KSA-KC-Ϯϳϳ-ϭϱ-ϰϵ VϳϴV-AϴϮL-FϴϳA 
KSA-Ϭϯ-ϱϴ KSA-KC-Ϯϳϳ-ϯϬ-ϯϯ VϳϴT-AϴϮL-FϴϳA 
KSA-Ϭϯ-ϲϭ KSA-KC-Ϯϵϳ-ϭϭ-ϳϵ VϳϴM-AϴϮL-FϴϳA 
KSA-Ϭϯ-ϲϰ KSA-KC-Ϯϵϳ-ϬϮ-ϱϳ VϳϴY-AϴϮM-FϴϳA 
KSA-Ϭϯ-ϲϳ KSA-KC-Ϯϳϳ-ϯϬ-ϴϰ VϳϴV-AϴϮM-FϴϳA 
KSA-Ϭϯ-ϳϬ KSA-KC-Ϯϳϳ-Ϭϯ-ϱϳ VϳϴM-AϴϮM-FϴϳA 
KSA-Ϭϯ-ϳϯ KSA-KC-Ϯϵϳ-Ϭϱ-ϭϵ VϳϴL-AϴϮM-FϴϳA 
KSA-Ϭϯ-ϳϲ KSA-KC-Ϯϳϳ-ϯϭ-ϰϳ VϳϴT-AϴϮM-FϴϳA 
KSA-Ϭϯ-ϳϵ KSA-KC-Ϯϵϳ-ϭϭ-ϵϲ VϳϴS-AϴϮM-FϴϳA 
KSA-Ϭϯ-ϴϮ KSA-KC-Ϯϵϳ-ϭϬ-ϰϲ VϳϴL-AϴϮH-FϴϳA 
KSA-Ϭϯ-ϴϱ KSA-KC-Ϯϳϳ-ϬϮ-ϰϰ VϳϴL-AϴϮF-FϴϳA;aͿ 
KSA-Ϭϯ-ϴϴ KSA-KC-Ϯϳϳ-ϮϬ-ϴϲ VϳϴI-AϴϮF-FϴϳA 
KSA-Ϭϯ-ϵϭ KSA-KC-Ϯϵϳ-Ϭϳ-ϭϰ VϳϴM-AϴϮF-FϴϳA 
KSA-Ϭϯ-ϵϰ KSA-KC-Ϯϳϳ-ϭϳ-Ϭϵ VϳϴL-AϴϮF-FϴϳA;aͿ 
;aͿ MutaŶt Ϯϳϳ-ϭϳ-Ϭϵ ;LFͿ ĐoŶtaiŶs iŶ posiioŶ ϳϴ a TTG;LeuͿ, iŶ posiioŶ ϴϮ a TTT ;PheͿ aŶd iŶ posiioŶ ϴϳ a 
GCA ;AlaͿ ĐodoŶ Đoŵpaƌed to ŵutaŶt Ϯϳϳ-ϬϮ-ϰϰ, ǁhiĐh ĐoŶtaiŶs CTG ;LeuͿ, TTC ;PheͿ aŶd GCG ;AlaͿ, 
ƌespeĐiǀelǇ. EŶzǇŵaiĐ aĐiǀitǇ iŶ plate sĐƌeeŶiŶgs is loǁeƌ iŶ the lateƌ Đase. 
   
   
   
   
   
   
   
   
   
   
AppeŶdiǆ ϭϭ  -   Details foƌ SaďƌiŶa’s ColleĐioŶ 
_________________________________________________ 
 
 
 
| ϭϰϱ 
   
Plate/posiioŶ ID Ŷuŵďeƌ  of ŵutaŶt ŵutaioŶs 
KSA-Ϭϰ-Ϭϭ FϴϳA FϴϳA 
KSA-Ϭϰ-Ϭϰ KSA-KC-Ϯϳϳ-Ϭϯ-ϴϬ VϳϴT-AϴϮF-FϴϳA 
KSA-Ϭϰ-Ϭϳ KSA-KC-Ϯϵϳ-ϬϮ-ϱϲ VϳϴT-AϴϮN-FϴϳA 
KSA-Ϭϰ-ϭϬ KSA-KC-Ϯϵϳ-ϭϬ-Ϯϰ VϳϴW-AϴϮV-FϴϳA 
KSA-Ϭϰ-ϭϯ KSA-KC-Ϯϵϳ-Ϭϲ-ϴϳ VϳϴW-AϴϮT-FϴϳA 
KSA-Ϭϰ-ϭϲ KSA-KC-Ϯϳϳ-ϮϬ-ϱϮ VϳϴM-AϴϮW-FϴϳA 
KSA-Ϭϰ-ϭϵ KSA-KC-Ϯϳϳ-ϬϮ-ϵϬ VϳϴT-AϴϮW-FϴϳA 
KSA-Ϭϰ-ϮϮ KSA-KC-Ϯϵϳ-Ϭϴ-ϲϮ VϳϴV-AϴϮW-FϴϳA 
KSA-Ϭϰ-Ϯϱ KSA-KC-Ϯϳϳ-ϭϲ-ϳϵ VϳϴS-AϴϮW-FϴϳA 
KSA-Ϭϰ-Ϯϴ KSA-KC-Ϯϵϳ-ϭϭ-ϭϭ VϳϴL-AϴϮW-FϴϳA 
KSA-Ϭϰ-ϯϭ KSA-KC-Ϯϳϳ-ϭϭ-ϰϬ VϳϴN-AϴϮW-FϴϳA 
KSA-Ϭϰ-ϯϰ KSA-KC-Ϯϳϳ-Ϭϭ-Ϭϴ VϳϴA-AϴϮW-FϴϳA 
KSA-Ϭϰ-ϯϳ KSA-KC-Ϯϳϳ-ϮϬ-ϳϭ VϳϴC-AϴϮW-FϴϳA 
KSA-Ϭϰ-ϰϬ KSA-KB-ϬϴϬ-Ϭϱ-ϴϰ MϭϴϱD-LϭϴϴG-FϴϳA 
KSA-Ϭϰ-ϰϯ KSA-KC-ϮϯϬ-Ϭϴ-ϴϯ MϭϴϱN-LϭϴϴG-FϴϳA 
KSA-Ϭϰ-ϰϲ )FE-)B-Ϭϵϴ-ϮϮ-Ϯ-ϲϯ MϭϴϱG-LϭϴϴG-FϴϳA 
KSA-Ϭϰ-ϰϵ KSA-KB-ϬϴϬ-Ϭϰ-Ϭϱ MϭϴϱR-LϭϴϴG-FϴϳA 
KSA-Ϭϰ-ϱϮ KSA-KB-ϬϴϬ-Ϭϯ-ϭϭ MϭϴϱS-LϭϴϴG-FϴϳA 
KSA-Ϭϰ-ϱϱ KSA-KB-ϬϴϬ-Ϭϱ-ϲϬ MϭϴϱS-LϭϴϴA-FϴϳA 
KSA-Ϭϰ-ϱϴ )FE-)B-Ϭϵϴ-ϯϰ-ϰϱ MϭϴϱS-LϭϴϴS-FϴϳA 
KSA-Ϭϰ-ϲϭ KSA-KB-ϬϴϬ-Ϭϰ-ϯϯ MϭϴϱN-LϭϴϴC-FϴϳA 
KSA-Ϭϰ-ϲϰ KSA-KB-ϬϴϬ-ϭϬ-ϵϰ MϭϴϱD-LϭϴϴC-FϴϳA 
KSA-Ϭϰ-ϲϳ )FE-)B-Ϭϵϴ-Ϯϰ-ϱϴ MϭϴϱR-LϭϴϴC-FϴϳA 
KSA-Ϭϰ-ϳϬ KSA-KB-ϬϴϬ-Ϭϯ-ϭϱ MϭϴϱM-LϭϴϴC-FϴϳA 
KSA-Ϭϰ-ϳϯ )FE-)B-Ϭϵϴ-ϯϰ-ϭϴ MϭϴϱS-LϭϴϴC-FϴϳA 
KSA-Ϭϰ-ϳϲ )FE-)B-Ϭϵϴ-ϮϮ-Ϯ-ϲϬ MϭϴϱG-LϭϴϴC-FϴϳA 
KSA-Ϭϰ-ϳϵ KSA-KB-ϬϴϬ-Ϭϯ-ϱϬ MϭϴϱS-LϭϴϴD-FϴϳA 
KSA-Ϭϰ-ϴϮ KSA-KB-ϬϴϬ-ϭϭ-ϵϲ MϭϴϱG-LϭϴϴT-FϴϳA 
KSA-Ϭϰ-ϴϱ KSA-KC-ϮϯϬ-Ϭϰ-ϴϮ MϭϴϱG-LϭϴϴV-FϴϳA 
KSA-Ϭϰ-ϴϴ KSA-KB-ϬϴϬ-Ϭϰ-ϰϳ MϭϴϱD-LϭϴϴV-FϴϳA 
KSA-Ϭϰ-ϵϭ )FE-)B-Ϭϵϴ-Ϯϯ-ϲϬ MϭϴϱG-LϭϴϴL-FϴϳA 
KSA-Ϭϰ-ϵϰ )FE-)B-Ϭϵϴ-ϯϰ-ϭϱ MϭϴϱG-LϭϴϴI-FϴϳA 
   
   
   
   
   
   
   
   
   
   
   
   
   
AppeŶdiǆ ϭϭ  -   Details foƌ SaďƌiŶa’s ColleĐioŶ 
_________________________________________________ 
 
 
 
ϭϰϲ | 
   
Plate/posiioŶ ID Ŷuŵďeƌ  of ŵutaŶt ŵutaioŶs 
KSA-Ϭϱ-Ϭϭ FϴϳA FϴϳA 
KSA-Ϭϱ-Ϭϰ )FE-)B-Ϭϵϴ-Ϯϯ-ϳϳ MϭϴϱR-LϭϴϴS-FϴϳA 
KSA-Ϭϱ-Ϭϳ KSA-KB-ϬϴϬ-Ϭϭ-Ϭϯ MϭϴϱG-LϭϴϴS-FϴϳA 
KSA-Ϭϱ-ϭϬ KSA-KB-ϬϴϬ-ϭϬ-Ϭϯ MϭϴϱR-LϭϴϴN-FϴϳA 
KSA-Ϭϱ-ϭϯ KSA-KB-ϬϴϬ-Ϭϰ-ϰϲ MϭϴϱH-LϭϴϴC-FϴϳA 
KSA-Ϭϱ-ϭϲ KSA-KB-ϬϴϬ-Ϭϱ-ϭϭ MϭϴϱN-LϭϴϴN-FϴϳA 
KSA-Ϭϱ-ϭϵ )FE-)B-Ϭϵϴ-ϯϰ-ϵϰ MϭϴϱS-LϭϴϴF-FϴϳA 
KSA-Ϭϱ-ϮϮ )FE-)B-Ϭϵϴ-ϯϰ-Ϯϰ MϭϴϱG-LϭϴϴT-FϴϳA 
KSA-Ϭϱ-Ϯϱ )FE-)B-Ϭϵϴ-Ϯϲ-Ϯϲ MϭϴϱR-LϭϴϴR-FϴϳA 
KSA-Ϭϱ-Ϯϴ KSA-KC-ϮϯϬ-ϬϮ-ϱϯ MϭϴϱC-LϭϴϴN-FϴϳA 
KSA-Ϭϱ-ϯϭ KSA-KC-ϮϯϬ-Ϭϴ-ϱϵ MϭϴϱN-LϭϴϴH-FϴϳA 
KSA-Ϭϱ-ϯϰ KSA-KB-ϬϴϬ-Ϭϭ-ϱϱ MϭϴϱP-LϭϴϴC-FϴϳA 
KSA-Ϭϱ-ϯϳ KSA-KC-ϮϯϬ-Ϭϳ-ϮϬ MϭϴϱI-LϭϴϴH-FϴϳA 
KSA-Ϭϱ-ϰϬ KSA-KC-ϮϯϬ-Ϭϴ-Ϯϭ MϭϴϱH-LϭϴϴN-FϴϳA 
KSA-Ϭϱ-ϰϯ )FE-)B-Ϭϵϴ-ϯϰ-ϰϴ MϭϴϱP-LϭϴϴH-FϴϳA 
KSA-Ϭϱ-ϰϲ KSA-KC-ϮϯϬ-Ϭϴ-ϵϲ MϭϴϱI-LϭϴϴR-FϴϳA 
KSA-Ϭϱ-ϰϵ KSA-KD-ϯϰϰ-Ϭϭ-ϰϵ RϰϳY-TϰϵF-VϳϴI-AϴϮM-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϱϮ KSA-KD-ϯϰϰ-Ϭϭ-ϳϰ RϰϳY-TϰϵF-VϳϴL-AϴϮM-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϱϱ KSA-KD-ϯϰϱ-Ϭϭ-ϰϯ RϰϳY-TϰϵF-VϳϴA-AϴϮF-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϱϴ KSA-KD-ϯϰϱ-Ϭϭ-Ϯϲ RϰϳY-TϰϵF-VϳϴT-AϴϮF-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϲϭ KSA-KD-ϯϰϱ-Ϭϭ-ϳϱ RϰϳY-TϰϵF-VϳϴW-AϴϮF-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϲϰ KSA-KD-ϯϰϭ-Ϭϭ-ϴϮ RϰϳY-TϰϵF-VϳϴW-AϴϮG-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϲϳ KSA-KD-ϯϰϲ-Ϭϭ-ϮϮ RϰϳY-TϰϵF-VϳϴS-AϴϮW-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϳϬ KSA-KD-ϯϰϲ-Ϭϭ-ϲϰ RϰϳY-TϰϵF-VϳϴM-AϴϮW-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϳϯ KSA-KD-ϯϰϲ-Ϭϭ-ϴϰ RϰϳY-TϰϵF-VϳϴT-AϴϮW-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϳϲ KSA-KD-ϯϰϲ-Ϭϭ-ϯϯ RϰϳY-TϰϵF-VϳϴV-AϴϮW-FϴϳA-KϮϮϰE-VϯϭϰI 
KSA-Ϭϱ-ϳϵ Miǆ of ŵutaŶts 
 KSA-Ϭϱ-ϴϮ KSA-KD-ϯϱϵ-Ϭϭ-ϵϬ VϳϴL-AϴϮF-FϴϳA-HϮϲϲR 
KSA-Ϭϱ-ϴϱ KSA-KD-ϯϱϳ-Ϭϭ-ϲϮ VϳϴL-AϴϮF-FϴϳA-VϭϳϴE 
KSA-Ϭϱ-ϴϴ KSA-KB-ϬϴϬ-Ϭϰ-ϰϳ MϭϴϱD-LϭϴϴV-FϴϳA 
KSA-Ϭϱ-ϵϭ eŵptǇ eŵptǇ 
KSA-Ϭϱ-ϵϰ eŵptǇ eŵptǇ 
 
 
 
 
  
  
_________________________________________________ 
 
 
 
| ϭϰϳ 
AppeŶdiǆ ϭϮ. Details foƌ ϵϲeƌ ColleĐioŶ 
Taďle ϳ-ϴ.  List of PϰϱϬBMϯ ǀaƌiaŶts iŶ the ϵϲeƌ ĐolleĐioŶ. SouƌĐe pƌojeĐts: aͿ RaioŶal desigŶ ŵutaŶts, 
ďͿ ϭst ƌouŶd MegaSite pƌojeĐt, ĐͿ ϮŶd ƌouŶd MegaSite pƌojeĐt, dͿ IŶtƌoduĐioŶ of N-teƌŵiŶal 
His-tag foƌ puƌiiĐaioŶ; eͿ ϯƌd ƌouŶd MegaSite pƌojeĐt, fͿ ϭst GeŶeƌaioŶ uŶĐagiŶg; gͿ Regio- 
aŶd steƌeoseleĐiǀitǇ of PϰϱϬ-ĐatalǇsed hǇdƌoǆǇlaioŶ.[ϭϲϭ] 
EŶ
tƌǇ
 BMϯ 
Đode 
SouƌĐe/ 
PƌojeĐt Pla
s-ŵ
id MutaioŶs 
H-T
ag 
Rϰ
ϳ 
Tϰ
ϵ 
Yϱ
ϭ 
Eϲ
ϰ 
Sϳ
Ϯ 
Vϳ
ϴ 
Fϴϭ
 
Aϴ
Ϯ 
Fϴϳ
 
Eϭ
ϰϯ
 
Vϭ
ϳϴ
 
Lϭϴ
ϭ' 
Lϭϴ
ϴ 
EϮ
ϲϳ
 
Vϯ
ϭϰ
 
Aϯ
ϯϬ
 
Gϰ
ϭϱ
 
Lϰϯ
ϳ 
ϭ pRSF RuďeŶ Agudo pRSF -                   
Ϯ WT RuďeŶ Agudo pRSF -                   
ϯ V ACE-AB- ϲϲ-ϬϮa pRSF -         V          
ϰ I ACE-AB- ϲϲ-Ϭϲ a pRSF -         I          
ϱ LV ACE-AB- ϯϳ-ϯϬ a pRSF - L        V          
ϲ LVQ ACE-AB- Ϯϴ a pRSF - L        V    Q      
ϳ LVQS ACE-AB- ϯϰ-ϯϯ a pRSF - L        V    Q    S  
ϴ MϬϭ ;LVQVSͿ 
ACE-AB- 
ϰϲ-Ϭϭ a pRSF - L        V    Q V   S  
ϵ MϬϭ-W ACE-AB- ϰϲ-Ϭϭ a pRSF - L       W V    Q V   S  
ϭϬ MϬϭ-IW ACE-AB- ϱϯ-Ϭϭ a pRSF - L    I   W V    Q V   S  
ϭϭ MϬϭ-VW ACE-AB- ϱϯ-ϬϮ a pRSF - L    V   W V    Q V   S  
ϭϮ MϬϭ-GIG ;MϭϭͿ 
ACE-AB- 
ϱϰ-Ϭϭ a pRSF - L   G   I  V G   Q V   S  
ϭϯ Mϭϭ-I ACE-AB- ϱϯ-Ϭϯ a pRSF - L   G I  I  V G   Q V   S  
ϭϰ Mϭϭ-II ACE-AB- ϲϲ-ϭϬ a pRSF - L   G I  I  I G   Q V   S  
ϭϱ MϬϭ-WI ACE-AB- ϲϲ-ϭϰ a pRSF - L       W I    Q V   S  
ϭϲ WWV ACE-AA-ϭϲϮ-ϬϮ-Ϯϴ ď pRSF - W       W V          
ϭϳ WMV ACE-AA-ϭϲϮ-ϬϮ-ϲϭ ď pRSF - W       M V          
ϭϴ WMI ACE-AA-ϭϲϮ-ϬϮ-ϲϵ ď pRSF - W       M I          
ϭϵ WV ACE-AA-ϭϲϮ-ϬϮ-ϳϮ ď pRSF - W        V          
ϮϬ LIFII ACE-AA-ϭϲϮ-Ϭϱ-Ϯϲ ď pRSF - L    I   F I         I 
     
     
AppeŶdiǆ ϭϮ  -   Details foƌ ϵϲeƌ ColleĐioŶ 
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ϭϰϴ | 
     
EŶ
tƌǇ
 BMϯ 
Đode 
SouƌĐe/ 
PƌojeĐt Pla
sŵ
id MutaioŶs 
H-T
ag 
Rϰ
ϳ 
Tϰ
ϵ 
Yϱ
ϭ 
Eϲ
ϰ 
Sϳ
Ϯ 
Vϳ
ϴ 
Fϴϭ
 
Aϴ
Ϯ 
Fϴϳ
 
Eϭ
ϰϯ
 
Vϭ
ϳϴ
 
Lϭϴ
ϭ' 
Lϭϴ
ϴ 
EϮ
ϲϳ
 
Vϯ
ϭϰ
 
Aϯ
ϯϬ
 
Gϰ
ϭϱ
 
Lϰϯ
ϳ 
Ϯϭ TIMI ACE-AA-ϭϲϮ-Ϭϱ-ϳϴ ď pRSF - T    I   M I          
ϮϮ LIFI ACE-AA-ϭϲϮ-Ϭϲ-Ϯϴ ď pRSF - L    I   F I          
Ϯϯ LWIS ACE-AA-ϭϲϮ-Ϭϳ-ϭϵ ď pRSF - L       W I         S 
Ϯϰ LIFI-WQ ACE-AB- ϱϮ-Ϭϭ-Ϭϰ Đ pRSF - L  W  I   F I    Q      
Ϯϱ LIFI-WQW 
ACE-AB- 
ϱϮ-Ϭϭ-ϱϮ Đ pRSF - L  W  I   F I    Q   W   
Ϯϲ LIFI-WQ'Q 
ACE-AB- 
ϱϮ-Ϭϭ-ϲϬ Đ pRSF - L  W  I   F I   Q Q      
Ϯϳ LIFI-CW ACE-AB- ϱϮ-Ϭϭ-ϲϳ Đ pRSF - L    I   F I    C   W   
Ϯϴ LIFI-WQM 
ACE-AB- 
ϱϮ-Ϭϯ-Ϯϳ Đ pRSF - L  W  I   F I    Q   M   
Ϯϵ LIFI-WQ'M 
ACE-AB- 
ϱϮ-Ϭϰ-ϱϳ Đ pRSF - L  W  I   F I   Q    M   
ϯϬ LIFI-WC' ACE-AB- ϱϮ-Ϭϳ-ϯϵ Đ pRSF - L  W  I   F I   C       
ϯϭ LIFI-HQ' ACE-AB- ϱϮ-Ϭϳ-ϳϰ Đ pRSF - L  H  I   F I   Q       
ϯϮ WWV-HH'M 
ACE-AB- 
ϱϮ-ϭϭ-ϭϵ Đ pRSF - W  H     W V   H    M   
ϯϯ WWV-WQW 
ACE-AB- 
ϱϮ-ϭϭ-ϱϱ Đ pRSF - W  W     W V    Q   W   
ϯϰ WWV-Q' ACE-AB- ϱϮ-ϭϮ-ϰϬ Đ pRSF - W       W V   Q       
ϯϱ WWV-M ACE-AB- ϱϮ-ϭϱ-ϯϲ Đ pRSF - W       W V       M   
ϯϲ WT ACE-AB- ϴϭ-Ϭϭ d pRSF +                   
ϯϳ LIFI-WC' ACE-AB- ϵϵ-ϭϬ d pRSF + L  W  I   F I   C       
ϯϴ WWV-Q' ACE-AB- ϵϭ-ϭϯ d pRSF + W       W V   Q       
ϯϵ Mϭϭ-II ACE-AB- ϴϰ-Ϭϭ d pRSF + L   G I  I  I G   Q V   S  
ϰϬ MϬϭ-WI ACE-AB- ϵϵ-Ϭϭ d pRSF + L       W I    Q V   S  
ϰϭ KIFI-WC' OutsouƌĐed e pRSF + K 
 
W 
 
I 
  
F I 
  
C 
      ϰϮ WIFI-WC' OutsouƌĐed e pRSF + W 
 
W 
 
I 
  
F I 
  
C 
      ϰϯ LIFI-HC' OutsouƌĐed e pRSF + L 
 
H 
 
I 
  
F I 
  
C 
      ϰϰ LIFI-YC' OutsouƌĐed e pRSF + L 
 
Y 
 
I 
  
F I 
  
C 
      ϰϱ LIFI-WCC' OutsouƌĐed e pRSF + L 
 
W 
 
I C 
 
F I 
  
C 
      
ϰϲ LIFI-WMC' OutsouƌĐed e pRSF + L  W  I M  F I   C       
ϰϳ LIEI-WC' OutsouƌĐed e pRSF + L 
 
W 
 
I 
  
E I 
  
C 
      
AppeŶdiǆ ϭϮ  -   Details foƌ ϵϲeƌ ColleĐioŶ 
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| ϭϰϵ 
                       
EŶ
tƌǇ
 BMϯ 
Đode 
SouƌĐe/ 
PƌojeĐt Pla
sŵ
id MutaioŶs 
H-T
ag 
Rϰ
ϳ 
Tϰ
ϵ 
Yϱ
ϭ 
Eϲ
ϰ 
Sϳ
Ϯ 
Vϳ
ϴ 
Fϴϭ
 
Aϴ
Ϯ 
Fϴϳ
 
Eϭ
ϰϯ
 
Vϭ
ϳϴ
 
Lϭϴ
ϭ' 
Lϭϴ
ϴ 
EϮ
ϲϳ
 
Vϯ
ϭϰ
 
Aϯ
ϯϬ
 
Gϰ
ϭϱ
 
Lϰϯ
ϳ 
ϰϴ LIWI-WC' OutsouƌĐed e pRSF + L 
 
W 
 
I 
  
W I 
  
C 
      ϰϵ LIFV-WC' OutsouƌĐed e pRSF + L 
 
W 
 
I 
  
F V 
  
C 
      ϱϬ LIFI-WG' OutsouƌĐed e pRSF + L 
 
W 
 
I 
  
F I 
  
G 
      ϱϭ LIFI-WQ' OutsouƌĐed e pRSF + L 
 
W 
 
I 
  
F I 
  
Q 
      ϱϮ LWV-Q' OutsouƌĐed e pRSF + L 
      
W V 
  
Q 
      
ϱϯ WWV-WQ' OutsouƌĐed e pRSF + W  W     W V   Q       
ϱϰ WWV-CQ' OutsouƌĐed
 e pRSF + W 
    
C 
 
W V 
  
Q 
      
ϱϱ WWV-MQ' OutsouƌĐed
 e pRSF + W 
    
M 
 
W V 
  
Q 
      
ϱϲ WFV-Q' OutsouƌĐed e pRSF + W 
      
F V 
  
Q 
      ϱϳ WWI-Q' OutsouƌĐed e pRSF + W 
      
W I 
  
Q 
      ϱϴ WWV-C' OutsouƌĐed e pRSF + W 
      
W V 
  
C 
      
ϱϵ WWV-G' OutsouƌĐed e pRSF + W 
      
W V 
  
G 
      
ϲϬ LFFA MS-Ϭϭ-Ϯϲ f pRSF - L 
   
F 
  
F A 
         ϲϭ TSWIA MS-Ϭϭ-Ϭϯ f pRSF - T 
      
W I 
        
A 
ϲϮ SIFIS MS-Ϭϭ-ϱϮ f pRSF - S 
   
I 
  
F I 
        
S 
ϲϯ TFFI MS-Ϭϭ-ϰϭ f pRSF - T 
   
F 
  
F I 
         ϲϰ TVFFS MS-Ϭϭ-ϲϱ f pRSF - T 
   
V 
  
F 
         
S 
ϲϱ TFWIN MS-Ϭϭ-ϵϬ f pRSF - T 
   
F 
  
W I 
        
N 
ϲϲ TFFVS MS-Ϭϭ-ϯϭ f pRSF - T 
   
F 
  
F V 
        
S 
ϲϳ FIS MS-Ϭϭ-ϰϰ f pRSF - 
       
F I 
        
S 
ϲϴ LIFI MS-Ϭϭ-ϱϵ f pRSF - L 
   
I 
  
F I 
         ϲϵ LFFFA MS-ϬϮ- ϰϵ f pRSF - L 
   
F 
  
F 
         
A 
ϳϬ TSFVS MS-ϬϮ-ϴϱ f pRSF - T 
      
F V 
        
S 
ϳϭ TFFIS MS-Ϭϯ-ϯϭ f pRSF - T 
   
F 
  
F I 
        
S 
ϳϮ TSFFN MS-Ϭϰ-ϳϰ f pRSF - T 
      
F 
         
N 
ϳϯ TVFVS MS-Ϭϰ-Ϯϴ f pRSF - T 
   
V 
  
F V 
        
S 
ϳϰ WFFFS MS-Ϭϰ-ϳϵ f pRSF - W 
   
F 
  
F 
         
S 
ϳϱ uŶ-kŶoǁŶ MS-Ϭϰ-ϴϰ f pRSF -                   
ϳϲ FFIN MS-Ϭϱ-Ϯϭ f pRSF - 
    
F 
  
F I 
        
N 
ϳϳ TSWIA MS-Ϭϱ-ϱϳ f pRSF - T 
      
W I 
        
A 
ϳϴ WFWIS MS-Ϭϲ-ϲϭ f pRSF - W 
   
F 
  
W I 
        
S 
ϳϵ TFV MS-Ϭϲ-ϳϳ f pRSF - T 
   
F 
  
V 
          ϴϬ LSWIN MS-Ϭϳ-ϴϱ f pRSF - L 
      
W I 
        
N 
ϴϭ RVFFA MS-Ϭϳ-ϲϮ f pRSF - 
    
V 
  
F 
         
A 
ϴϮ TIFFN MS-Ϭϳ-ϲϱ f pRSF - T 
   
I 
  
F 
         
N 
ϴϯ WSWIA MS-Ϭϴ-ϯϮ f pRSF - W 
      
W I 
        
A 
AppeŶdiǆ ϭϮ  -   Details foƌ ϵϲeƌ ColleĐioŶ 
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ϭϱϬ | 
     
EŶ
tƌǇ
 BMϯ 
Đode 
SouƌĐe/ 
PƌojeĐt Pla
sŵ
id MutaioŶs 
H-T
ag 
Rϰ
ϳ 
Tϰ
ϵ 
Yϱ
ϭ 
Eϲ
ϰ 
Sϳ
Ϯ 
Vϳ
ϴ 
Fϴϭ
 
Aϴ
Ϯ 
Fϴϳ
 
Eϭ
ϰϯ
 
Vϭ
ϳϴ
 
Lϭϴ
ϭ' 
Lϭϴ
ϴ 
EϮ
ϲϳ
 
Vϯ
ϭϰ
 
Aϯ
ϯϬ
 
Gϰ
ϭϱ
 
Lϰϯ
ϳ 
ϴϰ LSFIS MS-Ϭϴ-Ϭϵ f pRSF - L 
      
F I 
        
S 
ϴϱ LSWIS MS-Ϭϴ-ϴϰ f pRSF - L 
      
W I 
        
S 
ϴϲ TVFVS MS-Ϭϵ-ϲϰ f pRSF - T 
   
V 
  
F V 
        
S 
ϴϳ VFIN MS-ϭϬ-Ϭϰ f pRSF - 
    
V 
  
F I 
        
N 
ϴϴ IFA SC-Ϭϯ-ϴϴ f pET-Mϭϭ +      I  F A          
ϴϵ MFA SC-Ϭϯ-ϵϭ f pET-Mϭϭ +      M  F A          
ϵϬ WVA SC-Ϭϰ-ϭϬ f pET-Mϭϭ +      W  V A          
ϵϭ FWVII SC-Ϭϱ-ϲϭ f pET-Mϭϭ + Y F    W  F A      I    
ϵϮ LFAE SC-Ϭϱ-ϴϱ f pET-Mϭϭ +      L  F A  E        
ϵϯ YFAFAI SC-Ϭϱ-ϱϱ f pET-Mϭϭ + Y F    A  F A      I    
ϵϰ A SaďƌiŶa  Kille g 
pET-
Mϭϭ +         A          
ϵϱ IIIA SaďƌiŶa  Kille g 
pET-
Mϭϭ + I I I      A          
ϵϲ YFLMA SaďƌiŶa  Kille g 
pET-
Mϭϭ + Y F    L  M A          
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Supeƌǀisoƌ of the Masteƌ Thesis: Pƌof. Peteƌ Klüfeƌs 
IƌoŶ Tƌilate as a PƌeĐuƌsoƌ foƌ Coŵpleǆes ĐoŶtaiŶiŶg WeaklǇ CooƌdiŶaiŶg LigaŶds 
Ludǁig-MaǆiŵiliaŶs-UŶiǀeƌsitǇ MuŶiĐh  
BaĐheloƌ of SĐieŶĐe iŶ CheŵistƌǇ aŶd BioĐheŵistƌǇ ;gƌade Ϯ.ϭͿ 
Supeƌǀisoƌ of the BaĐheloƌ Thesis: Pƌof. AŶdƌeas KoƌŶath 
PƌotoŶaioŶ of AĐetaŵide aŶd ThioaĐetaŵide iŶ SupeƌaĐidiĐ SǇsteŵs 
FƌaŶz-MaƌĐ-GǇŵŶasiuŵ Maƌkt SĐhǁaďeŶ ;SeĐoŶdaƌǇ SĐhoolͿ 
aǁaƌded ƋualiiĐaioŶ: Aďituƌ – uŶiǀeƌsitǇ eŶtƌaŶĐe diploŵa ;gƌade ϭ.ϳͿ  
Majoƌ SuďjeĐts: CheŵistƌǇ, EŶglish 
 
EǆpeƌieŶĐe Aďƌoad     
ϭϬ/ϮϬϭϬ –  
ϭϮ/ϮϬϭϬ 
 
 
Ϭϯ/ϮϬϬϰ– 
Ϭϰ/ϮϬϬϰ 
UŶiǀeƌsitǇ of AuĐklaŶd, Neǁ )ealaŶd  
ReseaƌĐh IŶteƌŶship ;gƌade ϭ.ϬͿ  
Supeƌǀisoƌ: Pƌof. PeŶŶǇ Bƌotheƌs 
SǇŶthesis aŶd ChaƌaĐteƌizaioŶ of Co;IIIͿ-HǇdƌoǆaŵates  
JohŶ F. KeŶŶedǇ High SĐhool, Seatle, WA, USA  
StudeŶt EǆĐhaŶge Pƌogƌaŵ
